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Abstract 
Rett syndrome (RTT) is a neurodevelopmental disorder that is caused by 
mutations in the X-linked gene MECP2 and results in cognitive impairment, 
epilepsy and motor dysfunction. Deletion or silencing of Mecp2 in the brain of 
mice recapitulates many of the main phenotypes of the disorder and has been 
fundamental in understanding the actions of MeCP2 although the precise 
molecular function remains unknown. MeCP2 is classically thought to have a role 
in repressing gene transcription through recruitment of histone deacetylase 
proteins.  Studies have also shown that Mecp2 can be modified 
posttranslationally in response to neuronal activity.  
The aim of this thesis was to investigate the activity-dependent alterations in 
MeCP2 and the association this has with levels of acetylated histone proteins, a 
marker of active gene transcription thus gaining a better insight into how 
neuronal activity affects the function of MeCP2. Furthermore at the network 
level, a second objective was to characterise the effects loss of functional 
MeCP2 has on the regulation of network circuitry in the brain and in particular 
the development of epileptiform activities. To study this I focussed on the 
hippocampus in wild-type and Mecp2 mutant mice and in vivo administered the 
convulsant drug kainic acid (25mg/kg; IP) followed by seizure scoring and in 
vitro by application of various epileptogenic agents (kainic acid, bicuculline and 
4-aminopyridine) to acute hippocampal slices. Having characterised the network 
properties, I then quantified protein alterations in phosphorylation of Mecp2, 
acetylated histone H3 and H4 and immediate early genes, c-Fos and Egr-1 in the 
hippocampus using western blot and quantitative immunohistochemistry 
techniques. 
Based on a modified seizure scale (eight stages with lower being less severe), 
administration of kainic acid in vivo to Mecp2-deficient male mice resulted in a 
higher seizure score (mean = 6 ± 0.7 vs. 4 ± 0.2 units in wild-type) and more 
rapid onset (77% of mice show seizures after 10 minutes compared to 5% of wild-
type mice). Field recording data collected in vitro following application of kainic 
acid to hippocampal slice from Mecp2-deficient mice show a significant increase 
in gamma power oscillation (1059 ± 379µV2) compared to slices from WT mice 
(287 ± 178µV2) which had a lower mean power. Application of bicuculline 
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revealed hippocampal slices from Mecp2-deficient mice had increased frequency 
of spontaneous epileptiform field events (1µM and 3µM bicuculline) and elevated 
duration of spontaneous and evoked epileptiform field events (10µM 
bicuculline). Similarly, 4-aminopyridine (4-AP) administration to hippocampal 
slices resulted in Mecp2-deficient mice displaying increased frequency of 
spontaneous field events (50µM 4-AP) and epileptic ictal-like events (88% of 
slices from Mecp2stop/y mice displayed these events compared to 43% of slices 
from WT mice). Furthermore there was an increase in spontaneous and evoked 
field events following application of 30µM and 10µM 4-AP. 
Western blot experiments using hippocampal extracts from WT and Mecp2-
deficient male mice treated with the convulsant drug kainic acid or saline 
(vehicle control) revealed Mecp2 is highly phosphorylated  at serine 421 (3.4 ± 
0.5 fold, p< 0.01) upon induction of neuronal activity compared to saline 
controls but there was no change in histone H3 or H4 acetylated proteins. A 
complementary quantitative immunohistochemistry approach was used to assess 
variations in histone H3 or H4 acetylated proteins at the single cell level from 
heterozygous female mice (displaying a mosaic expression of Mecp2) treated 
with kainic acid or saline. These results revealed there was no difference in the 
levels of either acetylated histone H3 of H4 protein between Mecp2 positive and 
negative nuclei. However there was a clear cell-autonomous effect in terms of a 
5% reduction in the nuclear volume of Mecp2-deficient cells. 
Quantification of immediate early gene signal in Mecp2+/- heterozygous female 
mice treated with kainic acid or saline using the same immunohistochemistry 
method showed there was no difference in the distribution of c-Fos intensities 
between Mecp2 positive and negative nuclei following any treatment. However 
there was a greater proportion of Mecp2-deficient nuclei (~20%) expressing c-Fos 
under saline control conditions and following neuronal activity. Furthermore 
there was a reduction in the percentage of Mecp2 negative nuclei in the top 25% 
of Egr-1 intensities in the CA1 following three hours of neuronal activity (33.5 ± 
2.3% for Mecp2 negative nuclei and 19.1 ± 1.7% for Mecp2 positive nuclei). 
In summary my results show at the network level there is a reduction in seizure 
threshold and increase power of gamma oscillations in the hippocampus of 
Mecp2-deficient mice which could lead to a state of network hyperexcitability 
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and switch activities from physiological oscillatory rhythms to more pathological 
ones. An imbalance in inhibitory neuron regulation could partially contribute to 
alterations in network excitability to overall promote epileptogenesis. At the 
cellular level I report that Mecp2 can become phosphorylated following 
induction of neuronal activity but this is not associated with alterations in global 
histone acetylation. Nonetheless Mecp2-deficient cells display a reduction in 
nuclear volume and have alterations in c-Fos and Egr-1 levels following induction 
of neuronal activity. Overall my data contribute to the understanding of how the 
presence or absence of MeCP2 affects network excitability and how in turn 
neuronal excitability affects MeCP2 phosphorylation, histone acetylation and the 
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CRH  Corticotrophin-releasing hormone 
CTD  C-terminal domain 
DAPI  4‟,6-diamidino-2-phenylindole 
DG  Dentate gyrus 
dH2O  Distilled water 
ddH2O  Double distilled water 
DNA   Deoxyribonucleic acid 
DNMT  DNA methyltransferase 
DPSS  Diode-pumped solid-state laser 
DREAM Downstream repressor element antagonist modulator 
EEG  Electroencephalography 
fEPSP  Field excitatory postsynaptic potential 
GABA  γ–aminobutyric acid 
GFAP  Glial fibrillary acidic protein 
GFP  Green fluorescent protein 
H1  Histone H1 
H2A  Histone 2A 
H2B  Histone 2B 
H3   Histone 3 
H3Ac  Histone H3 acetylation 
H4  Histone 4 
H4Ac  Histone H4 acetylation 
HAT  Histone acetyltransferase 
HDAC  Histone deacetylase 
Het  Heterozygous 
HPA  Hypothalamic-pituitary-adrenal 
Hsp90  Heat shock protein 90 
ID  Inter domain 
IEG  Immediate early gene 
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KA  Kainic acid 
LTD   Long term depression 
LTP   Long term potentiation 
L-VSCC Long-lasting voltage sensitive calcium channels 
MAPK  Mitogen-activated protein kinases 
MBD   Methyl-CpG binding domain 
Me  Methylated 
MeCP1 Methyl-binding protein 1 
MECP2 Human Methyl-binding protein 2 gene 
Mecp2  Mouse Methyl-binding protein 2 gene 
MeCP2  Human Methyl-binding protein 2 protein 
Mecp2  Mouse Methyl-binding protein 2 protein 
mEPSC Miniature excitatory postsynaptic currents 
mIPSC  Miniature inhibitory postsynaptic currents 
N   Number 
NBQX  2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo(f)quinoxaline-2,3-dione 
NCS  Neuronal calcium signal 
NeuN  Neuron nuclear antigen rbfox3 
NF-ĸB  Nuclear factor-ĸB 
NLS  Nuclear localisation signal 
NMDA  N-methyl-D-aspartate 
NTD  N-terminal domain 
PB   Phosphate buffer 
PBS   Phosphate buffer saline 
PCR   Polymerase chain reaction 
PFA  Paraformaldehyde 
S421   Serine 421 
S424  Serine 424 
S80  Serine 80 
SA  Saline 
Sgk1  serum glucocorticoid-inducible kinase 1 
Syn1   Synapsin1 promoter 
SD   Standard deviation 
SDS   Sodium dodecyl sulphate 
SEM   Standard error of mean 
RFP   Red fluorescent protein 
RNA   Ribonucleic acid 
rpm   round per minute 
RTT   Rett syndrome 
TBS  Tris buffered saline 
TF  Transcription factor 
TRD   Transcription repression domain 
TrK  Tyrosine kinase 
UV  Ultraviolet 
Viaat  Vesicular inhibitory amino acid transporter 












1.1 General introduction 
Epigenetic control of gene expression is important for normal development of 
the central nervous system (CNS) and mutations in genes that play an integral 
part of this process can cause various congenital diseases. Rett syndrome is a 
neurodevelopmental disorder caused by mutations in the X-linked gene MECP2 
(Amir et al., 1999) and leads to neurological deficits and severe mental 
retardation. A variety of mouse models have been generated which replicate the 
key phenotypes of this disorder (Chen et al. 2001; Guy et al. 2001) and the 
symptoms have even been reversed in gene reactivation studies (Guy et al., 
2007). However the underlying function of MeCP2 and how its 
dysfunction/absence leads to Rett syndrome is still unclear. Activity-dependent 
transcription in the brain is important because it is required for experience-
dependent synaptic changes which underlie maturation of neural networks 
(Dragunow et al., 2000). Studies have revealed that Mecp2 protein can be 
modified posttranslationally in response to neuronal activity (Zhou et al., 2006). 
Furthermore, it is now appreciated that some epigenetic mechanisms in the 
adult brain are amenable to external stimuli (Crosio et al., 2000). In this thesis I 
explore this phenomenon further at the cellular level by correlating activity-
dependent changes in MeCP2 with alterations in histone acetylation, a 
recognised epigenetic mechanism. At the network level I attempt to characterise 
potential changes in network excitability as a result of MeCP2 deficiency thus 
gaining further insight into the role MeCP2 has in activity-dependent brain 
processes. 
1.2 Control of gene expression in the brain 
The brain is the most complex organ in the human body. There are many 
different neuronal cell types which have unique functions. The intricacy of 
neuronal networks is further enhanced with synapse and receptor location, 
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composition and interactions dictating the specificity of signalling pathways.  
Appropriate expression of genes throughout development and adulthood is 
important for neuronal identity and maintenance of these systems. Two key 
influences which play a significant role in regulating gene expression in the brain 
are transcription factors and epigenetic mechanisms. 
1.2.1 Transcription factors 
Transcription factors (TFs) are regulatory proteins which can bind to short DNA 
sequences up- or downstream of genes and influence transcription in a positive 
or negative manner. The importance of these proteins is highlighted by their 
conservation between organisms and the increase in their numbers in proportion 
to the size of the genome (van Nimwegen, 2003). TFs function as part of a 
complex, and by binding to specific recognition sequences in DNA (regulatory 
elements) near a gene they can recruit multiple proteins to facilitate binding by 
RNA polymerase II, (RNA pol II) thus initiating transcription (Matsui et al., 1980). 
There are two types of regulatory elements, promoter elements that exert 
control near the gene promoter and enhancer elements which exert their effect 
at a distance. The transcription factor complement of a cell is crucial in the 
control of gene expression during development and in determining adult cell 
identity (reviewed by Collingwood et al., 1999).  
During development and differentiation many TFs work together to regulate 
specific neuronal lineages, the acquisition of neuronal phenotypes as well as 
their own expression. This control is essential in the mature nervous system. TFs 
also play an important role in controlling gene expression under basal conditions 
and in response to external stimuli. Activity dependent control of neurite 
outgrowth and synapse formation and pruning is essential in maintaining a 
balance of inhibitory and excitatory synapses in the brain, and this is thought to 
occur through the regulation of gene expression (reviewed by West and 
Greenberg, 2011). There are two main classes of genes that are regulated by 
neuronal activity in the adult nervous system, immediate early gene TFs, which 
are general response factors in neurons, and neuronally enriched gene products, 
which have a specific function at synapses during development and plasticity. 
TFs can alter their function and localisation following activity-dependent 
signalling pathway activation to control expression of these genes. Examples of 
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how this is achieved in some well-studied TFs is shown in Figure 1-1 and 
explained in more detail below. 
1.2.1.1 CREB (cAMP response element binding protein)  
The transcription of certain genes can be detected within minutes following 
induction of neuronal activity; including immediate early genes such as Fos 
(Greenberg et al., 1986). This is aided by TFs such as CREB being prebound to 
gene promoters enabling them to quickly initiate gene transcription. Upon 
stimulus induced calcium entry via excitatory N-methyl-D-aspartate (NMDA) 
receptors and long-lasting voltage-sensitive calcium channels (L-VSCCs)  in the 
brain, CREB bound to DNA at the calcium–response element (CRE) become 
phosphorylated at serine 133 (Shaywitz and Greenberg, 1999). 
Calcium/calmodulin (CaM)-dependent protein kinase (CaMKs) results in rapid 
phosphorylation and mitogen-activated protein kinases (MAPKs) contributed to 
the sustained phosphorylation at later stages (Dolmetsch et al., 2001). This 
phosphorylation enables the recruitment of transcription coactivators such as 
CREB-binding protein (CBP) which activates transcription via histone acetylation 
(Chrivia et al., 1993). The CREB family are essential for neuronal survival and 
synaptic plasticity (Benito and Barco, 2010).  
1.2.1.2 NF-ĸB (Nuclear factor-kB) 
In comparison to CREB which is prebound to DNA and recruits co-factors, other 
TFs act through nuclear translocation. These responses are slower than prebound 
TFs and represent a later control of activity-regulated transcription.  In many 
cells (except immune cells were it is constitutively active) NF-ĸB is detained in 
the cytosol in an inactive state through association with an inhibitor of NF-ĸB 
(IĸB) (Meffert and Baltimore, 2005). Upon synaptic stimulation, phosphorylation 
of IĸB results in degradation of this protein and nucleocytoplasmic shuttling of 
NF-ĸB into the nucleus of cells (Mercurio et al., 1997). As with CREB, NF-ĸB also 
requires CaMKII (calcium/calmodulin-dependent protein kinase II) pathway for 
activation through calcium influx into the cell (Meffert et al., 2003). NF-ĸB has a 
major role in injury and stress in the CNS which is analogous to its immune 
system role. However NF-ĸB is also postulated to function in specialised 
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signalling from the synapse to the nucleus which is important for synaptic 
plasticity (Meffert et al., 2003). 
1.2.1.3 DREAM (Downstream repressor element antagonist modulator) 
Another mechanism by which TFs can exert their control over gene expression is 
through regulated DNA binding upon induction of neuronal activity and calcium 
influx into the cell. DREAM is a TF which belongs to the Neuronal Calcium Sensor 
(NCS) family of proteins which can bind calcium similar to the calcium effector 
protein CaM (Burgoyne, 2007). It is abundantly expressed in the CNS and 
interacts with DNA via a response element called downstream regulatory 
element (DRE) to repress transcription in the absence of calcium (Carrión et al., 
1999). Calcium influx into the cell opposes this action resulting in a reduction in 
its affinity for DNA. DREAM has a role in vesicle trafficking and various forms of 























Figure 1-1 Transcription factor modulation of gene transcription in response to neuronal 
activity 
Following neuronal activity, there are a variety of mechanisms in which transcription factors (TFs) 
can control gene expression. Firstly there is an influx of calcium (Ca
2+
) through long-lasting voltage 
-sensitive calcium channels (L-VSCC) or N-methyl-D-aspartate receptors (NMDAR) into the 
cytoplasm. This increase in calcium can negatively (-) regulate some TFs directly such as the 
repressor protein Downstream Repressor Element Antagonist Modulator (DREAM) by binding to it 
directly. This alters the affinity it has for DNA and releases it from DNA binding sites causing 
activation in gene expression. Alternatively elevated calcium levels can activate 
calcium/calmodulin-dependent protein kinase (CaMK) pathways which positively (+) regulate some 
TFs by phosphorylating those that are prebound to DNA such as cAMP response element binding 
protein (CREB). This enables them to recruit other co-factors including CREB-binding protein 
(CBP) in the case of CREB to activate gene transcription. Furthermore CaMKII can also positively 
regulate the translocation of TFs into the nucleus. For example Nuclear Factor-kB (NF-ĸB) is bound 
to an inhibitor protein (IĸB) in the cytoplasm but phosphorylation of this protein enables NF-ĸB to 
shuttle into the nucleus and regulate gene expression. This diagram is modified from 
Zhou et al. 2006. 
1.2.2 Epigenetic mechanisms 
In conjunction with TFs, epigenetic mechanisms also play an important role in 
regulating gene expression in the brain. The term epigenetics can be defined as 
‘the structural adaptation of chromosomal regions so as to register, signal or 
perpetuate altered activity states’, (Bird, 2007). In other words, the focus is on 
chromosomes and genes where mechanisms are in place to control heritable 
gene expression states without changing the underlying DNA sequence. These 
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changes are important in cellular differentiation throughout life, which allow 
cells to maintain different characteristics despite containing the same genomic 
material. It is now appreciated that epigenetic regulatory networks are not 
static and play an essential role in cell development, homeostasis and ageing 
(Dulac, 2010; Mehler, 2008). Their ability to respond to environmental stimuli 
makes these processes imperative to the correct function of neuronal networks 
in the CNS. Two major epigenetic mechanisms which contribute to alterations in 
gene expression are histone modifications and DNA methylation which regulate 
the availability of TF binding sites on DNA. A summary of these mechanisms are 
shown in Figure 1-2 and explained in more detail below. 
1.2.2.1 Histone modifications 
Chromatin is a complex of DNA, histones and non-histone proteins in the 
nucleus. The basic component of chromatin is the nucleosome which contains 
four core histones – H2A, H2B, H3 and H4. Two copies of each of these histones 
assemble to form an octamer core around which DNA wraps. This aids in DNA 
packing within the nucleus, regulates access of TFs and cofactors, and assists in 
DNA repair. The shape of chromatin can be condensed (heterochromatin) 
resulting in compact DNA which is unable to be transcribed. Alternatively, 
chromatin can be in a more open form (euchromatin) enabling access of gene 
transcription machinery. This is facilitated by posttranslational modifications on 
the N-terminal tails of histones proteins, by histone modifying enzymes, which 
alters their affinity for DNA  (reviewed by MacDonald and Roskams, 2009). 
Importantly histone modifying enzymes cannot access their substrates unless 
targeted by prebound DNA activators or repressors. There are at least eight 
types of modifications that occur on histone residues including acetylation, 
methylation, phosphorylation, ubiquitylation, SUMOylation, ADP (adenosine 
diphosphate) ribosylation, deimination and proline isomerisation (reviewed by 
Kouzarides, 2007). Histone acetylation, methylation and phosphorylation are 
amongst the well-studied modifications.  Methylation of histone H3 and H4 at 
lysine and arginine residues is mediated by methyltransferase enzymes which 
can mono-, di- or trimethylate histone tail residues. The functional 
consequences of methylation depend on the specific amino acid modified.  For 
example, methylation of lysine 4 on histone H3 is associated with active gene 
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transcription but methylation of lysine 9 on histone H3 is associated with 
repression of transcription (Noma K et al., 2001).  
In contrast to methylation of histone residues, phosphorylation and acetylation 
can be regulated by neuronal activity (Crosio et al., 2000). Histone H3 can be 
phosphorylated at a number of serine residues and phosphorylation of histone H3 
at serine 10 has been shown to be involved in chromosome condensation during 
mitosis (Wei et al., 1999). This residue can also be phosphorylated upon 
induction of neuronal activity and correlates with activation of immediate early 
genes (Crosio et al., 2000). Furthermore MAPKs signalling pathways have been 
linked to the phosphorylation at this residue (Cheung et al., 2000; Chwang et 
al., 2006). Finally acetylation of histone H3 and H4 can be regulated by histone 
acetyl transferase (HAT) and histone deacetylase (HDAC) enzymes which activate 
genes by the addition of acetyl groups to lysine resides or repress genes by 
removal of acetyl groups from lysine residues respectively. Acetylation at lysine 
residue 5, 8, 12 and 16 for histone H4 (Clarke et al., 1993) and lysine residue 9 
and 14 for histone H3 (Roh et al., 2005) have been identified as key regulatory 
sites which are amenable to stimulus induction (reviewed by Riccio, 2010). 
1.2.2.2 DNA methylation 
Another important epigenetic mechanism is DNA methylation which contributes 
to the stability of gene expression states (reviewed by Jaenisch and Bird, 2003). 
For example DNA methylation is involved in genomic imprinting in which some 
genes will only express the maternal or paternal allele specifically (Li et al., 
1993). However recent studies have shown that DNA methylation is amenable to 
stimulus-dependent regulation in the mature nervous system too which results in 
demethylation of DNA. For instance, seizure events in the hippocampus result in 
reduced DNA methylation at the promoter regions of neuronally enriched gene 
products (Ma et al., 2009). DNA methylation is catalysed by DNA 
methyltransferase (DNMTs) enzymes which modify DNA bases to add a methyl 
group to carbon-5 of the cytosine pyrimidine ring; principally at CpG 
dinucleotides (cytosine and guanine separated by a phosphate). There are two 
types of DNMTs – maintenance (Dnmt1) and de novo (Dnmt3a and Dnmt3b) 
DNMTs. The former is important during DNA replication to preserve methylation 
patterns in replicated cells (Yoder et al., 1997) and the latter has a role in 
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targeting unmethylated CpG dinucleotides (Okano et al., 1999). The significance 
of DNA methylation during development is highlighted by the lethality 
experienced in knockout DNMT mice (Okano et al., 1999). 
The effect of DNA methylation on gene expression is mainly mediated indirectly, 
through the binding of proteins to methylated CpG dinucleotides – specifically 
methyl binding domain proteins (MBDs) which repress transcription. The first 
MBD discovered was methyl-CpG binding protein 1 (MeCP1; Meehan et al., 1989) 
and the second was methyl-CpG binding protein 2 (MeCP2; Lewis et al., 1992). 
MeCP2 has a more simplistic protein structure than MeCP1 and the identification 
of an MBD sequence (required for recruitment to methylated DNA) in its 
structure enabled the identification of four more MBD proteins - MBD1, MBD2, 
MBD3 and MBD4  (Hendrich and Bird, 1998). Recruitment of HDAC proteins is the 
most common method for repression of gene transcription employed by all MBDs, 
except MBD4 which has role in DNA repair (Hendrich et al., 1999),  and is 
mediated by a transcriptional repression domain (TRD) in their protein structure 

























Figure 1-2 Epigenetic regulation of gene expression through histone modifications and DNA 
methylation 
(A) Chromatin is a complex of DNA (red) wrapped around a histone (orange) octamer (two copies 
of each core histone – H2A, H2B, H3 and H4) in the nucleus. Modifications to the histone tails can 
change the accessibility of chromatin to transcriptional machinery through alterations such as the 
enzymatic addition of acetyl (Ac, yellow), phospho (P, green) or methyl (Me, blue) groups thus 
altering gene expression (histone modifications). Furthermore addition of a methyl group to carbon-
5 of the cytosine pyrimidine ring (chemical structure) by methyltransferase enzymes (DNMTs) can 
also modify the chromatin structure typically leading to repression of genes (DNA methylation). (B) 
Example of how these epigenetic mechanisms can alter chromatin to regulate gene expression. 
Closed chromatin has methylated DNA (black circles) and deacetylated histone tails which typically 
lead to repression of gene transcription. However a more open chromatin structure has 




1.3 MeCP2 and Rett syndrome 
1.3.1 Rett Syndrome caused by mutations in MECP2 
Rett Syndrome (RTT, OMIM 312750) is a sporadic neurodevelopmental disorder 
that affects roughly 1 in every 10,000 female live births and is the second 
leading cause of all mental retardation in girls (Neul et al., 2010). The 
restriction of the disease to females suggested an X-linked dominant mode of 
inheritance, with the mutation presumed to be lethal in males (Xiang et al., 
1998). However, due to the unpredictable occurrence of RTT, it was hard to map 
the locus on the chromosome. From the use of genetic linkage studies and the 
investigation into rare family cases with RTT, the most probable location was 
indicated as Xq28 (Amir et al., 1999). Subsequently, following further gene 
sequencing analysis into plausible disease-causing mutations of candidate genes 
in this locus, it was found that a mutation in MECP2 was the cause of RTT (Amir 
et al., 1999). This was surprising as MeCP2 had no previous known involvement in 
the CNS or brain development and is in fact a widely expressed transcriptional 
regulator involved in epigenetic mechanisms as described above. 
1.3.2 Clinical manifestations of RTT  
RTT was first identified as a distinct disorder based on clinical studies carried 
out by Dr Andreas Rett in 1966 (Rett, 1966), and Dr Bengt Hagberg in 1983 
(Hagberg et al., 1983). The necessary criteria for diagnosis often found in classic 
forms of RTT (Neul et al., 2010) are displayed in Table 1-1.  
Table 1-1 Necessary criteria for classic RTT diagnosis 
 
In classic RTT a stage progression of the disorder is speculated (Hagberg 2002), 
although some variable overlap is still present. Initially after birth, sufferers 
appear to develop normally for about 6-18 months with some even learning to 
Classic RTT diagnostic criteria 
1. Partial or complete loss of purposeful hand skills 
2. Partial or complete loss of purposeful spoken language 
3. Gait abnormalities 
4. Stereotypical hand movements 
5. Period of regression followed by recovery or stabilization 
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walk and talk. Subsequently, signs of RTT slowly begin to appear. Foremost is a 
decrease in the average circumference of the head, advancing to full 
developmental stagnation by the age of three consisting of stunted growth, 
weight loss and muscle hypotonia. Patients then enter a period of rapid 
regression where autistic features become more prevalent such as avoidance of 
eye contact, communication dysfunction and lack of social interaction. During 
this time sufferers can also lose vital hand skills and develop stereotypic 
movement (e.g. clasping of hands); experience psychomotor abnormalities; 
encounter breathing abnormalities such as protracted inspirations and profound 
mental retardation. One of the most challenging symptoms is the high risk of 
seizure development ranging from mild to severe epilepsy 
(Chahrour and Zoghbi 2007; Hagberg 2002).  
By the age of 4 onwards, patients commonly reach the stationary stage where 
signs of improvement may become evident in social behaviour. Nonetheless, the 
risk of suffering from scoliosis and decreased bone mineral density is increased 
due to a continual loss in weight; anxiety levels are heightened and further 
autonomic abnormalities can manifest such as cardiac irregularities. Reaching 
teenage years, the intensity of seizures begins to reduce but most patients enter 
a late motor deterioration phase where motor function depreciates further, 
often leading to immobility. However, it is still possible for patients to live 
beyond early adulthood although the risk of further disability is greatly enhanced 
with sudden death occurring in 25% of cases commonly from autonomic 
dysfunction (Chahrour and Zoghbi 2007; Hagberg 2002; Hagberg 2005)  
The age of onset and the development of symptoms are known to vary between 
each patient ranging from severe to mild cases. This leads to development of 
atypical forms of RTT in which a regression stage is required for the diagnosis. 
There are three distinct variant forms of RTT – the preserved speech variant, the 
congenital variant and the early seizure variant. The first of the three has 
mutations in MECP2 in the majority of cases however the latter two are rarely 
associated with MECP2 mutations (Neul et al., 2010). 
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1.3.3 Structure of MeCP2 protein and mutations  
Around 95-97% of classical RTT cases are caused by mutations in MECP2 (Neul et 
al., 2008) and in 50-70% of atypical RTT cases (Percy et al., 2007). A vast 
majority of these mutations have now been identified and are compiled 
regularly in comprehensive databases (www.mecp2.org.uk; RettBase: 
http://mecp2.chw.edu.au/). The structure of the MeCP2 protein and the typical 







Figure 1-3 MeCP2 protein structure and common mutations types 
Representative diagram showing the basic structure of the MeCP2 protein (wild-type protein) and 
the common mutation types (missense, nonsense and frameshift) that occur in RTT. The wild-type 
protein contains several functionally distinct domains including the N-terminal domain (NTD), 
methyl binding domain (MBD), inter domain (ID), transcriptional repressor domain (TRD), C-
terminal domain (CTD) and the nuclear localisation signals (NLS). Black arrows under each 
mutation type give a hypothetical situation of where each mutation could occur and the effect. 
Missense mutations are a type of point mutation result in a single nucleotide change which typically 
leaves the entire protein intact. Nonsense mutations are a type of point mutation which results in a 
single nucleotide change leading to a premature stop codon and the formation of a shortened 
protein. Frameshift mutations are insertions or deletions of a number of nucleotides that lead to a 
loss of the open reading frame. They terminate at the first stop codon (end of X in diagram) causing 
a truncated protein.  
MECP2 is comprised of four exons but due to alternative splicing exon can be 
differentially expressed giving rise to two isoforms of the protein. They differ 
only at their N-termini with exons three and four remaining unchanged 
(Mnatzakanian et al., 2004). There are three known functional domains in the 
latter two exons, the methyl-CpG binding domain (MBD), the transcription 
repression domain (TRD) and a nuclear localisation signal (NLS). More than 600 
mutations are known (RettBase: http://mecp2.chw.edu.au/mecp2/), and the 
majority occur in the exons coding for these domains. As identified in 1999, the 
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basic spectrum of mutations includes missense, nonsense and frameshift 
mutations (Amir et al., 1999). 
Frameshift mutations arise from the addition or loss of DNA bases which change 
the reading frame of a gene (three bases that code for an amino acid). These 
types of mutation can occur over the entire length of the protein but are 
clustered at the C-terminal region and usually result in a non-functional product. 
Nonsense mutations arise from a single nucleotide change which prematurely 
signals the cell to stop building a protein. The majority of these occur within the 
MBD and TRD producing a shortened protein that might be functional or not. 
Missense mutations arise from a change in one DNA base pair resulting in the 
substitution of one amino acid for another. The bulk of mutations typically occur 
in the MBD with the rest of the protein left intact 
(Free et al. 2001; Yusufzai and Wolffe 2000). 
Around 70% of all cases  are eight missense and nonsense mutations (R106, R133, 
T158, R168, R255, R270, R294 and R306) and C-terminal deletions account for 
about 10% (Christodoulou et al. 2003; Moretti and Zoghbi 2006). It was found 
that mutations in the NLS region or causing premature stop codons cause more 
severe symptoms than missense mutations. In comparison, C-terminal deletions 
appear to produce a milder outcome (Smeets et al., 2005). In general, MECP2 
mutations are not conserved. Consequently depending on the type of MECP2 
mutation inherited, the symptoms developed in each patient will differ. 
1.3.4 Occurrence in males 
Following the discovery of mutations in MECP2 causing RTT, it was questioned 
whether the disorder was indeed restricted to girls. After genetic testing, males 
were found to exhibit similar symptoms to those seen in classic RTT (Jan et al., 
1999) or other disorders such as mental retardation and encephalopathy, but 
most males with this mutation will die within the first year of life. Males with 
mutations in the gene can show a similar phenotype to females in the rare case 
of concurrent Klinefelter syndrome, in which the presence of an extra 
chromosome leads to males having one functional copy of the gene 
(Schwartzman et al. 1999).  
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MECP2 is an X-linked gene in which RTT females are heterozygous for the WT or 
mutant MECP2 allele. Due to X-chromosome inactivation, in which one of the 
two copies of the X- chromosome in each cell will become inactive, female RTT 
patients have a cell population that is mosaic for expression of the mutant 
allele. The inactivation is a random and independent process from cells in the 
embryo with the majority inherited from the paternal germ line (Trappe et al., 
2001). It is therefore uncommon for males to inherit the disorder but those that 
do will have a declined chance of survival due to mutations in MECP2 being on 
all of their X chromosomes. Although inactivation is generally balanced in 
women, determination of the severity of the phenotype will ultimately depend 
on the number of cells that are affected and the mutation type. 
1.3.5 Mouse models of RTT 
To enable research into RTT and its pathology the use of mouse models which 
closely mimic the disorder is required. Table 1-2 summarises all the current 
mouse models that have contributed significantly to understanding the RTT 
phenotype.  After the discovery of MECP2 as the dominant cause of RTT, gene 
targeting procedures were used to create mice in which Mecp2 was knocked out 
in order to recapitulate the phenotype (Chen et al. 2001; Guy et al. 2001). 
Although RTT predominantly affects females, the majority of models are of 
hemizygous male mice. This is because heterozygous female mice have a 
variable phenotype, resulting from random X-chromosome inactivation causing 
differences in the percentage of cells expressing Mecp2, and delayed symptom 
onset (six to nine months) making them difficult to study. In comparison, the 
onset of symptoms in male mice is consistent and rapid (roughly seven weeks) 
making this a more useful model for studies of the disorder. 
Constitutive knockouts generated by both Chen et al and Guy et al in 2001 
produced Mecp2 knockout mouse models that had a remarkable similarity in 
phenotypes to the human condition. Using Cre-loxP technology, the mice 
created by Guy et al lacked exon three and four of the Mecp2 gene therefore 
preventing MeCP2 expression altogether (Mecp2-/y). Alternatively, Chen et al 
used Cre-loxP technology to only delete exon three of the Mecp2 gene but the 
symptoms generated were still very similar (Mecp21lox/y). In the former model, 
male mice appeared normal until the third postnatal week before they began to 
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show symptoms including uncoordinated gait, less spontaneous movements, hind 
limb clasping, irregular breathing, wearing of the teeth and varied body weight. 
The severity of symptoms increased with age resulting in death of hemizygous 
male mice around postnatal week eight (Guy et al., 2001). The Chen et al model 
was comparable with symptoms in mice arising around postnatal week four 
which included abnormal gait, body tremors, hind limb clasping, loss of body 
weight and irregular breathing (Chen et al., 2001). Conversely in 2002, a male 
mouse model with a truncated Mecp2 mutation (premature stop codon 
positioned after codon 308;  Mecp2308/y) was generated which produced a milder 
RTT phenotype – longer survival (up to a year), normal body weight and fertile 
mice (Shahbazian et al., 2002). This model enables the study of male mice with 
RTT symptoms over longer experimental periods. 
Since the development of these constitutive knockouts and truncation model, 
several other mouse models have been generated which has increased the 
knowledge of RTT pathology further. A conditional knockout of Mecp2 using a 
nestin-Cre transgene generated a mouse model in which Mecp2 was deleted in 
the brain (Guy et al., 2001). Animals in this model displayed an identical 
phenotype to constitutive knockouts with both showing neurological symptoms 
at six weeks of age and heterogeneous females displaying abnormalities after a 
few months. Furthermore, other studies have also shown deleting Mecp2 using a 
neuron-specific promoter (microtubule-binding-protein, Tau) prenatally 
(Luikenhuis et al., 2004) and inactivating Mecp2 postnatally using an inducible 
Cre-ESR/Lox system in the whole brain at 3, 11 and 20 weeks after birth (Cheval 
et al., 2012) can generate Rett-like phenotypes. These latter three studies 
highlight the importance of MeCP2 function in the brain with a specific role for 
MeCP2 in mature neurons. 
Following the replication of RTT phenotypes in the brain, recent studies have 
focused on deleting Mecp2 in specific neurons to see which cell type contribute 
to RTT pathology. The use of Cre-loxP technology to remove Mecp2 from Sim1-
expressing neurons in the hypothalamus (Fyffe et al., 2008) and aminergic 
neurons (Samaco et al., 2009) produced mice that were dysfunctional in social 
and feeding behaviours or displayed either motor dysfunction and aggression 
respectively. Viral-mediated basolateral amygdala-specific deletion of Mecp2 
(AAV-CreGFP; Mecp22lox/y) generated mice with heightened anxiety levels 
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(Adachi et al., 2009). Furthermore using a bacterial artificial chromosome 
containing the Viaat (vesicular inhibitory amino acid transporter) promoter to 
target Cre dependent deletion of Mecp2 in neurotransmitter γ–aminobutyric acid 
(GABA) secreting  neurons (Viaat-Mecp2-/y), produced several Rett-like features 
including repetitive behaviours, motor dysfunction, respiratory dysfunction and 
weight loss (Chao et al., 2010). These studies demonstrate that Mecp2 plays an 
important role in many neuronal subtypes. 
Imperative to understanding the functioning of MeCP2 in the brain and specific 
cell types, was the development of a transgenic mouse that had a two-fold 
overexpression of MeCP2 (Mecp2Tg1/y) compared to wild-type (WT) levels (Collins 
et al., 2004). Initially the mice appeared to have enhanced motor learning and 
synaptic plasticity but after 20 weeks they developed seizures, displayed 
diminished mobility and around 30% died within the first year. The same group 
also showed that by removing the endogenous allele, thus reducing Mecp2 levels 
to normal, the effects observed were reduced. Furthermore, overexpression of a 
Mecp2 transgene in the brain using the Tau-promoter generated mice with 
severe motor impairments (Luikenhuis et al., 2004). These findings demonstrate 
tightly controlled levels of MeCP2 protein are required for appropriate regulation 
of target genes and functioning of cells.  
A landmark study in which conditionally silenced Mecp2 was reactivated 
postnatally demonstrated the feasibility of reversing the disorder in RTT patients 
(Guy et al., 2007). Endogenous Mecp2 was silenced in the mouse by insertion of 
a lox-stop cassette (Mecp2Stop/y) which can be conditionally activated through 
Cre-mediated deletion of the cassette (tamoxifen-inducible Cre transgene). 
Small repeated doses of tamoxifen injections caused reversal of most 
phenotypes seen in male and female symptomatic mice and prolonged their 
lifespan. These findings suggest that that the dysfunction caused by MeCP2 
absence is not permanent and that the majority of phenotypes can be rescued. 
One theory behind this is the proposal that MeCP2 target sites are characterised 
by conserved DNA methylation patterns and thus when Mecp2 is reintroduced 
into a knockout mouse, read-through of the predefined patterns can occur and 
enable normal functioning (Guy et al., 2007). Partial reversal of RTT symptoms 
has also been observed with re-expression of Mecp2 specifically in prenatal 
(Luikenhuis et al., 2004) and postnatal neurons  (Giacometti et al., 2007). 
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Furthermore, re-expression of Mecp2 in astrocyte specific cells in the brain using 
a Cre transgene driven by the human astrocytic glial fibrillary acidic protein 
(hGFAP) promoter (Mecp2Stop/y- hGFAPcreT2) improves locomotion, anxiety 
levels, respiratory dysfunction and prolonged lifespan (Lioy et al., 2011). These 
studies show that targeting neurons in the brain can reverse RTT symptoms and 
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1.3.6 Neuropathology of RTT 
1.3.6.1 RTT Patients 
Before the development of Mecp2 mouse models, studies performed to 
understand the pathology of RTT were done on human post-mortem subjects. 
Brain autopsies of RTT patients revealed a smaller brain size (Schultz et al., 
1993) with reduced neuronal cell size and increased cell packing density in many 
brain regions including the cerebral cortex, hypothalamus and hippocampus 
(Bauman et al., 1995). There have also been reports of impaired dendritic 
growth and complexity of pyramidal cells in the frontal and motor cortices 
(Armstrong et al., 1995), and reduced synaptic spine density in pyramidal 
neurons in the hippocampus (Chapleau et al., 2009) and frontal cortex 
(Belichenko et al., 1994). Consistent with this reduction of neuronal complexity, 
the density of a number of excitatory neurotransmitter including NMDA, 2-
amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid (AMPA) and 
metabotropic glutamate receptors in the frontal cortex was reduced in older 
RTT patients but higher in younger patients (Blue et al., 1999). However, at the 
macroscopic level there appears to be no major neuronal degeneration or 
malformations present in the brains of RTT patients. 
1.3.6.2 Neuronal pathology in RTT mouse models 
This phenomenon of alteration in dendritic and axonal growth is consistent in 
animal models of the disease. Adult Mecp2 knockout mice have been shown to 
exhibit abnormal neuronal growth, especially with respect to dendrite 
formation. For example, knockout mice have thinner dendrites and reduced 
spine number in pyramidal neurons of the somatosensory cortex at six weeks of 
age (Fukuda et al., 2005). The same group also showed delayed maturation of 
postsynaptic densities (Fukuda et al., 2005). More recently, neural stem cells 
from the dentate gyrus (DG) of the hippocampus in knockout and WT animals 
were found to proliferate at the same rate and have a comparable cell density 
(Smrt et al., 2007). This suggests that MeCP2 is not important for early 
neurogenesis. Further evidence shows that immature neurons in the same area 
of knockout animals exhibit horizontal and short processes, typical attributes of 
new neurons during differentiation, indicating impairment in maturation (Smrt 
et al., 2007). 
  39 
 
 
Additional work studying the morphology of dendrites and axons in two mouse 
models of RTT (Mecp2-/y and Mecp2308/y) supports the previous findings with 
extensive deformities in the motor cortex, CA1 (Cornu Ammonis Area 1) and 
fascia dentata of the hippocampus found (Belichenko et al., 2009b). Dendrites 
were swollen, had diminished spine head area and reduced spine density. 
Equally axons displayed disrupted organisation of their processes. Intriguingly 
the changes observed in the dendrites varied extensively between neighbouring 
neurons (Belichenko et al., 2009b). More work carried out on neuronal cultures 
transfected with mutant MECP2, confirmed the latter findings of decreased 
spine densities in CA1 region of the hippocampus. Interestingly the effects 
observed in CA3 (Cornu Ammonis area 3) neurons were milder (Chapleau et al., 
2009). Furthermore a recent study has shown that postnatal loss of Mecp2,  
specifically at five (late juvenile stage) or ten (adult stage) weeks displayed 
smaller brains, increased neuronal density, retraction of dendritic arbour and 
reduction in spine density in the hippocampus (Nguyen et al., 2012). They also 
showed reduction in excitatory synaptic proteins including receptor (NMDA and 
AMPA) and vesicle proteins. Overall, the above data suggest that MeCP2 is 
important in mature neuron development, specifically with respect to dendrites 
with subsequent effects on synapse and circuit formation. 
The above studies suggest that mutations in MeCP2 could have a cell autonomous 
effect on morphology. However further work carried out on dendritic 
morphology has revealed that neurons carrying the mutant Mecp2 gene could 
affect neighbouring cells as well (Belichenko et al., 2009). With X-chromosome 
inactivation, if mutant cells have a direct influence on adjacent neurons which 
are positive for MeCP2, inevitably there would be some neuropathological 
effects. Belichenko et al examined dendritic spines in the motor cortex and 
found a decrease in spine density, head size and increases in spine neck length, 
spots and long spines in both Mecp2-deficient and Mecp2 positive neurons from 
heterozygous female mice in comparison with cells from female WT mice. This 
suggests that Mecp2 mutant cells are having deleterious effects on nearby 
neurons in a non-cell autonomous manner. However, Mecp2-deficient cells in 
heterozygous female mice displayed an increase in dendritic swellings or 
narrowings whereas Mecp2 positive cells in heterozygous female mice did not 
signifying that some effects are restricted to Mecp2 negative cells (Belichenko et 
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al., 2009a). Overall, effects such as these will be an important factor to consider 
when investigating synaptic dysfunction and other pathological impairments 
associated with mutations in Mecp2. 
1.3.6.3 Neuroglia pathology in RTT mouse models  
In agreement with the previous work, Ballas et al also claim to see a non-cell 
autonomous influence of Mecp2 deficiency on dendritic morphology, however 
most interestingly this discrepancy involves glia cells (Ballas et al., 2009). Even 
though MeCP2 is widely expressed throughout the body, the results from neuron 
specific conditional knockouts, suggested that neuronal deficiency of MeCP2 
caused the majority of RTT phenotypes (Guy et al., 2001; 
 Luikenhuis et al., 2004). Glia cells were not considered to express any MeCP2 
(Kishi and Macklis, 2004); however most recent studies contradicted this. For 
example, non-neuronal cells in the embryo have been shown to express Mecp2 
and that deficiencies in Mecp2 causes impairment in growth (Nagai et al., 2005). 
More recently, Ballas et al used an antibody that bound to the C terminus of 
Mecp2, in combination with improved immunostaining, to show that the protein 
is present in all types of glia in rat and mouse brain (Ballas et al., 2009).  
Subsequently, Mecp2 deficiency in astrocytes (the most abundant glial cell) was 
investigated by co-culturing WT and Mecp2 mutated hippocampal neurons in 
astrocyte conditioned media (ACM) from WT or Mecp2 mutated astrocytes. The 
ACM from mutant astrocytes failed to support normal neuronal growth of WT or 
mutant hippocampal neurons but mutant neurons grown in WT ACM displayed 
normal dendritic morphology (Ballas et al., 2009). Collectively, this work 
highlights the importance of MeCP2 in glia cells for normal neuronal function. 
The toxicity effect that astrocytes appear to have on neighbouring neurons could 
be mediated by a reduction in certain secreted factors that are fundamental for 
dendritic morphology or by secretory factors that have a more lethal effect on 
neurons. 
Conversely, another study using conditioned media (CM) from another type of 
glia cell, microglia (present in macrophages), have shown that hippocampal 
neurons treated with this CM from Mecp2-deficient microglia but not astrocytes 
exhibit dysfunctional dendritic morphology and abnormalities in postsynaptic 
  41 
 
 
glutamate components (Maezawa and Jin, 2010). They identified glutamate as 
the toxic secretory factor mediating these effects due to the presence of 
elevated glutamate levels in microglia from Mecp2-deficient mice and blockage 
of glutamate inhibiting the toxic effects. Furthermore the transplantation of WT 
microglia into the bone marrow of Mecp2-deficient mice (irradiated for mutant 
microglia) in a recent study (Derecki et al., 2012) resulted in arrest of RTT like 
pathology including increased lifespan, reduced respiratory abnormalities, 
increased body weight and improved motor function. Overall the above studies 
show glia cells, especially microglia, have a significant influence on 
neuropathology of RTT. 
1.3.7 Neurophysiological deficits in RTT 
Despite obvious alterations in dendritic morphology, the full extent of 
abnormalities resulting from MeCP2 deficiency is still not clear. Considering 
normal brain function is based on a balance between excitatory and inhibitory 
neurotransmission, any factors that disturb this equilibrium will result in 
aberrant brain development. Alterations in synaptic output can interfere with 
information coding in neural circuits and potentially long-term plasticity. 
Subsequently, a variety of studies have performed a more functional approach to 
understand the neuronal basis of MeCP2 dysfunction.  
1.3.7.1 RTT patients 
The development of epilepsy in ~70-80% of RTT patients is a prominent 
phenotype (Hagberg, 2002) with the severity of seizures appearing to fall in late 
adolescence (Steffenburg et al., 2001). Furthermore RTT patients with epilepsy 
appear to have greater motor dysfunction and cognitive impairment thus 
highlighting the significance of this phenotype (Kim et al., 2012). 
Electroencephalography (EEG) is a useful tool for studying epilepsy allowing 
characterisation of the events and the ability to determine the specific region of 
the brain from which seizures arise. Although there are no characteristic EEG 
patterns in RTT patients (Glaze, 2005), the EEG is still invariably abnormal. For 
example, epileptiform discharges are common during sleep (Aldrich et al., 
1990), prominent rhythmical theta activity (Niedermeyer et al., 1997) and loss 
of developmental features associated with EEGs including the loss of a dominant 
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rhythm that usually occurs in the visual cortex at ages 1-4 years (Glaze et al., 
1987). 
1.3.7.2  General abnormalities in RTT mouse models 
As with neuropathological deficits, studies in mouse models of RTT have been 
advantageous in investigating the neurophysiological deficits in RTT and thus 
giving insight into the function of MeCP2. In contrast to RTT patients, 
constitutive Mecp2 knockout mice do not display a prominent epileptic 
phenotype (Chen et al., 2001; Guy et al., 2001). However, the male mouse 
model with a truncated Mecp2 mutation develop spontaneous myoclonic seizure 
(Shahbazian et al., 2002) and overexpression of Mecp2 in mice cause frequent 
clonic seizures to occur in older (~one year) animals (Collins et al., 2004). These 
studies suggest that specific mutation types and levels of MeCP2 predispose the 
development of abnormal neuronal activity in the brain. Although Mecp2-
deficient mice display abnormalities in EEG activity including spontaneous 
epileptiform discharges in the cortex (D’Cruz et al., 2010; Colic et al., 2011), 
dysfunction of cortical delta slow wave activity which usually occurs during sleep 
(Wither et al., 2012) and gamma and beta band abnormalities in response to 
auditory stimulation  (Liao et al., 2012). Collectively these suggest there is an 
alteration in network circuitry in Mecp2-deficient mice.  
1.3.7.3 Intrinsic and synaptic property deficits in RTT mouse models 
To investigate these discrepancies in circuitry, other studies have focused on 
whether a dysfunction in excitatory and inhibitory input to the brain is present 
in Mecp2-deficient mice as these are important factors for regulating neuronal 
circuitry. The majority of these studies have performed electrophysiological in 
vitro brain slice experiments or culture preparations to investigate the 
differences in intrinsic and synaptic properties in neurons between WT and 
Mecp2-deficient mice. Firstly, despite the morphological differences in soma 
size, the intrinsic membrane properties between genotypes are similar. For 
example, CA3 and CA1 pyramidal neurons in the hippocampus (Zhang et al., 
2008), pyramidal neurons in layer V of the somatosensory cortex (Dani et al., 
2005) and cortical later II/III pyramidal (Wood et al., 2009) all showed 
comparable resting membrane potentials, input resistance and firing patterns 
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between WT and mutant mice. A lack of change in intrinsic excitability suggests 
that the physiology of cells in Mecp2-deficient mice is normal.  
Despite similarities in intrinsic properties, there are documented alterations in 
both excitatory and inhibitory synaptic properties between WT and Mecp2-
deficient mice. Whole-cell recordings from Mecp2 mutant mice coronal brain 
slices detected a reduction in spontaneous action potential firing in layer V of 
the somatosensory cortex (Dani et al., 2005). They attributed this to impaired 
quantal neurotransmitter release from excitatory synapses as spontaneous 
miniature excitatory postsynaptic currents (mEPSCs) were smaller in mutant 
mice and no difference was seen in spontaneous miniature inhibitory 
postsynaptic currents (Dani et al., 2005). Complementary to this work, another 
group performed experiments in the middle cortical layers of Mecp2-knockdown 
neurons and detected a significant reduction in local excitatory input pathways 
and unaltered synaptic inputs (Wood et al., 2009). Moreover, another study 
recorded a reduction in spontaneous mEPSC frequency in hippocampal 
dissociated cultures but no change in miniature inhibitory postsynaptic currents 
(mIPSC) properties when compared with WT cultures (Nelson et al., 2006). 
Further experiments conducted using hippocampal cultures have also shown that 
neurons grown from Mecp2-deficient mice show a reduction in evoked EPSC 
amplitude and spontaneous mEPSC frequency whereas doubling the levels of 
Mecp2 results in an increase in these parameters (Chao et al., 2007). 
Collectively, all these studies suggest that loss of MeCP2 manifests abnormalities 
in excitatory neurotransmission leading to a reduction in excitatory synaptic 
strength and an imbalance in synaptic output which could be linked to aberrant 
presynaptic transmission properties in mutant animals. 
Alterations in inhibitory synaptic properties have also been proposed in Mecp2-
deficient mice. Whole-cell patch clamp recordings in the brain stem of Mecp2 
knockout mice have revealed impairments in GABAergic synapses (Medrihan et 
al., 2008). A reduction in the frequency of mIPSPs was observed which is the 
opposite to some of the studies described above (Dani et al., 2005). There are 
two inhibitory components in the brain stem, glycine- and GABAA- receptor 
mediated currents and it is therefore important to distinguish the specific 
pathways affected in RTT. No disparity was observed in glycinergic events but 
isolation of GABAergic currents demonstrated a similar trend as before with a 
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decrease in frequency in knockout mice. This data suggests abnormalities with 
presynaptic components in GABAergic interneurons (Medrihan et al., 2008). 
Furthermore whole-cell recordings from the CA3 region of the hippocampus in 
Mecp2-deficient mice show elevated spontaneous IPSCs (Zhang et al., 2008). This 
was accompanied by a decrease in spontaneous EPSCs amplitude leading to the 
reduced basal inhibitory rhythmic activity also documented in the CA3 (Zhang et 
al., 2008). Finally recordings from the thalamus reveal alterations in the number 
and frequency of quantal GABAergic events in excitatory and inhibitory neurons 
(Zhang et al., 2010). More recently, mEPSC amplitude and frequency were 
unchanged but mIPSC quantal size reduced  in striatal neurons from mice in 
which Mecp2 was deleted from GABAergic neurons (Chao et al., 2010). These 
data suggest that MeCP2 is also required for the normal development of 
GABAergic circuits and loss of MeCP2 disrupts inhibitory neurotransmission. 
It is evident from the above experiments performed on Mecp2 knockout mice 
that an alteration in synaptic output is present. However, identification of the 
underlying components involved has caused some controversy. Possible 
explanations for varied results could be region or pathway specific differences or 
even variability caused by the different ages of the animals studied. A 
combination of both inhibitory and excitatory deficits is also plausible. 
Considering glutamategic neurons can synapse onto GABAergic interneurons, 
discrepancies in either constituent would directly affect the other and therefore 
contribute to overall changes in synaptic activity. Moreover all the work thus far 
has emphasised the importance of a balance between inhibitory and excitatory 
transmission for appropriate MeCP2 function which may be complementary to 
the morphological deficits observed.  
1.3.7.4 Long-term potentiation abnormalities in RTT mouse models 
Long term potentiation (LTP), is a form of synaptic plasticity and typically 
consists of a prolonged increase in synaptic transmission strength requiring NMDA 
receptor activation. Several studies, involving various mouse models of RTT, 
have demonstrated deficits in synaptic plasticity in symptomatic Mecp2 knockout 
mice through impairment in LTP at the Schaffer-collateral to CA1 pyramidal cell 
synapse (Asaka et al., 2006). To specify which synaptic elements are affected, 
Asaka et al did further work on paired-pulse facilitation (PPF) properties of 
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hippocampal neurons which is an assessment of presynaptic function. Mecp2 
knockout animals had lower PPF values compared to wild-type controls implying 
that deficits observed in excitatory neurotransmission may be linked to 
presynaptic function (Asaka et al., 2006). Another study found a reduction in LTP 
in the CA1 region of the hippocampus from symptomatic –mildly symptomatic 
Mecp2-deficient mice and that the LTP response became saturated, indicative of 
a ‘ceiling’ effect (Weng et al., 2011).  This suggests that a reduction in LTP 
could be associated with synapses from Mecp2-deficient mice already operate 
close to a maximal effect. Furthermore, decreases in LTP in the CA1 region of 
the hippocampus, motor and sensory cortex were also observed in mice 
expressing a truncated form of Mecp2 (Moretti et al., 2006). In contrast, LTP was 
enhanced in Mecp2 overexpressing mice (Collins et al., 2004). These results 
highlight the critical role for tightly regulated MeCP2 levels and that there are 
age dependent alterations in excitatory synaptic plasticity. 
In conjunction with deletion or overexpression of Mecp2 in neurons, deletion in 
specific neurons also recapitulates deficits in LTP. For example deletion of 
Mecp2 from GABAergic neurons results in an a reduction in fEPSP (field 
excitatory post synaptic potential) slope which becomes saturated upon a 
continual increase in stimulus (Chao et al., 2010), Furthermore, impairments in 
long term depression (LTD), the other synaptic plasticity phenomenon (a long-
lasting decrease in synaptic strength), have also been documented in Mecp2 
mutant mice. Low frequency stimulation in the CA1 region of the hippocampus in 
symptomatic Mecp2-deficient mice failed to elicit LTD (Asaka et al., 2006) and 
mice with a truncated  form of Mecp2 had an impairment in LTD (Moretti et al., 
2006). Collectively dysfunction in LTP and LTD could be the result of alterations 
in excitatory synaptic transmission or GABAergic mediated control of excitatory 
synaptic plasticity. This is evident upon the onset of RTT symptoms thus 
highlighting the important role MeCP2 has in the maturing nervous system.  
1.4 Function of MeCP2 
1.4.1 Transcriptional repressor 
Before the discovery of MECP2 as the primary cause of RTT (Amir et al., 1999), 
MeCP2  was shown to repress gene transcription upon binding to methylated DNA 
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(Nan et al., 1997). As mentioned previously, MeCP2 is a methyl binding domain 
protein which binds to DNA following the addition of a methyl group to carbon-5 
of the cytosine pyrimidine ring (DNA methylation); principally at CpG 
dinucleotides (cytosine and guanine separated by a phosphate). Once bound, the 
proteins are traditionally thought to recruit a large repressor complex and 
chromatin remodelling proteins such as HDAC proteins which suppresses gene 
transcription by chromatin compaction (Jones et al., 1998). Figure 1-5 below 
demonstrates how MeCP2 is postulated to function and what might happen 








Figure 1-4 Conventional function of MeCP2 as a transcriptional repressor 
The left diagram represents how MeCP2 is postulated to function by binding to methylated DNA 
and recruitment of downstream genes through recruitment of chromatin remodelling proteins such 
as HDAC. The right diagram is a hypothetical situation of what might happen if there was a 
mutation in MeCP2. The protein would become non-functional potentially inhibiting the binding of 
MeCP2 to DNA and thus transcription of genes. This diagram is modified from 
McIntyre et al., 2007. 
MeCP2 binds to methylated DNA through interaction with the methyl-CpG-
binding domain and recruits transcription factors and chromatin remodelling 
proteins, such as Sin3A, HDAC and methyl transferases, through the 
transcriptional repression domain (Jones et al., 1998; Nan et al., 1997). 
However, it is suggested the transcriptional repression of MeCP2 could be 
chromatin independent too by means of inhibiting the basal transcriptional 
machinery through interaction with general transcription factor IIB (Kaludov and 
Wolffe, 2000). Furthermore, repression is also thought to occur by MeCP2-
mediated chromatin remodelling. This involves MeCP2 acting to form a loop of 
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inactive, methylated chromatin which regulates gene expression by containing 
deacetylated histones which condense the DNA and restrict transcription (Horike 
et al., 2005). Either way, mutations in MECP2 could affect any area of these 
processes resulting in a partially functioning protein or a complete breakdown in 
operation. Consequently, the progression of aberrant gene expression was 
expected with mutations in MeCP2 and a role as a transcriptional repressor. 
1.4.1.1 Altered gene expression 
Since MeCP2 is postulated to a repressor of gene expression it would be 
expected that its absence would lead to increased expression of downstream 
genes. General gene expression profile analysis has reported that less than 5% of 
genes show considerable differences in regulation (Tudor et al., 2002). One 
reason for this might be that MeCP2 regulates different sets of genes in diverse 
cell types, therefore whole brain studies would fail to produce accurate results.  
However several target genes have been identified. Firstly through the use of 
chromatin immunoprecipitation (ChIP) and mouse models expressing different 
gene types, brain-derived neurotrophic factor (Bdnf) was first discovered as a 
target of MeCP2 (Chen et al., 2003). In knockout mice they found a two-fold 
increase in the Bdnf exon IV-specific mRNA compared to WT and suggest that 
neuronal activity regulates BDNF in a promoter specific manner whereby MeCP2 
is released from a BDNF promoter upon depolarisation. BDNF is a member of the 
neurotrophin family that are classified as secretory proteins involved in neuronal 
survival and differentiation during early brain development therefore 
highlighting a potential role for MeCP2 in regulating this process. Conversely, 
mice lacking Mecp2 have been shown to have a reduction in Bdnf protein levels 
in the cortex (Chang et al., 2006). However as levels of BDNF are controlled by 
neuronal activity the overall decline in cortical neuronal activity seen in Mecp2 
knockout mice could explain this occurrence. 
Other targets of MeCP2 include imprinted genes, such as DLX5. Parental 
imprinting involves epigenetic marks such as methylation being placed on certain 
genetic loci during early embryonic development causing the silencing 
(imprinting) of expression of a specific gene on one parental chromosome only 
(LaSalle, 2007). Dlx5 and neighbouring gene Dlx6 reside on chromosome six and 
regulate the production of GABAergic neurons in the brain. These genes appear 
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to be up-regulated in Mecp2 knockout mice but have unmethylated CpG islands 
(Horike et al., 2005). However, Mecp2 binds to methylated sequences and forms 
a silent chromatin loop (compact DNA) between the two genes which regulates 
Dlx5 expression.  Mecp2-deficient mice have  active chromatin and wider loops 
resulting in greater access to the Dlx5 region and a subsequent increase in 
expression (Horike et al., 2005), however other studies have contradicted this 
process. Schüle et al analysed the imprinting of the Dlx6 gene using real time 
quantitative reverse-transcriptase polymerase chain reaction assays for the 
expression of Dlx5 and Dlx6 in the forebrain of mutated mice and found that 
there was no significant difference between control and mutated samples. 
Similar results were found in human cell lines (Schüle et al., 2007). This suggests 
that DLX5 and DLX6 are not imprinted in humans and are unlikely to be 
modulated by MeCP2 thereby questioning their role in RTT and highlighting the 
importance of specificity in brain cell type for the clarification of results. 
Glucocorticoid genes, including corticosterone (McGill et al., 2006), and  
glucocorticoid-inducible genes, serum glucocorticoid-inducible kinase 1 (Sgk1) 
and FK506-binding protein 51 (Fkbp5; Nuber et al., 2005) have also been shown 
to be upregulated in Mecp2 mutant mice. Normally, activation of the 
hypothalamic-pituitary-adrenal (HPA) axis via corticotrophin-releasing hormone 
(CRH) leads to the release of a steroid hormone corticosterone from the adrenal 
cortex into the bloodstream whereby it can moderate stress levels (Bale et al., 
2002). In a study containing truncated Mecp2 mice, there was elevation in 
corticosterone levels, which suggests increased HPA axis activity giving rise to an 
amplified response to stress. A considerable over-expression of the Crh gene in 
areas of the brain essential for behavioural and physiological responses to stress 
is reported such as the hypothalamus and central nucleus of the amygdala 
(McGill et al., 2006). Furthermore, another study using Mecp2-deficient mice 
and cDNA microarrays, has also reported an increase in the expression of two 
glucocorticoid-inducible genes Sgk1 and Fkbp5 (Nuber et al., 2005). Methylated 
CpG sites are present in these regions and MeCP2 is speculated to bind the 
regulatory regions of these genes and modulate their function. Sgk1 is involved 
in neurotransmission, for example through sodium and potassium channel 
activation and is therefore likely to be involved in a various aspects of neuronal 
communication, and thus development. Fkbp5 encodes a glucocorticoid 
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receptor-regulating co-chaperone of Hsp90 (heat shock protein 90), a chaperone 
involved in steroid hormone signalling (Nuber et al., 2005). Consequently 
modulation of neuronal maturation and transmission could be indirectly affected 
by MeCP2. 
1.4.2 Regulation by activity  
Corresponding with the hypothesis of repression is the concept of neuronal 
activity regulating gene expression profiles (Zhou et al., 2006). At an early age, 
sensory experience is thought to play an important part in synaptic organization 
of the brain. Considering that  RTT symptoms first become prominent at the 
same time as synapses are being intensively pruned in response to environmental 
stimuli, it is possible that inappropriate connectivity due to irregular 
experience-dependent synaptic modifications may be a cause of pathology. 
Membrane depolarization together with a calcium influx into the cell has been 
linked to phosphorylation of MeCP2 and the activation of downstream target 
genes (Chen et al., 2003). Using a phospho-site-specific antibody, 
phosphorylation of MeCP2 specifically at amino acid residue S421 in the brain has 
been connected with dissociation from methylation sites and activation of genes 
associated with dendritic growth and spine maturation (Zhou et al., 2006). 




















Figure 1-5 Activity-dependent phosphorylation of MeCP2 
Upon induction of neuronal activity, calcium influx into the cell via long-lasting voltage sensitive 
calcium channels (L-VSCCs) or N-methyl-D-aspartate receptors (NMDAR) activates a 
calcium/calmodulin-dependent protein kinase II (CaMKII) which phosphorylates MeCP2 at S421. 
Alternatively neurotrophins, such as BDNF binding to tyrosine kinase (TrK) receptors, can also 
trigger the phosphorylation of MeCP2 via calcium independent mechanisms. This results in 
detachment from methylated DNA sites (black dots) and activation of gene transcription. This 
diagram is adapted from McIntyre et al., 2007 and Zhou et al., 2006. 
It is possible that some missense MECP2 mutations could lead to a deficiency in 
the ability of MeCP2 to be phosphorylated in response to activity. This could lead 
to abnormal regulation of neuronal connectivity and maturation and could 
explain some of the milder Rett phenotypes seen in some patients. More 
recently, phosphorylation of Mecp2 at a different site, serine 80 (S80), is thought 
to be negatively regulated by neuronal activity whereby dephosphorylation 
occurs upon membrane depolarisation (Tao et al., 2009). It is suggested that S80 
phosphorylation is associated with MeCP2 function in resting neurons and S421 
phosphorylation in depolarised neurons thus altering gene transcription from a 
repressed to activated state respectively (Tao et al., 2009). Mutations in MECP2 
at either of these regions would interfere with this process leading to altered 
gene expression. Overall, these findings suggest a role for activity-dependent 
regulation of MeCP2. 
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1.4.3 Transcriptional activator 
It is hypothesised that in addition to MeCP2s role as a transcriptional repressor it 
could also be involved in activation of genes (Chahrour et al., 2008;  
Yasui et al., 2007). Using a ChIP-on-chip approach, Yasui and colleagues carried 
out an epigenomic binding analysis of known or implemented MeCP2 gene 
targets and discovered that 62.6% of MeCP2-bound promoters were actively 
expressed. In addition they found the binding sites for MeCP2 to be mainly non-
methylated. These results clearly challenge the previous theory of 
transcriptional repression however given the study was performed using 
neuroblastoma cells, the data may not truly reflect the product observed in 
normal neuronal tissue. 
Nonetheless in agreement with this work was a study carried out by Chahrour et 
al the following year (Chahrour et al., 2008). They decided to analyse the gene 
expression profiles in the hypothalamus of mice that have no Mecp2 present or 
those that have double the amount in the hope of deciphering more information 
into the molecular mechanism of MeCP2. Through the use of microarray analysis, 
a variety of genes were found to be altered in both cases. Surprisingly around 
85% of these genes appeared to be activated not repressed. ChIP work with the 
antibody for Mecp2 confirmed that Mecp2 bound to the promoter region of six of 
the activated genes (Sst, Oprk1, Mef2c, Gamt, Gprin1 and A2bp1). The same 
group also identified Mecp2 to bind to the promoter region of the transcriptional 
activator CREB1 and also associate with this protein at the promoters of 















Figure 1-6 Activation of target genes. 
MeCP2 is postulated to bind methylated DNA and recruit transcriptional activator proteins such as 
CREB1 at the promoters of active target genes thereby activating gene transcription. This diagram 
is adapted from McIntyre et al., 2007. 
This data supports the idea that MeCP2 has a role in activating target genes and 
not just repressing them. In this instance, one explanation for these results 
might be that MeCP2 is repressing a transcriptional repressor therefore 
activation of the targets of this repressor would occur. Another explanation is 
that the changes observed might be secondary to the physiological properties of 
the hypothalamus. In any case these results propose a more complex mechanism 
of transcriptional regulation by MeCP2 with a variety of genes being either 
positively or negatively regulated. 
1.4.4 Global regulator of chromatin structure 
More recently, MeCP2 has been hypothesized to have a genome wide function 
(Skene et al., 2010). Using ChIP analysis, Mecp2 was found to bind methylated 
regions of DNA in neurons globally throughout the entire genome and not at 
defined gene promoters. Consistent with this, the same group identified the 
levels of Mecp2 to be comparable to that of histone octamers, quantified as one 
molecule of Mecp2 to every two nucleosomes.  Furthermore they also found that 
Mecp2 can globally alter the chromatin state with a two fold increase in histone 
H3 acetylation levels found in Mecp2-deficient mice compared to WT controls 
(Skene et al., 2010). This data suggests that MeCP2 might have a genome wide 
effect on chromatin structure rather than control the expression of specific 
genes. 




The overall theme of this thesis is to explore the interactions between neuronal 
activity, the putative transcriptional repressor MeCP2 and levels of histone 
protein acetylation. My hypothesis is that neuronal activity modulates MeCP2 
and that this is in turn linked to alterations in histone acetylation. As histone 
acetylation is related with a more open chromatin state  (reviewed by 
MacDonald and Roskams, 2009), MeCP2 may link neuronal activity with the 
regulation of  gene transcription. This proposed interaction is shown in cartoon 
format in Figure 1-8. In addition to the actions of neuronal activity on MeCP2 
signalling, I am also interested the reverse relationship, that of how functional 
MeCP2 may in turn impact on neuronal activity. For this I pay particular 
emphasis on how MeCP2 may regulate excitability at the level of the neuronal 
network. This has significance in RTT in which lack of functional MeCP2 may 
have network excitability consequences. 
Thus, the specific research questions can be stated as follows: 
i. How does the presence or absence of functional MeCP2 affect neuronal 
network level activity and excitability in the brain? 
ii. How does neuronal network activity affect putative MeCP2 regulation of 


















































Figure 1-7 Hypothesis of how MeCP2 controls gene expression in response to neuronal 
activity. 
Under basal conditions, MeCP2 could bind methylated DNA (black dots) and repress downstream 
genes through recruitment of histone deacetylase proteins (HDACs) which lead to a closed 
chromatin state. However upon induction of neuronal activity, MeCP2 becomes phosphorylated (P) 
which could activate downstream genes through recruitment of histone acetyltransferase proteins 
(HATs). These proteins acetylate (Ac) lysine residues on histone tails and result in an open 
chromatin structure which enables transcriptional machinery to enter start transcribing genes. This 





Materials and Methods 
  
2.1 Animal Models 
2.1.1 Generation of the Mecp2 knockout mouse models 
Two mice models were used in which Mecp2 was either silenced or knocked out. 
The first model used Cre-loxP technology to delete exon 3 and 4 of the 
endogenous mouse Mecp2 gene to create a structural knockout mouse (Guy et al, 
2001). The second model used the insertion of a lox-Stop cassette into intron 2 
of the mouse Mecp2 gene to create a functional knockout mouse (Guy et al, 
2007). When heterozygous (Het) females are mated with wild-type (WT) males, a 
mixture of offspring is generated in a ratio of 1:1:1:1 as summarised in Table 2-
1. 
 
Table 2-1 Offspring generated from Mecp2 knockout mouse models 
Female  WT  male  (Mecp2+/y)   
Mecp2+/- Sex Female Female Male Male 








Mecp2stop/+ Sex Female Female Male Male 









Both models were housed at the University of Glasgow. Heterozygous females 
(Mecp2+/- and Mecp2stop/+) were bred on an inbred C57BL6/J background to 
generate offspring as mentioned above. Mice aged 6-10 weeks from these 
colonies were used in all experiments. However a subset of experiments were 
conducted using heterozygous female mice aged 10-13 weeks engineered to 
express a Mecp2-EGFP fusion by a targeted gene knock-in in mouse ES cells 
(generated in Adrian Bird’s laboratory at the University of Edinburgh; 
Mecp2tm3.1Bird, Jackson Laboratories stock no. 014610). Mecp2 status was 
detected in cells by the presence or absence of fluorescence in living or fixed 
cells. These heterozygous females (Mecp2GFP/-) were produced by breeding 
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Mecp2+/- females with Mecp2GFP/y males (supplied by Adrian Bird’s laboratory) on 
a C57BL6/J background.  
 
Offspring genotypes from all colonies were determined by Polymerase Chain 
Reaction (PCR).  Mice were housed in groups with littermates, maintained on a 
12 hour light/dark cycle and provided with food and water ad libitum. 
Experiments were carried out in accordance with the European Communities 
Council Directive (86/609/EEC) and a project license with local ethical approval 
under the UK Animals (Scientific Procedures) Act (1986). 
 
2.1.2 Genotyping 
2.1.2.1 DNA Extraction  
DNA samples were taken from mouse ear samples and placed into pre-labelled 
200µl PCR tubes (Fisher Scientific, UK) with 20µl of a DNAreleasy reagent 
(Anachem ltd, UK). Each sample was then positioned into a GeneAmp thermal 
cycler (PCR system 9700; Applied Biosystems, UK) and run under the following 
conditions stated in Table 2-2. 
Table 2-2 DNA extraction conditions 





2.1.2.2 PCR confirmation of genotypes 
Extracted DNA was diluted in autoclaved dH20 (1/10) before two sets of PCR 
reactions were carried out on each DNA sample to enable characterisation of 
genotype. The first reaction contained primers that would anneal to the WT 
Mecp2 allele (forward primer = P5, reverse primer = P7) and the second reaction 
include primers that would anneal to the Mecp2 knockout allele (forward primer 
= P5, reverse primer = P6). All primers were designed by Guy et al, 2001. The 
contents of each PCR reaction (placed in separate labelled PCR tubes) is 
summarised in Table 2-3.  
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Table 2-3 Contents of each PCR reaction 
Reagent WT Mecp2 allele Mecp2 knockout 
allele 
Thermo-start HP PCR master mix 13µl 13µl 
Autoclaved water 9µl  9µl 
Forward Primer P5 1µl (0.4µM) P5 1µl (0.4µM) 
Reverse Primer P7 1µl (0.4µM) P6 1µl (0.4µM) 
DNA sample 2 µl (5-10ng) 2 µl (5-10ng) 
Final Volume 26µl 26µl 
 
These two PCR reactions were subsequently run under identical conditions on a 
GeneAmp thermal cycler (PCR system 9700) as stated in Table 2-4. 
 
Table 2-4 PCR conditions for both reactions 
Step Temperature (°C) Time  
Initial de-naturation 94 15 minutes 
 X 35 cycles  
De-naturation 94 45 seconds 
Annealing 61 45 seconds 
Extension 72 45 seconds 
   
Final extension 72 10 minutes 
Hold 4 infinity 
 
Finally the PCR products from each PCR reaction were mixed with 3µl of 5 x DNA 
loading dye and separated according to their size by gel electrophoresis on a 
pre-made 0.8% agarose gel at 110 volts for one hour. Upon completion, 
separated PCR products were visualised using an UV transilluminator (UV-TM-40; 
Upland, USA; wavelength 254nm) and photographed using Canon digital camera 
(PC1192; Japan) to confirm genotype status. An example of such a gel is shown 
in Figure 2-1. 
As discussed previously, in order to distinguish the genotype of each DNA sample 
two PCR reactions were performed. The first lane of each sample was loaded 
with the PCR product from the WT Mecp2 allele (producing a 416bp band) and 




 1       2      3        4       5       6      7       8        9      10     11    12   13     14     15 
16  17  18  19  20   21  22   23  24  25   26  27  28  29  30   31  32  33   34   35 
       
          
POSITIVE NEGATIVE HET HET HET WT WT 
HET HET WT WT WT WT WT WT HEMI HEMI 
500bp 
the second lane was loaded with the PCR product from the Mecp2 knockout 
allele (generating a 470bp band). WT mice (male and female) were identified by 
the presence of a band only in the WT Mecp2 allele lane, a hemizygous male 
would only generate a band in the Mecp2 knockout allele lane, and a 
heterozygous female mouse would display a band in both lanes. 
 
Figure 2-1 Genotype verification by PCR 
Representative gel image showing the genotypes of mice that were verified by PCR. Each DNA 
sample from a mouse is represented by two lanes (two PCR reactions) – the first identifies the WT 
Mecp2 allele and the second identifies the Mecp2 knockout allele. Heterozygous (Het) female mice 
(blue) contain a band in both lanes (e.g. DNA sample in lane 6 and 7), WT mice (red) have a band 
in the first lane only (e.g. DNA sample in lane 12 and 13) and hemizygous (hemi) male mice 
(green) contain a band in the second lane only (e.g. DNA sample in lane 20 and 21). The genotype 
of a known heterozygous female mouse is used as a positive control for the PCR reaction (lane 2 
and 3) and a sample with no DNA is used as a negative control (lane 4 and 5). A 1kb DNA ladder 
(New England Biolabs, UK) is loaded in lane 1. 
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2.2 In vitro hippocampal slice experiments 
2.2.1 Acute slice preparation 
Mecp2stop/y mice and their wild-type litter mates were culled by cervical 
dislocation, followed by decapitation; all conducted under Schedule 1 
procedures under the Home Office Animals (Scientific Procedures) act 1986. The 
brain was quickly removed and transferred to ice-cold, oxygenated (95% O2, 5% 
CO2) sACSF. Next the cerebellum and a small section of the frontal cortex were 
removed before the brain was hemisected down the midline. The two 
hemispheres were then placed on the side that was just cut and the inside dorsal 
part of the brain was cut away as show in Figure 2-2. Subsequently this region of 
each hemisphere was fixed with cyanoacrylate glue (Loctite, UK) onto the stage 
of a vibratome (Leica VT1200S; Leica Microsystems, Germany). Transverse tissue 
slices (400µm) were cut and the hippocampus removed from the adjoining 
tissue. Slices were immediately transferred to a submerged chamber perfused 
with oxygenated (95% O2, 5% CO2) sACSF maintained at 34ºC. After 30 minutes, 
slices were either kept at 21°C in the same chamber (for later use) or placed 
directly into an interface chamber kept at 34°C where they were left to 
equilibrate for a further 30-60 minutes before recording commenced. This 





























   
Figure 2-2 Mouse brain orientation and hippocampal slice preparation. 
(A) Birds eye view of a real mouse brain and anatomical orientations. (B) Schematic diagram of 
how the brain is dissected in preparation for obtaining transverse hippocampal slices: (1) the frontal 
cortex and cerebellum are removed; (2)–(3) the brain is hemisected down the midline and (4) then 
the two hemispheres are placed on their side that was just cut and an incision is made into the 
inside dorsal part of each brain section. This region of each hemisphere is then fixed with 
cyanoacrylate glue onto a vibratome.  
2.2.2 Extracellular recording 
2.2.2.1 Bicuculline and 4-aminopyridine (4-AP) administration 
Recording glass microelectrodes were made from standard walled (1.2mm O.D. x 
0.69mm I.D.) borosilicate glass capillaries (Harvard Apparatus, UK) and pulled on 
a Flaming/Brown micropipette puller (Model P-87, Sutter Instrument Co., USA) 
with a tip resistance of ~1-5MΩ. Stimulating electrodes were made from bipolar 
tungsten wire (World Precision Instruments, USA) to which current was delivered 
through an isolated current stimulator box (Model D52A, Digitimer Ltd, UK). 
Recording electrodes were filled with ACSF and positioned in the stratum 
radiatum of area CA1 whilst stimulating electrodes were positioned in the 
Schaffer-collateral afferent fibres (axons from pyramidal cells in the CA3 region) 
to record field excitatory postsynaptic potentials (fEPSPs).  
Recordings were amplified (10X) using an Axoclamp 2A amplifier (Molecular 
Devices, USA) in bridge mode, filtered (100 kHz) with a Brownlee Model 440 
Signal Processor (Brownlee Precision Co, USA) and digitized at 10 kHz (Digidata 
1322A, Axon Instruments) onto two PC hard discs using WinWCP data acquisition 
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software (John Dempster, University of Strathclyde; Glasgow, UK) and Axoscope 
software (Molecular devices, USA). A Hum Bug 50/60Hz noise eliminator (Quest 
Scientific, UK) was also used to reduce background electrical noise (50Hz). All 
recordings used a stimulus protocol comprised of pulses that were 10ms apart. 
Stimulus intensity for each experiment was determined at the start by obtaining 
an input-output curve for each slice though increasing the stimulating current 
pulse in 0.2 increments from a low current pulse (~0.02mA-0.32mA) to the point 
a maximal fEPSP was generated. The current pulse equating to half of this 
maximal response was then used for the entire experiment. Subsequently, 
evoked fEPSPs and spontaneous fEPSPs were monitored simultaneously during a 
10 minute baseline and following either bicuculline (Abcam, UK) or 4-
aminopyridine (Sigma Aldrich, UK) administration. An input-output curve was 
also performed at the end of each experiment. 
2.2.2.2 Kainic acid administration 
ACSF-filled glass microelectrodes were placed in the CA3 stratum radiatum. 
Recordings were amplified (10X) with the signal low pass filtered at 100Hz as 
before. The signal was amplified by a further 1000X using the Brownlee model 
440 instrumentation amplifier and digitized at 4kHz onto PC hard disk using 
Axoscope software (Molecular devices). Following two minute baseline 
recording, kainic acid (Abcam; 400nM) was administered for one hour before a 
further two minute recording was taken from each slice in the chamber (up to 
six). Subsequently, NBQX (5µM) was co-applied and additional two minute 
recordings were collected. Gamma oscillations were identified as high frequency 
field potential oscillations and confirmed offline using power spectrum and 
autocorrelation analysis. 
2.2.3 Data analysis  
For extracellular bicuculline and 4-AP experiments event analysis was conducted 
offline using Christoph Schmidt-Hieber’s Stimfit 0.9 software (evoked EPSPs; 
http://www.stimfit.org/) and Clampfit 9.0 software (spontaneous EPSPs; 
Molecular devices, USA). Event analysis for extracellular kainic acid experiments 
was conducted using Axograph X software (Molecular devices) offline. Fast 
Fourier Transform (FFT) was used on each two minute recording to create a 
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power spectrum of gamma oscillations formed by averaging segments of 1024 
data points. Total power was calculated as the area under each power spectrum 
between 20-80Hz and peak frequency was taken as the dominant peak in this 
region. Samples were defined as epileptic and removed if moderate levels of 
spontaneous spiking events were detected in the baseline recording. 
Epileptiform baselines were defined as greater than 30 events in a two minute 
trace.  
2.3 In vivo kainate experiments 
2.3.1 Administration of anaesthesia and kainic acid 
Mecp2stop/y, Mecp2-/y, Mecp2+/-, Mecp2GFP/- mice and their WT littermates (male 
and female) were injected with kainic acid (Abcam; 25 mg/Kg IP in 0.9% saline) 
or 0.9 % saline (vehicle control). Each mouse was weighed just before the start 
of each experiment and the appropriate dose to be given was calculated.  For 
most experiments, mice were maintained under light isoflurane anaesthesia 
(2.5-3%) to reduce suffering. This involved mice being placed into a transparent, 
sealed plastic box with a constant and controlled supply of isoflurane added 
(5%). Once mice were unconscious (lying still with only breathing movements) 
kainic acid or saline was then given. A subset of experiments was also conducted 
in the absence of anaesthesia in which mice were injected with either kainic 
acid or saline and then placed into the same transparent plastic box (Figure 2-3). 
2.3.2 Seizure Score 
Initial seizure scoring of mice that were given kainic acid was carried out in real 
time by observing the animals and logging the score every five minutes for three 
hours. In addition, all experiments were captured by a video camera, positioned 
below the transparent plastic box, which was connected to a computer. This set-
up is shown in Figure 2-3. Furthermore, every mouse was marked with a 















Figure 2-3 Set-up used for monitoring the seizure scoring 
The set-up used for monitoring seizure scoring consists of a plastic transparent box with a video 
camera placed underneath which is connected to a computer. When the mice are under 
anaesthesia, the air vents are kept connected to the isoflurane. All mice have a different colour 
stripes on their tails to identify them during scoring. 
Seizure score was modified into eight stages from a previously documented scale 
(Racine, 1972) and an illustrated example of the seizures developed with and 
without anaesthesia can be seen in Figure 2-4. To ensure a roughly even number 
of animals was in each group, mice were genotyped before conducting the 
experiments. As all experiments were carried out by the same person, the 
seizure scoring of mice was not performed blind. Seizures comprised of fast 
breathing and erratic twitches in the early stages before development of tail 
shaking, forelimb clonus (front paw shaking) and ultimately full tonic-clonic 



















Stage Without anaesthesia With anaesthesia 
0 Normal exploratory activity Lying still with controlled 
breathing 
1 Hunched/immobile behaviour with 
fast breathing 
Lying still with fast breathing 
2 Generalised spasm/twitch or 
scratching behaviour 
Lying down with generalised 
spasm/twitch 
3 Tail extension (with or without 
shake) 
Lying down with tail extension 
(with or without shake) 
4 Forelimb clonus (forepaw shake) Lying down with forelimb clonus 
5 Forelimb clonus plus tail shake 
(one time)/ loss of balance 
Lying down with forelimb clonus 
plus tail shake (one time) 
6 Continuous forelimb clonus plus 
tail shake (>2)/ hyperactive 
seizures 
Continuous forelimb clonus plus 
tail shake (>2) 
7 Full body extension (full tonic 
extension) 
Full tonic-clonic seizures/ 
hyperactive seizures 
8 Death Death 
Figure 2-4 Illustrated example of seizure score upon IP injection of kainic acid in mice 
(A) Diagrammatic examples of the eight seizure score stages (amended from (Racine, 1972). Note, 
the examples are from mice without anaesthesia. (B) Descriptive explanation of each illustrated 
seizure stages with and without anaesthesia. Seizures comprised of fast breathing and erratic 
twitches in the early stages before they develop tail shaking, forelimb clonus (front paw shaking) 
and ultimately full tonic-clonic seizures in later stages. Animals with anaesthesia exhibit almost 
identical phenotypes to mice administered kainic acid without anaesthesia except they are lying flat 
from being unconscious.  
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2.3.3 Tissue preparation for protein analysis 
Following kainic acid-induced seizures, mice were handled in two manners. For 
western blot analysis, mice were killed by cervical dislocation and decapitation. 
The hippocampi were then quickly removed from each hemisphere and placed in 
1.5ml eppendorf tubes (Greiner bio-one, UK) before being snap frozen in liquid 
nitrogen to be stored at -20°C for later use. For tissues required for 
immunohistochemistry, mice were anaesthetised with sodium pentobarbital 
(Euthatal) at a dose of 100 mg/kg body weight (Merial Animal Health Ltd., 
Harlow, UK) in preparation for intracardiac perfusion. Subsequently having 
confirmed no reflexes were present in the mice, the chest of each mouse was 
opened up to expose the heart and a perfusion needle was inserted into the left 
ventricle. A small cut was made in the right atrium of the heart and saline 
solution was flushed through the animal briefly to clear blood vessels. Finally 
300ml of 4% paraformaldehyde (PFA) in 0.1M PB (pH 7.5) was perfused through 
the needle to fix the mouse. At the end of the process the mouse would be 
completely rigid with an almost clear liver. Whole brains were subsequently 
removed, post-fixed overnight in the same fixative at 4°C then transferred to 
30% sucrose (Fisher Scientific) in 0.1 PBS. Brains were cut into blocks and 
coronal brain sections (30µM) were cut on a vibratome (Leica VT1000 
microtome, Leica Microsystems) and then placed in a solution of 50% ethanol 
(BDH Laboratories, UK) dissolved in dH2O for 30 minutes to aid future antibody 
penetration. Finally sections were washed three times in 0.3M PBS and placed in 
100% glycerol (Sigma-Aldrich) to be stored at -20°C and used for 
immunohistochemistry. 
2.4 Protein analysis 
2.4.1 Western blot 
2.4.1.1 Protein quantification 
Hippocampal extracts for western blot analysis were homogenised in 500µl cell 
lysate buffer by grinding in a 1.5ml eppendorf tube (Greiner bio-one) with a 
plastic pestle (Sigma-Aldrich, Z359947) with no removal of tissue. Optimisation 
of this nuclear preparation method is shown in Appendix A (Supplementary 
Figure 1-1). A Bradford protein assay was then used to normalise the protein 
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content of the hippocampal lysates. This was achieved by comparing each 
hippocampal lysate against a standard curve of known protein content – Bovine 
Serum Albumin (BSA; Sigma-Aldrich) dissolved in dH2O to obtain a concentration 
range including (in mg/ml) 0, 0.25, 0.50, 1, 1.5 and 2. Each hippcampal lysate 
(diluted 1/100) and BSA standard was mixed with diluted (1:1 in dH2O) Bio-Rad 
protein assay dye reagent (Bio-Rad laboratories, UK). Subsequently each 
standard and hippocampal lysate was pipetted twice into a 96-well plate and the 
absorbance measured with an Opsys MR plate reader (Dynex Technologies, UK) 
using Revelation Quicklink software (Dynex Technologies, version 4.25) at a 
wavelength of 595nm. The average reading of the blank wells (0mg/ml BSA) was 
subtracted from the other standards and the standard curve plotted using a 
linear curve fit. An example of this curve fitting and absorbance calculation is 







Figure 2-5 BSA curve fitting in a Bradford protein assay. 
An example of a BSA standard curve used for quantifying the protein content of unknown 
hippocampal lysates. A linear regression is used to determine the line of best fit and calculate 
absorbance of the unknown samples.   
Finally, once read the measurements for each hippocampal lysate, taken from 
the Revelation Quicklink software, were multiplied by 100 to compensate for the 
dilution factor applied at the start.  
2.4.1.2 General method 
Hippcampal lysates of known protein content were made up to equal working 
concentrations using appropriate volumes of ddH2O. Samples were then 
thoroughly mixed with 4x lithium dodecyl sulfate (LDS) sample buffer (Life 
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Technologies, UK) at a ratio of 2/3 protein to 1/3 LDS before being boiled for 5 
minutes to shear genomic DNA. Equal amounts (20µg) of each sample and 
Prestained Protein Ladder (Fermentas, UK) were electrophoresed through a 4-
12% Bis-Tris NuPAGE gel (Life Technologies) in 20 X NuPAGE MOPS running buffer 
(diluted 1/20, Life technologies) at 120V for two hours. Proteins were then 
transferred using Transfer buffer to polyvinylidene difluoride (PVDF) membranes 
(Life Technologies) for 90 minutes at 30V, 220mA. Membranes were rinsed in 
ddH2O and soaked in Ponceau red (Sigma-Aldrich) for five minutes to check 
transfer efficiency. 
Subsequently, membranes were placed in blocking solution containing 5% (w/v) 
dried skimmed milk powder (Marvel), diluted in Tris buffered saline (TBS) for 
one hour and probed over night at 4ºC with primary antibodies (Table 2-5) in the 
same blocking solution. The only exception was the primary antibody anti-pS421 
MeCP2 which was incubated in a solution containing 5% (w/v) bovine serum 
albumin (Sigma-Aldrich) diluted in TBS. The next day, handling of the 
membranes differed depending on the exposure technique. With exposure to 
enhanced chemiluminescence (ECL), membranes were washed three times in  
TBS containing 0.1% Tween-20 (TBST; Sigma-Aldrich) for 10 minutes each before 
incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies 
(Table 2-5) in blocking solution for one hour at room temperature. Following 
three more washes in TBST, membranes were incubated in Immobilon Western 
Chemiluminescent HRP Substrate (Millipore, UK) using equal quantities of 
luminol and peroxide solution for five minutes on a shaker. Finally membranes 
were placed into a cassette and developed using x-ray films (Kodak, UK) on a 
Kodak X-OMAT 2000 processor with the exposure time varied depending on the 
antibody used. In each case the aim was to achieve an optimal balance between 
signal-background ratios. 
Conversely, membranes exposed to an infrared scanner were washed three times 
for 15 minutes each in TBST before being blocked for 30 minutes in 5% milk 
blocking solution. Fluorescent secondary antibodies (Table 2-5) were applied to 
the same solution for one hour in the dark. Membranes were washed four times 
in TBST (five minutes each) in the dark then a further five times in TBS to 
remove any Tween-20. Finally, results were visualised using an Odyssey Infrared 
Imaging Systems scanner (LI-COR Biosciences, USA). 
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Table 2-5 Primary and secondary antibodies used for western blots 
Antibody Dilution Supplier 
Primary    
Mouse anti-MeCP2 1/1000 Sigma- Aldrich 
Rabbit anti-MeCP2 1/1000 Millipore 
Rabbit anti-pS421 MeCP2 1/2000 Gift from Greenberg 
lab in the USA 
Mouse anti-NeuN 1/2000 Millipore 
Rabbit anti-acetyl-Histone H4 1/5000 Millipore 
Rabbit anti-acetyl-Histone H3 1/10,000 Millipore 
Rabbit anti-Histone H3 1/20,000 Abcam 
Rabbit anti-c-Fos 1/1000 Millipore 
Rabbit anti-Egr-1 1/1000 Santa Cruz 
Biotechnology, USA 
Mouse anti-GAPDH 1/2000 Santa Cruz 
Biotechnology 
  Secondary   
Goat anti-Rabbit IgG HRP 
(ECL) 
Range 1/5000-1/20,000, 
depending on primary 
Millipore 
Goat anti-Mouse IgG HRP 
(ECL) 
1/5000 Millipore 
IRDye 800CW Goat anti-Rabbit 
IgG (infrared) 
Range 1/5000-1/10,000, 
depending on primary 
LI-COR 




2.4.1.3 7% gel electrophoresis  
To resolve Mecp2 (75kDa in weight) and quantify absolute levels of 
phosphorylated Mecp2 protein, 7% gels were used for electrophoresis in some 
experiments to resolve the higher weight protein. 7% polyacrylamide resolving 
and stacking gels were prepared as stated in the general material section in this 
chapter and 60-80µg of hippocampal lysates were run in Tris-glycine buffer 
overnight (4°C) slowly at 15mA. The gel was kept running until the 55kDa band 
on the Prestained Protein Ladder ran off the gel. The gel was then cut at the 
appropriate size and the western blot performed as described above.  Mecp2 was 
immunostained with the rabbit anti-MeCP2 antibody from Millipore and 
visualised by ECL. 




The x-ray films developed from ECL were scanned onto a computer in colour 
using a flat-bed HP Scanjet 4400c scanner and protein intensity quantified using 
the analysis of gels option in Image J software (http://rsbweb.nih.gov/ij/) as 
shown in the example in Figure 2-6. This involved images being converted into 
grayscale and, using the rectangular selection tool, large rectangles were drawn 
around each band of interest in turn. Subsequently, a profile plot was created 
for each selected area and a straight line was drawn at the base of each peak, 
from one side to the other to enclose the area of the peak (the tails to either 
side of the peak were the background signal). Finally, using the wand tracing 
tool to select each peak, the size could be expressed as a percentage of the 
total size of all the measured peaks. If a loading control was present the 
percentage value of the protein of interest was divided by the loading control 
(NeuN) percentage to get a relative intensity.      






Figure 2-6 Analysis of western blots in Image J 
(A) Rectangles are drawn around the bands of interest and (B) a profile plot is then created for 
each band. A line is drawn at the base of each peak to enclose the area of each peak with tails on 
either side encompassing the background signal. Each peak is selected (yellow) and the size 
calculated. 
Probing for Mecp2 run on a 7% gel, highlighted two bands around 75 kDa in some 
hippocampal lysate samples (the top band = phosphorylated Mecp2 and the 
bottom band = unmodified MeCP2). To quantify the total levels of 
phosphorylated Mecp2, the percentage value of the top band was divided by the 
sum of the percentage values of both bands together to give a percentage 
difference. 
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Membranes scanned using an infrared scanner were analysed using Odyssey 
Infrared Imaging System version 3 (LI-COR Biosciences). A box was drawn around 
each fluorescent bands of interest and an integrated intensity measurement was 
determined. No background subtraction was needed as the software 
compensated for this already in the intensity outputs. Subsequently, the 
intensity readings of each main protein of interest were divided by their 
respective loading control (NeuN) to account for gel loading variations. Finally, 
most western blots contained two genotype (WT or Mecp2stop/y) and treatment 
(saline or kainic acid) group replicates on the one gel to minimise inter-gel 
variability. To enable comparison of results, integrated intensities of each main 
protein of interest were divided by the average of the WT saline group and 
plotted as fold change relative to this group.  
2.4.2 Immunohistochemistry 
2.4.2.1 General Method 
Free-floating coronal brain sections from Mecp2+/- and Mecp2GFP/- mice were 
washed three times (10 minutes each) in 0.3M NaCl buffered saline (PBS) at 
room temperature and blocked using 15% (w/v) normal goat serum in 0.3M PBS 
with 0.3% Triton-X-100 for one hour at room temperature. Sections were then 
incubated with primary antibodies (Table 2-6) in 0.3M PBS with 0.3% Triton-X-
100 (Sigma-Aldrich) at 4°C for two-three days. Subsequently sections were 
rinsed three times in 0.3M PBS before incubation with fluorescent secondary 
antibodies (Table 2-6) in 0.3M PBS with 0.3% Triton-X-100 (in the dark) overnight 
at 4°C. Sections were then washed a final three times in 0.3M PBS in the dark 
prior to incubation with the nuclei marker 4', 6-diamidino-2-phenylindole (DAPI, 
Sigma-Aldrich; dissolved in dH2O to make a 20mg/ml stock; 1/1000 working 
dilution) in 0.3M PBS for 30 minutes at room temperature. Finally sections were 
mounted in Vectashield (Vector labs, UK) on coverslips and optical image stacks 
collected on a Leica SP5 Confocal microscope (Leica Microsystems) equipped 
with diode (405nm), argon (488nm), diode pumped solid-state (DPSS; 561nm) 
and red helium-neon (633nm) lasers.  
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Table 2-6 Primary and secondary antibodies used for immunohistochemistry  
Antibody Dilution Supplier 
Primary   
Mouse anti-MeCP2 1/500 Sigma-Aldrich 
Rabbit anti-pS421 MeCP2 1/2000 Gift from Greenberg lab 







Rabbit anti-Histone H3 1/100 Abcam 
Mouse anti-Histone H4 1/200 Abcam 
Rabbit anti-c-Fos 1/4500 Millipore 
Rabbit anti-Egr-1 1/100 Santa Cruz Biotechnology 
Secondary   
Alexa fluor 488 goat 
anti-rabbit 
1/500 Life Technologies 
Alexa fluor 488 goat 
anti-mouse 
1/500 Life Technologies 
Alexa fluor 546 goat 
anti-mouse 
1/500 Life Technologies 
Alexa fluor 647 goat 
anti-rabbit 
1/500 Life Technologies 
 
Additionally, before sections were probed with primary antibodies, rabbit anti-
Histone H3 and rabbit anti-Histone H4, they had to undergo an antigen retrieval 
step. This involved, rinsing the free floating coronal brain sections three times 
(for 10 minutes each) in 0.1M phosphate buffer (PB) before transferring to 10mM 
sodium citrate buffer preheated to and maintained at 80°C in a water bath for 
30 minutes. Retaining the sections in the same solution, they were allowed to 
cool to room temperature then washed three times in 0.1M PB. Subsequently, 
sections were blocked using 2% (w/v) dried skimmed milk power (Marvel) in 0.1M 
PB containing 0.3% Triton X-100 for one hour. Sections were then be incubated 
for two-three days with rabbit anti-Histone H3 and rabbit anti-Histone H4 
primary antibodies in 0.3M PBS with 0.3% Triton-X-100 (Sigma-Aldrich) at 4°C 
and the immunohistochemistry continued as described above. 
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2.4.2.2 Image Analysis 
All images stacks (protein of interest, Mecp2 and DAPI) were taken on a Leica 
SP5 Confocal microscope (Leica Microsystems) and saved using LAS AF acquisition 
software (Leica Microsystems). At least two optical image stacks were taken for 
each hippocampal formation region (CA1 and DG) from every brain section 
(minimum of two per animal). All images were captured as a Z-series (15uM in 
depth) using a Z-step of 0.25µM, zoom factor 1, pinhole airy 1, 63x objective 
lens, image size 1024 x 1024 pixels, 0.48µM pixel size and in 12 bit to improve 
the intensity measurement accuracy. A subset of optical image stacks was also 
taken on a 20x objective lens. Detector gain and offset differed depending on 
which protein of interest was being investigated but were kept constant 
throughout imaging of all the replicates of that protein. The cells of interest 
were in the pyramidal cell layer of the hippocampus and using the antibodies 
from table 2-14, the nuclei of each pyramidal cell becomes brightly 
immunostained. 
Following image capture, cells were then analysed either manually or with an 
automated script. The automated script was developed in Image-Pro Plus 7.0 
(Media Cybernetics, UK) to quantify cell intensity differences between Mecp2 
positive and negative nuclei. The script was developed by Dr David Kelly at the 
University of Edinburgh and an annotated detailed version of the computer 
programming involved in this is described in Appendix B.  In addition, a 














































Figure 2-7 Steps involved in the automated script. 
Six steps are highlighted which explain in general how the automated script works to quantify 
nuclei measurements using all three image stacks (DAPI, Mecp2 and protein of interest). The DAPI 
image is turned into a 3D thresholded binary mask which is reapplied to the original Mecp2 and 
protein of interest image to determine the presence or absence of Mecp2 and nuclei intensity 
respectively. The scale (in pixels) is taken from the original DAPI image. 
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Importantly, during steps five and six the automated script stops at each 
selected nuclei in the ROI of the DAPI image before any measurements were 
taken enabling the user to manually check that the nucleus was intact. If the 
nucleus was incomplete it was discarded from the analysis at this point and the 
script proceeded to the next nucleus. This was done because nuclei in the image 
could have been cut in half due to being positioned at the boundary of the 
confocal stack or more usually they were incompletely thresholded. At this stage 
of the process the user is blind to whether the nucleus of this cell is positive or 
negative for Mecp2.  Once the nucleus was accepted the script proceeded to 
create a 2D binary mask outline of that nucleus based on the 3D volume.  This 
outline is applied segment by segment to the original protein of interest image 
stack to determine the mean nuclei intensity. Figure 2-8 describes in more detail 






Figure 2-8 Calculation of mean nuclei intensity from the script 
(1) A 3D nuclei is transferred back into a 2D binary image. A region of interest is created to enable 
accurate positioning of that nucleus on the original confocal image. (2) The image is split into the 
original segments of the image stack and (3) an average intensity is taken of each segment. (4) 
Finally all average intensities are added together and divided by the total number of segments (e.g. 
5) to obtain the mean intensity for that nucleus. 
Subsequently, the script identified the Mecp2 status from the same nuclei in the 
Mecp2 image. Mecp2 positive cells were determined by the mean intensity being 
>250 grey scale units in three consecutive segments of the Mecp2 image. Volume 
measurements were calculated from the 3D image before all measurements for 
each cell (mean intensity, Mecp2 status and volume) were exported 
automatically to an excel file. Volume measurements were important as 
afterwards the mean intensity for each nucleus was multiplied by the volume to 
obtain an integrated density value. Figure 2-9 demonstrates the significance of 
this in greater detail. 
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Figure 2-9 Measurement of integrated density 
(A) Example of nuclei with different volumes (V) and fluorescent intensities (I) (i-iii). (B) 
Measurement of the integrated density in two manners – dividing or multiplying by the volume. 
Note the importance of the latter calculation whereby the volume is taken into consideration in the 
correct manner and the data not skewed. For example in (iii) the cell is bright due to the small size 
of the nuclei. Dividing by the volume amplifies this result which is incorrect. Multiplying by the 
volume takes the size of the nuclei into account and an accurate integrated density is obtained.  
Finally, as Mecp2 positive nuclei were in the same image stack as Mecp2 
negative nuclei, the difference between the two nuclei types can be accurately 
determined. In order to avoid the problem of determining which parameter 
(stack, section or animal) to normalise the data to when quantifying intensities, 
a chi-square test was performed. A chi-square analysis was performed to 
determine whether there was a change in the distribution of Mecp2 positive and 
negative nuclei above the median intensity value. However if only some of the 
nuclei had the phenotype in the population then this would result in a dilution 
effect if all nuclei were considered. Therefore the percentage difference in 
nuclei types that were in the upper quartile intensity values was also 
determined.  
In addition, optical image stacks were also analysed manually using Image J 
software to quantify the difference between the total number of nuclei 
immunostained for a specific protein of interest in Mecp2 positive and negative 
nuclei. The Macro did not obtain an accurate measurement of the total number 
of nuclei in each section as nuclei were removed from the analysis for being 
incomplete. The z-stack was flattened for the protein of interest in a given 
image and all the nuclei that were positive for that protein counted. The counts 
for these nuclei were then overlaid onto the Mecp2 immunostained image and 
the proportion of nuclei that were positive or negative for Mecp2 calculated. 
Additionally the total number of DAPI immunostained nuclei and Mecp2 positive 
nuclei were counted (from flattened z-stacks) in some images regardless of the 
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protein of interest to compare the proportion of Mecp2 positive to negative 
nuclei in each image.  
2.5 Statistical Analysis 
All data was expressed as mean ± SEM and analysed using Graphpad Prism 
software (GraphPad, USA) or Minitab Statistical software (Minitab, USA). For 
parametric data normality of the data was confirmed using a Box-Cox 
Transformation or Johnson Transformation when necessary. Subsequently a 
Student’s unpaired t-test, Log-rank test, two-way ANOVA with Tukeys post hoc 
test and three-way ANOVA with Tukeys post hoc test was used where 
appropriate. Non parametric tests were also performed using a Mann Whitney U 
test and chi-squared test. Statistical significance was accepted at p<0.05 and 
the following abbreviations were used throughout: ns = no significant difference, 
* = p<0.05, ** = p<0.01 and *** = p<0.001. 
2.6 General materials  
2.6.1 Polymerase Chain Reaction (PCR) products 
2.6.1.1 Primers  
The primers used in PCR reactions are listed in Table 2-7. 
Table 2-7 Primers used in PCR reactions 
Primer Nucleotide Sequence 5’-3’ Supplier 
P7 (416bp) GGCTTGCCACATGACAAGAC Sigma-Aldrich 
New P6 (470bp) TCCACCTAGCCTGCCTGTACTTTG Sigma-Aldrich 
New P5 (416bp) TGGTAAAGACCCATGTGACCCAAG Sigma-Aldrich 
 
2.6.1.2 Enzymes 






  77 
 
 
Table 2-8 Enzymes used in PCR reactions 
Enzyme Supplier 
DNAreleasyTM  Anachem Ltd 




Solutions used for electrophysiology experiments are listed in Table 2-9 and 
Table 2-10. 






NaCl 87 5.084 BDH Laboratories 
KCl 2.5 0.186 BDH Laboratories 
NaHCO3 25.0 2.100 Fisher Scientific 
NaH2PO4 1.25 0.195 BDH Laboratories 
Glucose 25.0 4.504 Fisher Scientific 
Sucrose 75.0 25.673 Fisher Scientific 
Pyruvate 1 7 (mls) Sigma-Aldrich 
Ascorbate 1 0.5 (ml) Sigma-Aldrich 
MgCl2 7 0.110 BDH Laboratories 
CaCl2 0.5 0.198 BDH Laboratories 
 






NaCl 124 72.47 BDH Laboratories 
KCl 3 2.24 BDH Laboratories 
NaHCO3 26 21.84 Fisher Scientific 
NaH2PO4 1.25 1.95 BDH Laboratories 
MgSO4 1 2.46 BDH Laboratories 
Glucose 10 18.02 Fisher Scientific 
CaCl2 2 2 (mls) BDH Laboratories 
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2.6.2.2 General solutions  
Solutions used in all DNA or protein gel electrophoresis can be observed in Table 
2-11. All chemicals listed in this section were supplied from BDH Laboratories or 
Sigma-Aldrich unless otherwise stated. 
Table 2-11 Gel electrophoresis solutions 
Solution Chemical Components  
1 x Tris-borate-EDTA 
(TBE) 
90mM Trizma base, 90mM Orthoboric acid and 2mM 
EDTA. 
5 x DNA loading buffer 0.5% SDS (w/v), 0.25% Xylene cyanol (w/v), 0.25% 
Bromophenol blue (w/v) and 1.5% Ficoll®400 (w/v) 
in 3x TBE. 
Ethidium Bromide 10mg/ml in H2O 
Agarose gel 0.8% (w/v) agarose in 0.5M TBE buffer containing 
200 ng/ml ethidium bromide 
1.5M Tris pH 8.8 27 g Tris-base, 2 ml HCl and 150 ml dH2O 
1M Tris pH 6.8 3 g Tris-base, 50 ml dH2O and adjust to pH 6.8 with 
HCl 
7% (w/v) acrylamide 
resolving gel 
40% Acrylamide (7mls; 29:1 Bio-Rad laboratories, 
UK), 1.5M Tris pH 8.8 (10mls), dH2O (23mls), 20% 
SDS (200µl), Temed (20µl) and 10% APS (200µl) 
4.3% (w/v) acrylamide 
stacking gel 
40% Acrylamide (1.29 mls), 1M Tris pH 6.8 (3 mls), 
dH2O (7.71mls), 20% SDS (60µl), Temed (6µl) and 
10% APS (75µl) 
1 x Tris-glycine buffer 50mM Tris-base, 400mM Glycine 
  
General solutions used for western blotting are listed in Table 2-12.  
Table 2-12 General solutions used for western blotting 
Solution Chemical Components  
Cell lysate buffer 20mM HEPES, 10mM KCl, 1mM MgCl2, 0.5mM DTT, 
0.1% Triton X-100, 20% Glycerol, 2mM PMSF, 
5mg/ml Aprotinin, 5mg/ml Leupeptin and 10mM 
Sodium Butyrate 
Transfer buffer 20X NuPAGE Transfer Buffer (50mls; Life 
Technologies, UK), Methanol (100mls) and 850ml 
dH2O 
Tris Buffered Saline (TBS) 20mM Tris-HCL (pH8.0), 137mM NaCl 
Blocking solution 5% (w/v) dried skimmed milk powder (Marvel) 
diluted in TBS 
 
General solutions used for immunohistochemistry are listed in Table 2-13. 
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Table 2-13 General solutions used for immunohistochemistry 
Solution Chemical Components  
0.2M Phosphate Buffer 
(PB) 
Solution A: 18.72 g of NaH2PO4 (2H2O) in 600mls 
dH2O. Solution B: 42.45g of Na2HPO4 in 1500mls 
dH2O. Add 560mls solution A to 1440mls of solution 
B and adjust to pH 7.4. 
0.3M NaCl buffered saline 
(PBS) 
100mls 0.2M PB, 900ml dH2O and 36g NaCl. 
10mM sodium citrate 
buffer 
2.94g of Tri-sodium citrate, 1000ml dH2O and 
adjust to pH 8.5. 
4% Paraformaldehyde 
(PFA) 
40g of Paraformaldehyde, 500ml 0.2M PB, 400mls 
dH2O and a few drops of 1M NaOH 
 
2.6.3 Drugs 
The drugs used in experiments are documented in Table 2-14. 




Saline 0.9% 0.9g of NaCl dissolved 
in dH2O 
BDH Laboratories 
Kainic acid (10mg) 25mg/kg Worked out from a 
1mg/ml stock (dissolved 
in 0.9% saline) 
Abcam 
Kainic acid (1mg) 400nM 34µl from 4.69M stock 
added to 366ml ACSF  
Abcam 
NBQX (1mg) 5µM 333µl from a 3mM stock 
added to 199.68ml ACSF 
Abcam 
Bicuculline (1mg) 0.1, 1, 3 and 
10µM 
1µl, 10µl, 30µl and 
100µl respectively from 
a 10mM stock added to 
100mls ACSF. 
Abcam 
4-aminopyridine  1, 3, 10, 30 
and 50µM 
1µl, 3µl, 10µl, 30µl and 
50µl respectively from a 
100mM stock added to 
100mls ACSF. 
Sigma-Aldrich 
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Chapter 3 
Reduced seizure threshold and altered oscillatory 
properties in Mecp2 knockout mice 
  
3.1 Introduction 
A major phenotype in RTT is the propensity for 70-90% of patients to develop 
epilepsy (Hagberg et al., 2002) with diverse seizure types ranging from complex 
partial to myoclonic seizures (Steffenburg et al. 2001; Kim et al. 2012). RTT 
patients have an age-related onset  with frequency and severity of seizures 
declining in late adolescence (Steffenburg et al. 2001). Some authors report no 
significant clinical difference between patient genotypes (Cardoza et al., 2011) 
but a recent large scale study suggests that seizures may indeed vary by 
mutation type, with T158M (74%) and R106W (78%) mutations being most 
frequently associated with epilepsy (Glaze et al., 2010). Abnormalities in EEG 
recordings are also detected in RTT patients such as epileptiform discharges 
(Ishizaki et al., 1989) and slow oscillatory theta activity (Hagne et al. 1989; 
Niedermeyer et al. 1997). This could lead to an overall state of cortical 
hyperexcitability. Whilst the EEG is invariably abnormal at some stage, there is 
no characteristic or diagnostic EEG pattern for RTT (Glaze, 2005). 
EEG recordings from Mecp2 knockout mice display abnormal spontaneous 
rhythmic discharges of 6-9 Hz in the somatosensory cortex in awake but 
immobile mice, and increased peak frequency of theta rhythm in the 
hippocampus (D’Cruz et al., 2010); similar findings are observed in RTT patients. 
More recently, event related potentials (ERPs), brain activations that occur 
during certain behavioural tasks, were measured in Mecp2-/y mice and found to 
be altered in amplitude and latency of these events compared to WT controls; 
parameters that can reflect the strength and timing of cognitive processes 
(Goffin et al., 2012). This study also investigated the oscillations using passive 
EEG recordings and found an increase in high gamma (70-140 Hz) in Mecp2-/y 
mice compared to controls – activity that can be associated with epilepsy in the 
EEG before and during seizures (Goffin et al., 2012). Combining these EEG 
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findings in mice and RTT patients, it would suggest that disruption of MeCP2 
causes alterations in network excitability. 
Limitations exist in the use of EEG recordings in vivo. For example, intersubject 
variability and stage of disease process can vary and data outputs are complex. 
Further experiments have also been conducted in vitro which has tried to 
investigate this disparity in network circuitry in greater detail. Considering that 
a precise regulation of excitatory (Glutamatergic) and inhibitory (GABAergic) 
input is essential for normal brain function, any discrepancies in the balance of 
these factors could cause alterations in the properties of neuronal network 
circuitry. Mecp2-deficient mice show reduced spontaneous inhibitory 
postsynaptic potentials in the CA3 of the hippocampus attributed to decreased 
levels of spontaneous glutamate receptor–mediated synaptic currents (Zhang et 
al., 2008). Additionally, voltage sensitive dye studies revealed increased 
amplitude and spatiotemporal spread of neuronal depolarisations in the CA1 of 
the hippocampus. Isolation of the CA1 eliminated these differences suggesting 
alterations in network excitability originate from the CA3 (Calfa et al. 2011). 
Collectively these studies propose that an imbalance in inhibitory neuron 
regulation in the hippocampus render the entire network prone to 
hyperexcitability. Mice with no Mecp2 in GABA releasing neurons also 
recapitulate many RTT features (Chao et al., 2010) therefore suggesting a role 
for MeCP2 in regulation of inhibitory input. 
3.2 Study Aim 
In this study the aim was to investigate whether there were alterations in 
seizure threshold in Mecp2-deficient mice. The specific research questions in 
this chapter were to: 
i. Investigate the effects of kainic acid administration (a convulsant drug) on 
seizure development in WT and Mecp2-deficient mice. 
ii. Investigate further possible alterations in hippocampal network 
properties/excitability using a range of epileptogenic agents in vitro. 




To investigate the epileptic phenotype in vivo, the convulsant drug kainic acid 
(25 mg/Kg IP in 0.9% saline) or saline (vehicle control) was injected into 6-10 
week old symptomatic male Mecp2stop/y mice and their WT litter mates to 
monitor and analyse their seizure score. Seizure scores were amended from a 
previous documented scale (Racine, 1972) described in greater detail in chapter 
2. Most experiments were carried out with the mice under light (2.5-3%) 
isoflurane anaesthesia but a subset of experiments were performed on male 
Mecp2-/y, female Mecp2+/- mice and their WT litter mates (aged 6-10 weeks) 
without anaesthesia. 
Network excitability was examined in vitro by application of bicuculline, 4-
aminopyridine and kainic acid to hippocampal slices from Mecp2stop/y mice and 
their WT litter mates as described in chapter 2. Subsequently, field excitatory 
postsynaptic potentials (fEPSPs) and gamma oscillations were recorded from the 
CA1 and CA3 regions of the hippocampus respectively to characterise network 
properties in both genotypes. 
3.4 Results 
3.4.1 Mecp2-deficient mice have a heightened sensitivity to kainic 
acid-induced seizures in vivo 
3.4.1.1 Kainic acid application to mice under anaesthesia 
To systematically examine the susceptibility of mice lacking Mecp2 to develop 
seizures, we challenged male Mecp2stop/y mice (functional Mecp2 knockout) and 
their WT littermates with the convulsant drug kainic acid (25mg/Kg) or vehicle 
(saline). Whilst none of the mice showed spontaneous seizure-like activity under 
homecage conditions or prior to drug application, kainic acid resulted in the 
rapid development of seizure activity (comprising of fast breathing, erratic 
twitches, tail shaking, limb clonus, and tonic-clonic seizures) in both Mecp2stop/y 
and WT mice. However, semi-quantitative scoring of mice based on a modified 
Racine scale (Chapter two) revealed that the proportion of mice displaying overt 
epileptiform signs is greater in Mecp2stop/y mice (100% of Mecp2stop/y mice 
develop seizures within three hours post treatment in contrast to 80% of WT). 
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Moreover, the onset of seizure activity was more rapid in Mecp2stop/y mice 
(Figure 3-1A; p<0.001, log rank test; n=20 WT and 13 Mecp2stop/y) and the overall 
seizure profile (Figure 3-1B) and maximal seizure score (mean = 6 ± 0.7 vs 4 ± 
0.2 units in WT; Figure 3-1C; p>0.01, unpaired t-test) are greater in Mecp2stop/y 
mice.  





Figure 3-1 Heightened sensitivity to kainate-induced seizures in Mecp2
stop/y 
mice  
Plot showing the proportion of WT (grey circles) and Mecp2
stop/y
 mice (black squares) displaying 
overt seizures following administration of kainic acid (KA, 25 mg/Kg, IP). Mecp2
stop/y
 mice show a 
quicker onset of seizures (p<0.001, Log-rank test, n=20 WT and 13 Mecp2
stop/y
). (B) Time plot 
showing mean seizure score over 3 hours post-KA application (same symbols as in A). (C) Bar 
graph showing maximal seizure score in WT and Mecp2
stop/y
 mice (n=same as above; p<0.01, 
unpaired t-test). All data expressed as mean ± SEM. Note all mice were under anaesthesia. 
3.4.1.2 Kainic acid application to mice not under anaesthesia 
To omit the variable of anaesthesia, kainic acid was also applied to Mecp2- 
deficient mice without anaesthesia. Maximal seizure score was quantified and an 
increase in seizure severity was observed in Mecp2-/y mice (6± 0.8 units) when 
compared to their male WT littermates (2 ± 0.2 units; Figure 3-2A; p>0.01, 
unpaired t-test; n=6 mice for each genotype). This disparity was also observed in 
heterozygous female mice (6 ± 0.4 units; Mecp2-/+) when compared to female 
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 mice without anaesthesia  
(A) Column plot comparing the maximal seizure score in WT male to Mecp2
-/y
 mice without 
anaesthesia. An increase in seizure severity is observed in Mecp2
-/y
 mice (p<0.01, unpaired t-test, 
n=6 mice for each genotype). (B) Plot showing the maximal seizure score in Mecp2
+/- 
female mice 
compared to their WT littermates without anaesthesia. A greater seizure score is present in 
Mecp2
+/-
 mice (p<0.05, unpaired t-test, n=5-8 mice for each genotype). All data expressed as mean 
± SEM.  
3.4.2 Altered gamma network oscillations in the hippocampus of 
Mecp2stop/y mice. 
These in vivo studies have shown that Mecp2-deficient mice have a heightened 
sensitivity to kainic acid-induced seizures. One possible contributing factor to 
this could be alterations in the propensity of neuronal networks in Mecp2-
deficient mice to generate synchronous forms of network activity such as 
hippocampal gamma oscillations. In response to nanomolar concentrations of 
kainic acid, the hippocampus is capable of generating rhythmic oscillations, 
particularly in the gamma band (20-80Hz) which are considered to represent 
‘physiological’ forms of network oscillation but may result in pathological 
hypersynchrony if excessive  (Fisahn, 2005). Therefore, in order to test this 
theory we applied kainic acid (400nM) to hippocampal slices from Mecp2stop/y 
mice and their WT littermates. Under control (WT slices) conditions, kainic acid 
resulted in the appearance of regular gamma network oscillations (Figure3-3Ai). 
The activity was network driven and completely eliminated by addition of the 
AMPA/kainate receptor blocker, NBQX (5µM; Figure 3-3Aii). This kainic acid-
induced oscillatory activity was further examined by power spectrum analysis 
which showed dominant frequency at ~30-40Hz (Figure 3-3Aiv). Under the same 
experimental conditions, slices from Mecp2stop/y mice appeared to have more 
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Figure 3-3 Gamma frequency network oscillations before and after kainic acid application. 
(A) Representative extracellular field potential traces from WT hippocampus showing (i) baseline 
quiescence prior to application of kainic acid (400nM) following which (ii) trace becomes dominated 
by a gamma frequency (~30-40Hz) oscillation. This network oscillation was abolished following 
administration of the kainate receptor antagonist NBQX (5μM). (iv) Power spectrum from same 
experiments showing oscillation with a dominant frequency at ~40Hz. Inserts at end of each trace 
are corresponding autocorrelation plots which reveal the presence of regular oscillation in kainic 
acid-treated slices. (B) Similar representative data plots from a Mecp2
stop/y
 mouse hippocampal 
slice. Note the more prominent and higher power gamma frequency oscillation relative to the WT 
traces. All data expressed as mean ± SEM and scale bars: voltage traces, 25μV, 0.1 s; 
correlation=0.5, 50 ms. 
These observations were confirmed by power spectrum analysis from all the 
pooled data.  Slices from Mecp2stop/y mice displayed a higher mean power (1059 ± 
379µV2) compared to slices from WT mice (287 ± 178µV2) which had a lower 
mean power (Figure 3-4A-B; Mann-Whitney U test; n=14-26 slices for each 
genotype). Furthermore there was a significant difference in mean power 
between control and kainic acid treatment for each genotype (Figure 3-4B; 
p<0.05, Mann-Whitney U test). However, no difference was observed between 



























































































genotypes when quantifying the dominant frequency of each oscillatory activity 
after 60 minutes of kainic acid treatment with a WT slice frequency of 33 ± 
1.7Hz and 35 ± 2.1Hz for Mecp2stop/y slices (Figure 3-4C; p=0.579, Mann-Whitney 
U test). 










(A) Pooled data showing average power spectra from WT (n=26 slices from 9 mice) and Mecp2
stop/y
 
samples (n=14 slices from 6 mice). (B) Column plot showing mean oscillatory power before and 
following kainic acid (KA) application in WT and Mecp2
stop/y
 samples revealing a significant 
difference in mean power between treatment (p<0.05, Mann-Whitney U test, n=14-26 slices per 
genotype) and genotype (p<0.05, Mann-Whitney U test). (C) Plot showing dominant frequency 
which did not differ between genotypes (p= 0.579, Mann-Whitney U test, same n as above). All 
data expressed as mean ± SEM. 
3.4.3 Altered properties of bicuculline-induced epileptiform 
activity in the hippocampus of Mecp2stop/y mice. 
3.4.3.1 Spontaneous extracellular fEPSPs 
Considering fast spiking GABAergic interneurons are important for the generation 
of gamma oscillations in the hippocampus (Traub et al., 2003) and previous 
studies have suggested an important role for Mecp2 in the regulation of 
inhibitory input (Chao et al. 2010; Zhang et al. 2008) I applied the GABAA 
receptor antagonist bicuculline to hippocampal slices from Mecp2stop/y mice and 
their WT littermates. Extracellular field recordings obtained from the stratum 
radiatum in area CA1 in response to bicuculline (10µM) administration showed 
characteristic spontaneous epileptiform bursting activity (Figure 3-5A). Slices 
from Mecp2stop/y mice showed a greater frequency of these bursting events at 
low doses (0.1-1µM) of bicuculline (Figure 3-5B-C; p<0.05, two-way ANOVA with 
Tukeys post hoc test; n=18-22 slices for each genotype). Subsequently, analysis 
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of the duration of these spontaneous epileptiform bursts revealed the duration 
was longer in slices from Mecp2stop/y mice (713 ± 47ms) compared to WT controls 
(383 ± 55ms) after application of 10µM bicuculline (Figure 3-5D; p<0.001, two-










Figure 3-5 Increased frequency and duration of bicuculline-induced spontaneous 
epileptiform activity in hippocampal slices from Mecp2
stop/y 
mice 
(A) Representative extracellular fEPSP recording in area CA1 showing characteristic spontaneous 
epileptiform bursting activity in response to application of the GABAA receptor antagonist 
bicuculline (10µM). Insert shows individual burst event. (B) Scatter plot showing instantaneous 
burst frequency in representative recordings from WT (black symbols) and Mecp2
stop/y
 (grey 
symbols) slices in response to increasing bath concentration of bicuculline (0.1-10 μM). (C) Plot 
showing frequency of epileptiform bursting in response to increasing bath concentrations of 
bicuculline. There is a significant difference in burst frequency between genotypes at 0.1-1 μM 
concentrations (p<0.05, two-way ANOVA with Tukeys post hoc test, n=18 slices, from 5 WT mice 
and n=22 slices from 5 Mecp2
stop/y
 mice). (D) Plot showing increased duration of spontaneous 
epileptiform events (p<0.001, two-way ANOVA with Tukeys post hoc test) in slices from Mecp2
stop/y
 
mice in the presence of 10 μM bicuculline (same n as above). Scale bar: 0.2 mV, 1s and all data 
expressed as mean ± SEM. 
3.4.3.2 Evoked extracellular fEPSPs 
Evoked extracellular fEPSPs recorded in stratum radiatum of area CA1 showed 
characteristic polyspikes behaviour when delivered in the presence of 
bicuculline (10µM; Figure 3-6A). Quantification of the average number of these 
polyspike events that occur following synaptic stimulation revealed Mecp2stop/y 
mice (2.9 ± 0.5) had the propensity to develop a greater number of post-
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stimulated burst events at the highest concentration of bicuculline (10µM) 
compared to WT littermates (0.9 ± 0.2; Figure 3-6B; p<0.001, two-way ANOVA 
with Tukeys post hoc test; n=12 slices per genotype; n=18-22 slices for each 
genotype). Additionally, the duration of evoked fEPSPs was longer in Mecp2stop/y 
slices (416 ± 66ms) compared to WT (83 ± 25ms) at 10µM bicuculline (Figure 3-
6C; p<0.001, two-way ANOVA with Tukeys post hoc test). Finally the input-
output relationship between stimulus intensity and rise rate (60-80% of the 
initial slope of evoked fEPSP) during baseline control conditions and after 10µM 
bicuculline in Mecp2stop/y and WT slices was calculated. There was a trend 
towards Mecp2stop/y slices having higher rise rate values in both treatment groups 
compared to WT slices (Figure 3-6D; p<0.001 for an overall genotype affect, 
general linear model with genotype, treatment and stimulus as factors and 
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Figure 3-6 Altered evoked fEPSP properties in hippocampal slices from Mecp2
stop/y
 mice in 
the presence of bicuculline. 
(A) Representative fEPSP recordings in area CA1 showing characteristic polyspikes (arrows) in the 
presence of bicuculline (10µM) following synaptic stimulation. (B) Plot showing number of 
polyspikes present in response to increasing bath concentrations of bicuculline (0.1-10 μM). There 
was a significant difference in polyspike number between genotypes at 10 μM concentrations 
(p<0.001, two-way ANOVA with Tukeys post hoc test, n=18 slices, from 5 WT mice and n=22 
slices from 5 Mecp2
stop/y
 mice). (C) Plot showing increased duration of evoked fEPSP (3 and 10µM; 
p<0.05, two-way ANOVA with Tukeys post hoc test) in slices from Mecp2
stop/y
 mice in the presence 
of increasing bicuculline concentrations (same n as above).  (D) Input-output relationship between 
stimulus intensity and rise rate (60-80% of the initial slope of evoked fEPSP) during control 
conditions and after 10µM bicuculline in both genotypes. Note the trend towards higher rise rate 
values in Mecp2
stop/y
 mice (same n as above, p<0.001 for an overall genotype affect, general linear 
model with genotype, treatment and stimulus as factors and Tukeys post hoc test.) Scale bar: 1 
mV, 5s and all data expressed as mean ± SEM.  
3.4.4 Altered properties of 4-aminopyridine-induced epileptiform 
activity in the hippocampus of Mecp2stop/y mice 
3.4.4.1 Spontaneous extracellular fEPSPs 
In contrast to bicuculline-induced disinhibition of networks, the potassium 
channel blocker 4-aminopyridine (4-AP) promotes epileptiform activity via 
neuronal depolarization and strengthening glutamateric signalling (Traub and 
Jefferys, 1994). To further evaluate hippocampal network excitability, I applied 
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the potassium channel blocker 4-AP to hippocampal slices from Mecp2stop/y mice 
and their WT littermates. Extracellular field potential recordings were taken 
from the stratum radiatum in area CA1 of the hippocampus which showed 
characteristic spontaneous epileptiform bursting activity following application of 
50µM 4AP (Figure 3-7A). No difference in the frequency of these epileptiform 
bursting events was observed between genotypes upon incremented 
concentrations of 4AP except at the highest concentration administered (Figure 
3-7B-C; 50 µM, p<0.05, two-way ANOVA with Tukeys post hoc test; n=12 slices 
per genotype). Subsequently quantification of the duration of the spontaneous 
epileptiform burst events revealed that the duration was longer in slices from 
Mecp2stop/y mice (203 ± 24ms) compared to WT controls (134 ± 24ms) upon 
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Figure 3-7 Increased frequency and duration of 4-aminopyridine-induced spontaneous 
epileptiform activity in hippocampal slices from Mecp2
stop/y 
mice 
(A) Representative extracellular fEPSP recording in area CA1 showing characteristic spontaneous 
epileptiform bursting activity in response to application of the potassium channel blocker 4-
aminopyridine (4-AP, 50µM). Insert shows individual burst event. (B) Scatter plot showing 
instantaneous burst frequency in representative recordings from WT (black symbols) and 
Mecp2
stop/y
 (grey symbols) slices in response to increasing bath concentration of 4-AP (1-50 μM). 
(C) Plot showing pooled epileptiform burst frequency data in response to increasing bath 
concentrations of 4-AP. There was a significant difference in burst frequency between genotypes at 
the highest concentration tested (50 μM, p<0.05, two-way ANOVA with Tukeys post hoc test, n=12 
slices per genotype). (D) Plot showing increased duration of spontaneous epileptiform bursts 
(p<0.05, two-way ANOVA with Tukeys post hoc test) in slices from Mecp2
stop/y
 mice in the presence 
of 50 μM 4-AP (same n as above). Scale bar: 0.2 mV, 1s and all data expressed as mean ± SEM. 
In addition to an increase in the frequency and duration of epileptiform bursting 
activity after 50µM 4-AP administration in slices from Mecp2stop/y mice, these 
slices also had an increased propensity to display ictal-like events (distinctive 
epileptic events; Figure 3-8B). These events are characterised by a high 
frequency discharge followed by train of burst-like events (Figure 3-8Aiii). 88% of 
slices from Mecp2stop/y mice displayed these events compared to 43% of slices 
from WT mice (Figure 3-8B; p<0.05, chi-squared test; n=3 from a total of 7 slices 
for WT and n=8 from a total of 9 slices for Mecp2stop/y mice). 
 

















































Figure 3-8 Hippocampal networks from Mecp2stop/y mice have a greater propensity to 
display ictal-like events in response to 4-AP challenge. 
(Ai) Representative fEPSP recording from a Mecp2
stop/y
 hippocampus displaying typical baseline 
quiescence. (ii) Subsequent application of 4-AP (50 μM) results in the appearance of characteristic 
ictal-like events (high frequency discharge followed by train of burst-like events) as shown in insert 
(iii). (B) Column plots showing that the occurrence of ictal-like is more commonly observed in slices 
from Mecp2
stop/y
 mice compared to WT (p<0.05, chi-squared test, n=3 from a total of 7 slices for 
WT and n=8 from a total of 9 slices for Mecp2
stop/y
 mice). Scale bar: 0.2 mV, 10 s and all data 
expressed as mean ± SEM.  
3.4.4.2 Evoked extracellular fEPSPs 
Evoked extracellular fEPSPs recorded in stratum radiatum of area CA1 in the 
presence of 4-AP (50µM) resulted in the appearance of characteristic polyspike 
behaviour in response to synaptic stimulation (Figure 3-9A). Quantification of the 
average number of these polyspikes that occur showed that slices from 
Mecp2stop/y mice (2.6 ± 0.3) have a greater mean number of post-stimulus burst 
events when tested at the highest concentration of 4-AP (50µM) compared to WT 
littermates (1.8 ± 0.2; Figure 3-9B; p<0.05, two-way ANOVA with Tukeys post 
hoc test; n=12 slices per genotype). Additionally, the duration of evoked EPSPs 
was longer in Mecp2stop/y slices (30µm = 25 ± 6ms; 50µM = 93 ± 12ms) compared 
to WT slices (30µm = 10 ± 0.4ms; 50µM = 15 ± 3ms) in the presence of 
incremented concentrations of bicuculline (Figure 3-9C; p<0.05, two-way ANOVA 
with Tukeys post hoc test). Finally, Figure 3-9D shows the input-output 
relationship between stimulus intensity and rise rate (60-80% of the initial slope 
of evoked fEPSP) during baseline control conditions and after 50µM 4-AP in 
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Mecp2stop/y and WT slices. No significant difference between genotypes was 
present (general linear model with genotype, treatment and stimulus as factors 
and Tukeys post hoc test). 











Figure 3-9 Altered evoked fEPSP properties in hippocampal slices from Mecp2
stop/y
 mice in 
the presence of 4-AP. 
(A) Representative evoked fEPSP recordings in area CA1 showing characteristic polyspikes 
(arrows) in the presence of 4-AP (50µM) following synaptic stimulation. (B) Plot showing number of 
polyspikes present in response to increasing bath concentrations of bicuculline (1-50μM). There 
was a significant difference in polyspike number between genotypes at 50 μM concentration 
(p<0.05, two-way ANOVA with Tukeys post hoc test, n=12 slices per genotype). (C) Plot showing 
an increased duration of evoked fEPSP (p<0.05, two-way ANOVA with Tukeys post hoc test) in 
slices from Mecp2
stop/y
 mice in the presence of 30-50 μM 4-AP (same n as above). (D) Input-output 
relationship between stimulus intensity and rise rate (60-80% of the initial slope of evoked fEPSP) 
during control conditions and after 50μM 4-AP in both genotypes. No significant difference between 
genotypes is present (same n as above, p>0.05, general linear model with genotype, treatment and 
stimulus as factors and Tukeys post hoc test.). Scale bar: 1 mV, 5s and all data expressed as 
mean ± SEM. 




Epilepsy is a prominent feature of Rett syndrome (RTT) patients (Hagberg et al., 
2002) which can be very difficult to treat as the types of seizures patients 
exhibit vary widely (Steffenburg et al. 2001). Moreover, a recent study has 
highlighted the importance of MeCP2 in epilepsy generation as the levels of 
MeCP2 mRNA are up-regulated in intractable temporal lope epilepsy (Tao et al., 
2012). This current study focused on the factors which contribute towards 
network excitability and seizure development in RTT. Using a mouse model in 
which Mecp2 is silenced by the addition of a STOP cassette (Guy et al., 2007), I 
have found a reduced seizure threshold and altered network oscillatory 
properties in Mecp2-deficient mice, and suggest that these alterations could  
have a profound influence on epilepsy generation.  
The hippocampus is a focal point in epilepsy generation (Chang and Lowenstein, 
2003) and has a well described circuitry making it an ideal area of the brain to 
study seizure development. The application of kainic acid, an ionotropic 
glutamate receptor agonist, in vivo to mice is a common model used to 
investigate epilepsy which can lead to neurochemical and histopathological 
changes within the hippocampus (Sperk et al., 1983a). Furthermore, whilst an 
epileptic phenotype has previously been observed in Mecp2 mutant mice, the 
seizure phenotype of RTT mouse models has not been fully characterised. 
Therefore the application of kainic acid to WT and Mecp2stop/y mice enabled me 
to systematically examine the propensity of mice lacking Mecp2 to develop 
seizures. I found that the proportion of mice displaying overt epileptiform signs 
was greater and the onset of seizures more rapid in Mecp2stop/y mice which 
suggest they have a heightened sensitivity to seizure induction and potentially a 
lower seizure threshold (Figure 3-1). This data may explain the clinical 
predisposition that RTT patients have to the development of epileptic seizures. 
Furthermore, this propensity for seizure generation was also observed in 
Mecp2+/- heterozygous female mice (which display a mosaic expression to Mecp2) 
and Mecp2-/y male mice when compared to their WT littermates (Figure 3-2) in 
the absence of anaesthesia suggesting that the differences were genuine and not 
due to the confounding variability in the effects of anaesthesia.  
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To investigate the contributing factors to heightened sensitivity observed in 
vivo, I applied kainic acid (400nM) to hippocampal slices in vitro from WT and 
Mecp2stop/y mice male mice. In response to nanomolar concentrations of kainic 
acid, the hippocampus is capable of generating rhythmic oscillations, 
particularly in the gamma band (20-80Hz; Fisahn, 2005). Gamma oscillations are 
synchronous network activities in the brain and can be associated with cognition, 
consciousness and synaptic plasticity (Traub et al., 1998). In our studies, mice 
deficient in Mecp2 exhibited more powerful gamma oscillations (Figure 3-3 and 
Figure 3-4A-B) than their WT litter-mates after the addition of kainic acid; 
however the mean frequency in these oscillations was not significantly different 
between genotypes (Figure 3-4C). Oscillation frequency is mediated by the net 
excitation of interneurons and by the kinetics of the inhibitory postsynaptic 
potentials between them (Whittington et al., 1995). The fact that I do not see a 
difference in the dominant frequency is surprising as this has a major impact on 
the maintenance of gamma oscillations and studies in Mecp2 mutant mice have 
shown abnormalities in mIPSC properties (Chao et al., 2010; Medrihan et al., 
2008). However my results still suggest that an overall disruption in neuronal 
network circuitry is present.  Furthermore an increase in oscillatory power was 
also observed recently in a mouse model of RTT through electroencephalography 
(EEG) recordings (Goffin et al., 2012) in which an increase in the high gamma 
frequency range (70-140Hz) was observed. However, the major differences in 
this study compared to my results were that I observed a power increase below 
40Hz and my experiments were conducted in vitro compared to in vivo. 
The balance between excitation and inhibition is essential for the generation 
and maintenance of physiological oscillations, therefore an imbalance in this 
regulation may be responsible for aberrant gamma oscillations seen in this study. 
However the exact disruption at the network level cannot be determined by 
these results alone. As the observed power of these oscillations was increased, it 
can be concluded that either there is a decrease in inhibitory action or an 
increase in excitation throughout the network. Previous studies have 
demonstrated that a selective removal of Mecp2 in GABAergic neurons of the 
brain recapitulates many of the symptoms of RTT (Chao et al., 2010).  
Additionally, fast spiking GABAergic interneurons are important for the 
generation of gamma oscillations in the hippocampus. They are stimulated by 
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high frequency ectopic spiking of the principal cells axon plexus which results in 
their activation, this activity then feeds back onto the principal cells modulating 
their firing activity (Traub et al., 2003). Consequently it is possible that the 
observed increase in oscillatory power can be explained by a reduction in 
GABAergic inhibition in as shown in various papers documenting such a 
phenomenon in Mecp2-deficient mice (Chao et al., 2010; Medrihan et al., 2008; 
Zhang et al., 2008; Zhang et al., 2010). 
To investigate the involvement of GABAergic inhibition in epileptogenesis in the 
hippocampus of Mecp2-deficient mice, I applied bicuculline (10µM), a GABAA 
receptor antagonist to hippocampal slices from Mecp2stop/y mice and their WT 
littermates. I found an increase in the frequency of spontaneous epileptiform 
bursting activity at low doses of bicuculline (0.1-1µM) in the CA1 region in slices 
from Mecp2stop/y mice compared to WT controls (Figure 3-5A-C.). Mecp2stop/y mice 
also showed an increase in the duration of spontaneous (Figure 3-5D) and evoked 
(Figure 3-6C) epileptiform bursts and a greater number of polyspikes (Figure 3-
6A-B) in the presence of 10μM bicuculline. These results suggest Mecp2stop/y mice 
are more likely to develop epileptiform activity and that even in the absence of 
inhibition there are still excitability differences between genotypes, potentially 
from excitatory input. Additionally, Mecp2stop/y mice had the propensity to have 
higher rise rate values of fEPSPs, even without bicuculline application (Figure 3-
6D). This result could imply that Mecp2-deficient mice have alterations in basal 
synaptic transmission. Other studies using Mecp2 mutant mice have shown 
conflicting results on this topic with some showing an enhancement in basal 
synaptic in the hippocampus (Moretti et al., 2006) and alterations in basal 
inhibitory rhythms (Zhang et al., 2008) but others showing no difference 
(Asaka et al., 2006; Weng et al., 2011). Collectively, my data suggests there is a 
disruption of network excitability in Mecp2stop/y mice. The increase in frequency 
of spontaneous events and longer duration of evoked field potentials at low 
doses of bicuculline suggests there is a reduced threshold for the initiation of 
epileptiform activity.   
More specifically, this data implies that mice deficient in Mecp2 could have a 
disruption in GABAergic mediated control of network circuitry or that the 
principal cells in the hippocampus are more excitable. Other studies have shown 
that Mecp2-deficient mice have reduced spontaneous inhibitory postsynaptic 
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potentials in the CA3 of the hippocampus (Zhang et al., 2008). They also applied 
bicuculline to Mecp2-null slices and found prolonged evoked field potentials in 
the CA3, similar to our findings in the CA1, which suggest altered inhibitory 
rhythms are present in the hippocampus. Furthermore a recent study using 
voltage sensitive dyes within the hippocampus revealed an increase in amplitude 
and spatiotemporal spread of neuronal depolarisations in the CA1.  Isolation of 
this region eliminated these differences thus proposing alterations in network 
excitability originate from the CA3 (Calfa et al., 2011). The results of the above 
two studies propose an imbalance in inhibitory neuron regulation in the 
hippocampus rendering the overall circuitry prone to hyperexcitability. 
To further characterise the hyperexcitability phenotype I observed in 
hippocampal slices from Mecp2-deficient mice, I also applied the potassium 
channel blocker 4-AP to slices from Mecp2stop/y mice and their WT littermates. As 
with bicuculline, a more substantial increase in the frequency of spontaneous 
epileptiform bursting activity and duration of spontaneous epileptiform bursts 
was found in the CA1 of Mecp2stop/y mice (Figure 3-7). Additionally the duration 
of evoked epileptiform events (Figure 3-8C), the number of polyspikes (Figure 3-
8A-B) and the occurrence of high frequency discharges followed by a train of 
burst-like events (ictal-like events; Figure 3-9) was greater in Mecp2stop/y mice in 
the presence of 30-50µM 4-AP. Overall these data suggest there are alterations 
in neuronal network circuitry in Mecp2-deficient mice whereby they are more 
likely to develop seizures, there is an increase in the strength of the seizures 
and there is a greater diversity in seizure type in the presence of 4-AP. It also 
indicates the Mecp2stop/y mice could be sensitive to changes in ionic conductance 
in cells, important for cell function and communication.  
Altered receptor composition at the synapse in cells deficient in Mecp2 could 
ultimately render the cells more susceptible to changes in ionic conductance. 
Indeed, reduced synapse size (Moretti et al., 2006), reduced NMDA receptor 
subunits (Maliszewska-Cyna et al., 2010) and decreased dendritic branching and 
spine number (Chapleau et al., 2009) have all been documented in mouse 
models of RTT which suggest morphological changes at the synapse could be an 
important factor in the hyperexcitability phenotype observed.  Interestingly, in 
my lab one of my colleagues has shown that single cell recordings from principal 
CA1 neurons in the hippocampus of female WT and Mecp2+/- mice have no 
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significant differences between either their intrinsic or evoked properties 
(Louise Williams; unpublished data). However, heterozygous female mice do 
exhibit heightened sensitivity to kainic acid-induced seizures (Figure 3-2B) which 
suggests that at the cellular level excitability in Mecp2-deficient neurons is 
unaltered and that hyperexcitability differences are the consequence of the 
activity of the whole network.  
In summary, I report a reduction in seizure threshold and increased power of 
gamma oscillations in Mecp2-deficient mice which ultimately leads to a state of 
hyperexcitability at the network level. My results suggest there could be a 
switch from a physiological oscillatory rhythm to a more pathological 
hypersynchrony. Furthermore, an imbalance in inhibitory neuron regulation in 
the hippocampus could partially contribute towards this disruption in network 
excitability and seizure development in these mice. Seizures are particularly 
common, debilitating and damaging aspect of RTT (Glaze et al., 2010). As such, 
application of my kainic acid seizure challenge model may be beneficial in 
future studies testing novel pharmacological and genetic approaches therapies in 
RTT (Cobb et al., 2010, Gadalla et al., 2011) to establish whether putative 




Relationship between Mecp2 phosphorylation, 
histone acetylation and neuronal activity in wild-
type and Mecp2-deficient mice 
  
4.1 Introduction 
Mecp2 is one of the most abundant nuclear proteins in neurons (Skene et al., 
2010). However, the mechanisms by which MeCP2 regulates gene expression in 
the brain and leads to the abnormalities stated in chapter 3 remains ambiguous. 
A number of proposed theories have been put forward including the ability of 
Mecp2 to regulate the transcription of both inactive and active genes (Chahrour 
et al., 2008) through binding of methylated and unmethylated DNA respectively 
(Nikitina et al., 2007). Recently Mecp2 was shown to bind predominantly at 
methylated CpGs (Skene et al., 2010) thus considering methylated DNA is 
associated with a condensed chromatin state (reviewed by MacDonald and 
Roskams, 2009) this would imply a significant role in gene silencing.  
The capability of Mecp2 to act as a repressor is facilitated by the recruitment of 
chromatin remodelling proteins such as histone deacetylases (Nan et al., 1998). 
Histones are the main protein component of nucleosomes around which DNA is 
wrapped. There are four core histones – H2A, H2B, H3 and H4 in which two 
copies of each of these histones assemble to form one octameric nucleosome 
and function to pack DNA into the nucleus.  Unpacking and packing of DNA for 
gene regulation is facilitated by various posttranslational modifications at 
residues on histone tails, including methylation, acetylation, phosphorylation 
and ubiquitination (reviewed by Kouzarides, 2007).  Among the core histones, H3 
and H4 are the principal targets of these modifications (Turner, 1991). 
Acetylation and deacetylation of lysine residues are well studied modifications 
with the former being associated with active genes and the latter with silenced 
(reviewed by MacDonald and Roskams, 2009). The balance of this enzymatic 
process is pivotal for normal gene regulation in which a reduction in one protein 
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leads to an increase in the other. Consequently mutations in MECP2 could alter 
the stability of this system resulting in dysregulation of important genes.  
Activity–dependent regulation of gene expression plays an important role in 
postnatal neuronal maturation (reviewed by West and Greenberg, 2011).The 
ability of  Mecp2 to become phosphorylated upon membrane depolarization 
(Chen et al., 2003) suggests that MeCP2 could play in crucial role in linking 
neuronal activity with control of gene expression.  Using a phospho-site-specific 
antibody, phosphorylation of Mecp2 specifically at amino acid residue serine 421 
in the brain has been connected with dissociation from methylation sites and 
activation of genes (Zhou et al., 2006). An increase in histone acetylation would 
be predicted in this occurrence. Furthermore phosphorylation at a different site, 
serine 80 is thought to be negatively regulated by neuronal activity whereby 
dephosphorylation occurs upon membrane depolarisation. It is suggested that 
S80 phosphorylation is associated with MeCP2 function in resting neurons and 
S421 phosphorylation in depolarised neurons thus altering gene transcription 
from a repressed to activated state respectively (Tao et al., 2009). Other 
phosphorylation sites (Tao et al., 2009) are likely to be involved and could act as 
post-translational markers. Mutations in MECP2 at these sites could disrupt this 
regulatory process, and lead to changes in chromatin proteins involved in the 
control of gene expression. 
4.2 Study aim  
In this study, the aim was to investigate the interactions between neuronal 
activity, MeCP2 phosphorylation and histone (H3 and H4) acetylation in order to 
understand how they work together to regulate gene expression. The specific 
aims were to: 
i. Confirm the effect of neuronal activity on the phosphorylation of Mecp2 
at serine 421 (pS421 Mecp2) in the hippocampus of WT mice using the 
convulsant drug kainic acid. 
ii. Investigate whether there are differences in acetylated histone (H3 and 
H4) protein levels in the hippocampus of WT and Mecp2-deficient mice 
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under basal conditions and following kainic acid-induced neuronal 
activity. 
4.3 Methods 
To induce neuronal activity, 25mg/kg kainic acid or saline was applied 
intraperitoneally to symptomatic Mecp2stop/y male mice (under light isoflurane 
anaesthesia; 2.5-3%), Mecp2-/y male mice (not under anaesthesia) and their WT 
littermates aged 6-10 weeks as described in chapter two. At the end of each 
experiment, the mice were culled by cervical dislocation and decapitation 
before the hippocampus was removed and snap frozen in liquid nitrogen. 
Hippocampal samples from each animal were homogenized in cell lysate buffer 
and protein levels quantified using a Bradford assay. Proteins were 
electrophoresed  through a 4-12% Bis-Tris NuPAGE gel or 7% acrylamide gel (for 
absolute levels of phosphorylated Mecp2) and a western blot was performed as 
stated in chapter two to evaluate alterations in phosphorylated MeCP2 and 
histone (H3 and H4) acetylated protein levels between samples. Proteins were 
probed overnight with primary antibody rabbit anti-acetyl-Histone H3 
(acetylated on lysines 9 and 14; 1/10000), rabbit anti-acetyl-Histone H4 
(acetylated on lysines 5, 8, 12 and 16, 1/5000), rabbit anti-pS421 MeCP2 
(1/2000), rabbit anti-MeCP2 (1/1000) or mouse anti-NeuN (1/2000) as a loading 
control. Subsequently, anti-rabbit HRP-conjugated secondary (for anti-MeCP2 
primary only) or anti-rabbit and anti-mouse fluorescent secondary antibodies 
secondary antibodies were applied to membranes and results visualized and 
analysed using ECL or Odyssey infrared imaging systems respectively as described 
in chapter two. To normalise to a common measure in every western blot and 
enable comparison of results, integrated intensities of each main protein of 
interest were divided by the average of the WT saline group. This gave a fold 
change of integrated intensity relative to WT saline as plotted in each graph. 




4.4.1 Increase in Mecp2 phosphorylation following application of 
kainic acid to WT mice 
Phosphorylation of Mecp2 following addition of 50mM KCl to cultured rat cortical 
neurons was the first evidence that MeCP2 could be subject to  posttranslational 
modifications following neuronal activity (Chen et al., 2003). Later, the same 
group discovered that phosphorylation of Mecp2 at serine 421 (pS421 Mecp2) was 
important in regulating Mecp2 derepression at the BDNF promoter (Zhou et al., 
2006). A significant increase in phosphorylation at this site is present in specific 
brain regions, including the striatum, following psychostimulant administration 
(Mao et al., 2011) and in mesolimbocortical brain regions after amphetamine 
application (Hutchinson et al., 2012). Therefore, to investigate the effects of 
neuronal activity on pS421 MeCP2 levels, I applied the convulsant substance 
kainic acid in vivo to WT mice and quantified the levels of phosphorylation in the 
hippocampus by western blot. Experiments were conducted with mice under 
light isoflurane anaesthesia (2.5-3%) to minimize the discomfort of the mice. 
There was a 1.5 ± 0.3 fold increase in pS421 Mecp2 levels (fold difference 
compared to saline controls) following half an hour kainic acid treatment and 
2.6 ± 0.8 fold increase following three hours of kainic acid treatment (Figure 4-
1; p<0.05, unpaired t-test, n=6-8 mice for each genotype at every time point). 
However the effects observed following kainic acid treatment were quite 
variable and did not achieve significance. Additionally not all hippocampal 
samples display Mecp2 phosphorylation as can be observed in one of the samples 
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Figure 4-1 Subtle increase in pS421 Mecp2 protein levels in the hippocampus of WT mice 
following kainic acid treatment 
(A) Representative western blot comparing pS421 Mecp2 protein levels 0.5,1 and 3 hours after 
kainic acid (KA) administration to saline (SA) controls. Note the modest increase and variable 
phosphorylated levels (B) Bar plot showing pooled data (p<0.05 at 30 minutes, p<0.01 at 3 hours, 
unpaired t-test, n= 6 to 8 mice for both genotypes at every time point). Data expressed as mean ± 
SEM. Note experiments were conducted with mice under anaesthesia. 
4.4.2 Modest histone H3 acetylation (H3Ac) alterations in WT and 
Mecp2-deficient mice after kainic acid treatment 
Induction of neuronal activity through administration of kainic acid can increase 
the phosphorylation of Mecp2. However, this does not explain how MeCP2 might 
regulate gene expression. One proposed theory was that the dissociation of DNA 
bound Mecp2 from the BDNF promoter and subsequent elevation in BDNF levels 
upon phosphorylation of Mecp2 at pS421 (Zhou et al., 2006 but see recent 
publication Cohen et al., 2011) could result as a consequence of increased 
histone acetylation levels. Additionally, under basal conditions, whole mouse 
brain homogenates from Mecp2-deficient mice appear to have elevated levels of 
histone H3 acetylation (H3Ac) on a global scale (Skene et al., 2010). Therefore, 
under basal conditions when neuronal activity is low, MeCP2 could repress gene 
expression by binding at methylated DNA sites and recruiting histone 
deacetylases proteins to remove acetyl groups from lysine residues at histone H3 
tails. Upon neuronal activity, MeCP2 could dissociate from DNA methylation sites 
thus enabling histone acetyltransferases enzymes to add acetyl groups to lysine 
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residues at histone H3 tails and enable gene activation. To test this hypothesis, I 
applied saline or evoked kainic-acid- induced seizures in WT and Mecp2stop/y mice 
(under light isoflurane anaesthesia; 2-5-3%) and quantified the levels of H3Ac in 
the hippocampus by western blot. 
Samples were assessed at a number of different time points following the 
initiation of kainic acid or saline treatment (0.5, 1 and 3 hours). A 
representative blot of H3Ac protein levels produced after three hours of kainic 
acid treatment can be observed in Figure 4-2A. Quantification of results after 
three hours showed no difference was observed between any treatment or 
genotype (Figure 4-2B; p>0.05, two-way ANOVA with Tukeys post hoc test; n= 5 
to 8 for both genotypes and drug treatment groups). Furthermore, no significant 
change was observed in H3Ac protein levels in either genotype at any of the 
earlier 0.5 hour and 1 hour time points (Figure 4-2C; p>0.05, two-way ANOVA 

































































































Figure 4-2 H3Ac levels in the hippocampus of WT and Mecp2
Stop/y
 mice are unaltered 
following kainic acid-induced epileptogenesis 
(A) Representative blot comparing H3Ac levels in WT and Mecp2
stop/y 
mice before and after 3 hours 
of kainic acid treatment. (B) Quantification of H3Ac before and 3 hours post kainic acid 
administration reveal no significant change in acetylated protein levels in either WT or Mecp2
stop/y 
mice (p>0.05, two-way AVOVA with Tukeys post hoc test; n=5 to 8 for both genotypes and drug 
treatment groups). (C) Pooled data showing H3Ac levels at a range of time points (0.5, 1 and 3 
hours) post kainic acid treatment. No significant change in either genotype is revealed at any other 
time point (p>0.05, two-way AVOVA with Tukeys post hoc test). Data expressed as mean ± SEM. 
Note experiments were conducted with mice under anaesthesia 
4.4.3 Modest histone H4 acetylation (H4Ac) alterations in WT and 
Mecp2-deficient mice after kainic acid treatment 
Histone H4 protein is another core component of nucleosomes, forming histone 
H3-H4 tetramers (Xu et al., 2010). Therefore, interactions can occur between 
the two histones potentially including modifications of their lysine residues. A 
previous report has shown application of kainic acid to WT mice result in an 
acute increase in histone h4 acetylation (H4Ac) after three hours (Sng et al., 
2006). To assess whether MeCP2 has any influence on H4Ac levels, I applied 
saline or evoked kainic-acid- induced seizures in WT and Mecp2stop/y mice (under 
light isoflurane anaesthesia; 2-5-3%) and quantified the levels of H4Ac in the 
hippocampus by western blot. A representative blot showing H4Ac levels after 
three hours of kainic acid can is shown in Figure 4-3A. 







































































Quantification at this time point showed there was no difference in H4Ac protein 
between WT and Mecp2stop/y mice, however there was an overall significance in 
treatment towards an increase in H4Ac levels in both genotypes following kainic 
acid administration (Figure 4-3B; p<0.05, two-way ANOVA with Tukeys post hoc 
test, n = 5 to 8 for both genotypes and drug treatment groups). Analyse of H4Ac 
protein levels at the earlier 0.5 hour and 1 hour time points, revealed that there 
was no significant change in either genotype (Figure 4-3B; p>0.05, two-way 










Figure 4-3 H4Ac levels in the hippocampus of WT and Mecp2
stop/y 
mice are unaltered 
between genotypes following kainic acid-induced epileptogenesis 
(A) Representative blot comparing histone H4 acetylation (H4Ac) levels in WT and Mecp2
stop/y 
mice 
before and after 3 hours of kainic acid treatment. (B) Quantification of H4Ac before and post 3 
hours kainic acid administration. No difference was apparent between genotypes but there was an 
overall significance in treatment towards an increase in H4Ac (p<0.05, two-way AVOVA with 
Tukeys post hoc test, n=5 to 8 for both genotypes and drug treatment groups). (C) Pooled data 
comparing H4Ac levels post kainic acid treatment at a range of time points (0.5, 1 and 3 hours). No 
significant change in either genotype is revealed at any other time point (p>0.05, two-way AVOVA 
with Tukeys post hoc test, n= same as above for all time points). Data expressed as mean ± SEM. 
Note experiments were conducted with mice under anaesthesia. 
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4.4.4 Anaesthetic effects on phosphorylation of Mecp2 and 
histone H3 and H4 acetylation  
4.4.4.1 Robust increase in phosphorylation of Mecp2 
General anaesthesia was administered throughout in most experiments for 
animal welfare reasons. However, it is known to suppress overall activity in the 
brain (White and Alkire, 2003, Peltier et al., 2005) and this may have an impact 
on molecular pathways involved in neuronal activity such as the phosphorylation 
of MeCP2. To investigate the variable effects of pS421 Mecp2 levels following 
kainic acid treatment in WT mice under anaesthesia, a small number of 
experiments were conducted in the absence of anaesthesia and the results 
compared. As seen in Figure 4-4, the initial observations show that basal pS421 
Mecp2 levels were similar in mice with and without anaesthesia. Additionally, 
mice administered kainic acid but that did not display any overt seizure as 
indicated by lack of erratic twitches, tail shaking, forelimb clonus and full tonic-
clonic seizures had comparable levels of basal pS421 Mecp2 to saline treated 
mice. Conversely a prominent increase in pS421 Mecp2 protein levels was 
present in mice without anaesthesia after three hours of kainic acid treatment 
compared to the variable levels of pS421 Mecp2 protein in mice under 
anaesthesia.  
 
Figure 4-4 Comparison of kainic acid seizure-mediated alterations in pS421 Mecp2 in 
presence and absence of anaesthesia. 
Representative western blot comparing the phosphorylation of Mecp2 levels (pS421 Mecp2) in WT 
mice with anaesthesia and without. Application of kainic acid (for 3 hours) without anaesthesia 
produces a robust increase in phosphorylation levels in the presence of an epileptic seizure 
compared to hippocampal samples under anaesthesia. Note mice that did not display a seizure 
have weak Mecp2 phosphorylation levels at serine 421. 
Subsequently, more replicates of WT mice treated with saline or kainic acid 
without anaesthesia was performed and levels of pS421 Mecp2 quantified to 
confirm these observations. A robust increase was observed in pS421 Mecp2 



































levels (3.4 ± 0.5 fold) after three hours of kainic acid treatment (Figure 4-5A-B; 
p<0.01, unpaired t-test, n=6 mice for both drug groups). All principal cells in the 
hippocampus showed high levels of pS421 Mecp2 immunoreactivity when 
immunostained at three hours following administration of kainic acid compared 
to saline control treated (Figure 4-5C). Only a few cells were weakly labeled for 
pS421 Mecp2 under control (saline treated) conditions.  However full 
quantitative analysis was not performed on these images. 









Figure 4-5 Robust increase in pS421 Mecp2 levels in the hippocampus of WT mice without 
anaesthesia following kainic acid treatment. 
(A-B) Representative western blot and bar plot showing a robust increase in pS421 Mecp2 protein 
levels in WT mice at three hours following kainic acid (KA) treatment in the absence of anaesthesia 
when compared with saline (SA) controls (p<0.01; unpaired t-test, n=6 mice for both drug groups). 
(C) WT brain sections immunostained for pS421 Mecp2 and total Mecp2 in control (saline) and 
kainic acid treatment (3hrs) in the dentate gyrus (DG) of the hippocampus. Note all pyramidal cells 
are immunostained strongly with pS421 Mecp2 following kainic acid. Data expressed as mean ± 
SEM and scale bar: 50µM. 
To access the total amount of MeCP2 that becomes phosphorylated in response 
to neuronal activity, hippocampal protein samples from mice treated with saline 
and kainic acid for three hours (not under anaesthesia) were run on a low 
percentage gel to separate out Mecp2 and any modified bands that were 
present. As observed in Figure 4-6A, two Mecp2 bands appeared in all samples 
treated with kainic acid. The upper band represented phosphorylated Mecp2, as 
previously described by Chen et al, 2003 who performed a similar experiment on 
rat cortical neurons and found that alkaline phosphatase treatment of their 
nuclear preparation eliminated this band (Chen et al., 2003). Quantification of 
this upper band in relation to the total levels of Mecp2 (lower band) showed  a 
DG 

























50 ± 7% increase in the levels of phosphorylated Mecp2 after kainic acid 
treatment compared to only a 5 ± 0.5% increase in saline controls (Figure 4-6B; 
p<0.01, unpaired t-test, n=5 mice for each drug treatment group). 










Figure 4-6 50% of Mecp2 is phosphorylated in the hippocampus of WT mice after kainic acid 
treatment. 
(A) Representative blot  showing the total levels of phosphorylated Mecp2 in the hippocampus of 
WT mice (upper band; Mecp2 is the lower band) before and after kainic acid treatment. SA = saline 
hippocampal samples, KA = kainic acid hippocampal samples and –ve = negative control (no 
Mecp2 staining). (B) Plot showing a 50% increase in phosphorylated Mecp2 levels in kainic acid 
treated samples (p<0.01, unpaired t-test, n=5 mice for each drug treatment group). Data expressed 
as mean ± SEM.  
4.4.4.2 Modest alterations in histone H3 and H4 acetylation 
To confirm that the negative results for histone acetylation above were not as a 
result of any confounding effects of anaesthesia, the levels of acetylation were 
measured in the small number of experiments not conducted under anaesthesia. 
A representative western blot showing relative H3Ac protein changes before and 
after three hours of kainic acid treatment in both WT and Mecp2-deficient mice 
is shown in Figure 4-7A. Quantification showed there was no difference in the 
levels of H3Ac before and after kainic acid treatment in WT mice (Figure 4-7B; 
p>0.05, two-way ANOVA with Tukeys post hoc test; n=6 mice for each genotype 
and drug treatment group). Mice that lack Mecp2 showed no difference in their 
H3Ac levels compared to WT mice under control conditions but appeared to have 
greater levels (0.5 fold) following kainic acid treatment in relation to WT 
(Mecp2-/y = 1.3 ± 0.06; WT = 0.8 ± 0.09; Figure 4-7B; p< 0.01, two-way ANOVA 
with post hoc test). This significance could be attributed to the slight decline 
observed in H3Ac in WT mice after kainic acid treatment. 
 











































Figure 4-7 Increase in H3Ac levels after kainic acid administration in the hippocampus of 
Mecp2
-/y
 mice without anaesthesia. 
(A) Representative blot comparing H3Ac in WT and Mecp2-/y mice before and after 3 hours of 
kainic acid treatment without anaesthesia. (B) Pooled data showing a 0.5 fold increase (p<0.01, 
two-way ANOVA with Tukeys post hoc test, n=6 mice for both genotypes and drug treatment 
groups) in Mecp2
-/y
 mice compared to WT mice after kainic acid treatment. Data expressed as 
mean ± SEM. 
Levels of H4AC were also determined in mice that were administered saline and 
kainic acid in the absence of anaesthesia. A representative western blot of H4Ac 
protein changes before and after three hours of kainic acid treatment in both 
WT and Mecp2-deficient mice is shown in Figure 4-8A. Quantification of the 
pooled data (Figure 4-8B) showed that there was no difference in H4Ac levels in 
WT mice following kainic acid treatment. Furthermore, although mice deficient 
in Mecp2 appeared to have greater levels of H4Ac under control conditions when 
compared to WT, this did not achieve statistical significance (p=0.27). However, 
there was an overall significance in H4Ac between genotypes (Figure 4-8B; p< 
0.05, two-way ANOVA with Tukeys post hoc test; n = 6 mice for both genotypes 




















































Figure 4-8 Altered H4Ac levels between genotypes in the hippocampus of WT and Mecp2
-/y
 
mice without anaesthesia. 
(A) Representative blot comparing H4Ac in WT and Mecp2
-/y
 mice before and after 3 hours of 
kainic acid treatment without anaesthesia. (B) Pooled data showing an overall significance in H4Ac 
between genotypes (p<0.05, two-way AVOVA with Tukeys post hoc test, n=6 mice for both 
genotypes and drug treatment groups). Data expressed as mean ± SEM. 
4.5 Discussion 
The function of MeCP2 was originally thought to be as a transcriptional repressor 
and that loss of function mutations in the protein would result in an over 
expression of genes it regulated and lead to the phenotype associated with RTT. 
However the last 10 years has seen this model challenged and other mechanisms 
have been put forward, for example, a role as a transcriptional activator 
(Chahrour et al., 2008), global transcriptional repressor (Skene et al., 2010) or 
regulator of chromatin looping (Horike et al., 2005). One of the most interesting 
findings in this period was the discovery that MeCP2 could be dynamically 
regulated by neuronal activity (Chen et al., 2003). In experiments described in 
this chapter, I have tried to investigate the possible effects of neuronal activity 
on the posttranslational modifications of MeCP2 and link this to potential 
alterations in histone acetylation. It was hoped that this would gain further 
insight into how MeCP2 regulates gene expression.  Overall the main finding of 
the current study was to demonstrate that phosphorylation of MeCP2 was not 
linked to any alterations in histone acetylation (H3Ac or H4Ac) in WT mice 
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following kainic acid treatment. However studies performed in Mecp2-deficient 
mice (Mecp2stop/y and Mecp2-/y) show that lack of Mecp2 may result in alterations 
in the regulation of histone acetylation under basal conditions and following 
kainic acid-induced neuronal activity.  
More specifically, I have shown that Mecp2 can be phosphorylated at residue 
serine 421 in the hippocampus (Figure 4-1 and Figure 4-5) and that ~50% of 
Mecp2 molecules are phosphorylated (Figure 4-6) following kainic-acid induced 
seizures. Importantly, the presence of a seizure was required to obtain an 
increase in phosphorylation. Levels of pS421 Mecp2 from mice that did not 
display any seizure like activity were extremely weak and comparable to control 
(saline) treated mice (Figure 4-4). These results suggest that MeCP2 can be 
posttranslationally modified and that high levels of MeCP2 are phosphorylated 
upon induction of neuronal activity. However it should be noted that the 
seizures generated following application of kainic acid do represent excessive 
neuronal activity. It is not clear which sites other than serine 421 are important 
in the activity dependent regulation of MeCP2. Recently, using a similar 
electrophoresis method to separate Mecp2 as I did in Figure 4-6, a study also 
established two Mecp2 bands from epileptic mouse brains which they subjected 
to mass spectrometry (Tao et al., 2009).  They identified other sites on Mecp2 
that can become phosphorylated including serine residues 149, 164, 421 and 
424. The latter two residues were only observed in the upper band that was 
produced in epileptic samples suggesting that these two phosphorylation sites 
were important upon induction of neuronal activity.  
The Tao group also discovered phosphorylation at serine 80 was important in 
resting neurons which could become dephosphorylated upon neuronal activity  
(Tao et al., 2009). Knockin mouse models were created with mutations at either 
serine 80 or 421 and producing opposing behaviours with the latter displaying 
decreased motor control and the former increased locomotor control (Tao et al., 
2009). This suggests that phosphorylation at specific residues sites on MeCP2 
could have differing effects on MeCP2 function. These findings correlate with 
another recent study which highlights the specific site of phosphorylation on 
MeCP2, duration and type of the stimuli and exact gene being investigated are 
important for determining whether MeCP2 acts as a repressor or activator of 
gene transcription (Gonzales et al., 2012). Additionally, they could explain why 
  113 
 
 
another study found that mutating both serine 421 and 424 in Mecp2 enhanced 
Mecp2 occupancy at the Bdnf promoter and increased transcription in the 
hippocampus (Li et al., 2011) whereas the original work on phosphorylation at 
serine 421 identified a reduction in Bdnf transcription in cortical neurons (Zhou 
et al., 2006). 
Furthermore, phosphorylation of MeCP2 at specific residues and binding of 
MeCP2 to specific gene promoters, as mentioned in the previous studies, could 
potentially explain why I was unable to associate any alterations in 
phosphorylation with an increase in histone H3 or H4 acetylation in WT mice 
(Figure 4-2, 4-2, 4-7 and 4-8). My original theory focussed on MeCP2 having a 
role as transcriptional repressor and recruiting histone deacetylase proteins to 
silence genes when neurons were quiescent (Nan et al., 1998). Subsequently, 
upon neuronal activation MeCP2 could dissociate away from these genes 
resulting in gene activation, aided by histone acetylation.  However my data did 
not support this model. As the developing brain is constantly responding to 
various activity-dependent inputs (reviewed by West and Greenberg, 2011), 
differential posttranslational modifications of MeCP2 and the type of  external 
stimuli could determine the specific targets and function of MeCP2 in various 
brain regions throughout development.  
Conflicting with the idea of MeCP2 as a regulator of specific ‘target genes’, 
recent ChIP-seq analysis has established that the pan-MeCP2 antibody and 
phosphorylated Mecp2 are strongly associated with methylated DNA (silenced 
genes) throughout the entire genome regardless of whether any neuronal 
activation is present (Cohen et al., 2011). They also discovered that the 
induction of activity-dependent genes such as BDNF remains unaltered following 
phosphorylation at serine 421. These results suggest that there is a weaker 
association with phosphorylated MeCP2 and genes that are actively transcribed 
and interestingly contradicts the original findings from this group in which they 
reported an increase in the transcription of BDNF with phosphorylation of Mecp2 
(Zhou et al., 2006). The results obtained in this chapter, in which I could not 
show evidence for any increase in acetylation with elevated Mecp2 
phosphorylation levels is in support of this finding as lack of actively transcribed 
genes is usually associated with a condensed chromatin state and thus less 
histone acetylation (reviewed by MacDonald and Roskams, 2009). 
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Regardless of whether MeCP2 has a more specific or global role in the regulation 
of gene expression, how MeCP2 reacts and adapts to changes in neuronal activity 
in its immediate environment will be similar for both. For example accurate 
timing of events will be important for proper MeCP2 regulation of genes and 
histone deacetylase proteins it interacts with. As many transcriptional responses 
are dynamic and transient, there will be a rapid change in the levels of 
acetylated and deacetylated histone in order to restore gene expression to basal 
levels. Reversal of deacetylated proteins can occur in 5-8 minutes but 
acetylation can be reversed more rapidly, ~1.5 minutes (Katan-Khaykovich and 
Struhl, 2002). Any disruption to this tightly controlled process could lead to 
alterations in gene expression. Interestingly although I did not detect an 
increase in histone acetylation in WT mice following induction of neuronal 
activity with the convulsant drug kainic acid I observed a significant elevation in 
H3Ac following induction of neuronal activity in Mecp2-deficient mice (Figure 4-
7). This could suggest the mechanisms and timing by which Mecp2 regulates gene 
expression under dynamic processes is disrupted as more acetylated histone 
proteins were present than in WT conditions.  
The speed at which histone proteins become acetylated and deacetylated may 
also contribute to the lack of acetylation observed in WT mice in this chapter. As 
previous studies have shown a continuous increase in H4Ac in the hippocampus 
following kainic acid administration from 0.5-3 hours (Sng et al., 2006), I based 
my experimental design around these time points.  However as the histone 
acetylation turns over quickly (Katan-Khaykovich and Struhl, 2002), I could be 
missing early changes in histone acetylation. Alternatively, the time it takes for 
kainic acid to induce neuronal activity in cells and thus alter acetylation and 
deacetylation levels could take longer than the time points analysed (0.5-3 
hours) therefore centring the time after kainic acid administration could mean I 
have missed later events, although this is unlikely as I observe seizures within 
minutes of administering kainic acid without anaesthesia. Additionally, other 
experimental variables that could be contributing to the lack of increase in 
histone acetylation could be the lysine residues that the H3Ac antibody and H4Ac 
antibody bind to do not become acetylated. Although the antibodies used in this 
study bind regions on histone tails that are associated with active euchromatin 
(lysine residue 5, 8, 12 and 16 for H4Ac, Clarke et al., 1993; lysine residue 9 and 
  115 
 
 
14 for H3Ac, Roh et al., 2005), some histone acetyltransferase (HAT) enzymes 
which acetylate lysine amino acids can be quite specific in terms of the 
individual lysine residues and particular histones. For example, a specific type of 
HAT Gcn5 preferentially acetylates lysine 14 of histone H3 and lysine 8 and 16 of 
histone H4 (Kuo et al., 1996). This could mean that depending on which HAT 
kainic acid induced neuronal activity activates, the binding to all acetylated 
residues might be weakening the effect if the acetylation is more specific. 
However the antibody used by Sng et al, 2006 mentioned above was same H4Ac 
antibody I used in my experiments binding to all four lysine residues and they 
still observed elevated histone acetylation levels in WT mice following kainic 
acid treatment.  
There are other experimental differences from the Sng et al, 2006 group that 
might account for why my results contradict theirs. Firstly, since the strain of 
mouse can differentially influence cellular responses following kainic acid-
induced seizures (Schauwecker and Steward, 1997), the fact that my mice were 
on a C57BL6/J background compared to their Std-ddY mice could have an effect. 
Secondly, the method used for extracting nuclear proteins in the paper was 
significantly different to mine. My method was optimised in the first instance by 
homogenising whole hippocampal lysates without losing any protein to obtain a 
clear nuclear MeCP2 protein band (Appendix A, Supplementary Figure 1-1). 
However the above study used a more complex approach including sonication 
and precipitation of samples to obtain histone proteins.  My method may not be 
sensitive enough to detect changes in histone acetylation or potentially Sng et al 
are removing too much of their protein in their nuclear preparation thus their 
findings are not accurate. 
Finally, another major experimental variable that could have been influencing 
my results was anaesthesia. At the recommendation of the vet, I applied volatile 
isoflurane to the mice before kainic acid or saline was administered to minimise 
the stress to the mice.  However, anaesthesia is known to suppress overall 
activity in the brain (White and Alkire, 2003, Peltier et al., 2005) which may 
impact on activity-dependent alterations in cellular pathways such as the 
phosphorylation of MeCP2. Indeed only a subtle and variable increase in 
phosphorylation of Mecp2 was observed in WT mice that were administered 
kainic acid under anaesthesia (Figure 4-1). In comparison, samples from 
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unanaesthetised WT mice showed a robust increase in phosphorylation of Mecp2 
with all principal cells in the hippocampus strongly immunoreactive for pS421 
Mecp2 (Figure 4-4 and Figure 4-5). It is possible then that the dampening effect 
of anaesthetic administration could be minimizing the extent of phosphorylation.  
Isoflurane anaesthetics bind to a variety of target proteins in the brain including 
GABAA receptors, glycine receptors (Harrison et al., 1993), AMPA and NMDA 
receptor mediated ion channels (Carlà and Moroni, 1992) and two-pore 
potassium channels (Patel et al., 1999). The overall effect is to alter the balance 
of excitation and inhibition in the brain and dampen activity. Although the 
effects of anaesthetic are evident on phosphorylation of Mecp2, alterations in 
histone acetylation were less pronounced. The results in both the presence and 
absence of anaesthesia showed only subtle differences and it is possible that the 
excitability threshold for phosphorylation of MeCP2 and histone acetylation is 
different and thus the strength of neuronal activity applied could have a 
differential effect on their activity.    
In conclusion, my work and the above studies on phosphorylation of MeCP2 
highlight the complex role neuronal activity has on controlling MeCP2 and gene 
expression. In this chapter I have shown that induction of neuronal activity using 
the convulsant drug kainic acid leads to an increase in the phosphorylation of 
Mecp2 but was not linked to any alterations in histone acetylation (H3Ac or 
H4Ac) in WT mice following kainic acid treatment. This could be due to histone 
acetylation and phosphorylation of MeCP2 at specific target genes. The effect 
could be getting diluted as I am looking at global changes in histone acetylation 
in the hippocampus. Future experimental approaches studying this phenomenon 
over specific gene locus using ChIP and antibodies against pS421 MeCP2 and 
acetylated histones could help explore this theory. The experiments performed 
on Mecp2-deficient mice in this chapter show that lack of Mecp2 may result in 
alterations in the regulation of histone acetylation following kainic acid-induced 
neuronal activity. However, this result is still quite subtle and variable leading 
to controversy in the results. Designing a study with a higher degree of 
specificity and resolution will enable a more definitive judgment to be made on 




An investigation of histone protein levels in Mecp2 






In the previous chapter I investigated the influence of neuronal activity on the 
posttranslational modifications of Mecp2 and levels of histone acetylation in WT 
and Mecp2-deficient mice. I demonstrated that neuronal activity can lead to the 
phosphorylation of MeCP2 at serine 421 in WT mice but the changes in histone 
acetylation levels, as measured by western blot, in both WT and Mecp2-deficient 
mice were subtle and highly variable. The inconsistencies in histone measures 
could be partially due to the confounding actions of anaesthetic administration 
which may have dampened neuronal activity and prevented the occurrence of 
clear effects on histone acetylation. Another contributing factor could be the 
sensitivity of the assay being used to determine effects and, in particular, the 
difficulty of detecting very subtle changes in histone acetylation by western 
blot. To overcome this, another approach was devised and refined to investigate 
the potential relationship between MeCP2 and histone acetylation in neurons. 
For a more accurate assessment of MeCP2 influence on histone acetylation 
levels, I utilised  female mice heterozygous for Mecp2 null mutation, a more 
accurate model of RTT in girls (Chen et al. 2001; Guy et al. 2001). As MECP2 is 
an X-linked gene random X-chromosome inactivation at the cellular level results 
in inactivation of either the WT or mutant allele. Therefore, the female RTT 
patients or heterozygous mice will have a cell population that is mosaic for 
expression of the mutant allele. This phenomenon in heterozygous female mice 
creates a valuable internal standard by which quantitative immunofluorescence 
imaging can be used to compare differences in cells that express the mutant 
gene with those that have a normal copy. Normally there are variables 
associated with quantitative immunofluorescence imaging that make it difficult 
to compare the fluorescence intensity between two different samples (e.g. brain 
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sections/mice) accurately. For example, if I was observing the fluorescence 
intensity of histone acetylation in brain sections from WT and Mecp2-deficient 
mice, variables from the immunostaining process such as the amount of antibody 
that can penetrate the tissue and differential fixation in the mice (more or less 
crosslinking) could introduce unknown variability in to the results. However, as I 
am comparing the effects of two cells within the same section, most variables 
are minimised as the ratio difference between Mecp2 positive and negative 
nuclei in theory should be consistent. Furthermore there is power in this analysis 
to look at many cells from specific regions at once therefore highlighting any 
subtle differences that are present. 
5.2 Study aim 
A dominant hypothesis is that MeCP2 regulates gene expression through 
influencing histone protein acetylation. In this study my aim was to investigate 
the relationship between Mecp2 levels and the levels of histone H3 and H4 
acetylation using an immunohistochemistry based method in Mecp2+/- 
heterozygous mice. The specific aims were to: 
i. Determine whether there is any difference in histone H3 and H4 
acetylation and total levels of histone H3 and H4 in nuclei positive and 
negative for Mecp2 protein in the hippocampal formation. 
ii. Investigate the effect neuronal activity has on the regulation of these 
histone proteins in nuclei positive and negative for Mecp2 in the 
hippocampal formation. 
5.3 Methods 
Kainic acid (25mg/kg) or saline (controls) was applied intraperitoneally to pre-
symptomatic Mecp2GFP/- female mice aged 10-13 weeks (in the absence of 
anaesthesia) and monitored for seizure score over a three hour period. At the 
end of each experiment, mice were culled humanely by overdose of sodium 
pentobarbital (Euthatal) and fixed by intracardiac perfusion as described in 
chapter two. The brains were removed, post-fixed in the same fixative and 
coronal brain sections (30µm spanning) cut on a vibratome ready for 
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immunohistochemistry. This technique was performed as stated in chapter two, 
whereby brain sections underwent an antigen retrieval step before incubation 
with primary antibodies rabbit anti-acetyl-Histone H3 (acetylated on lysines 9 
and 14, 1/200), rabbit anti-acetyl-Histone H4 (acetylated on lysines 5, 8, 12 and 
16, 1/100), rabbit anti-Histone H3 (1/100) and mouse anti-Histone H4 (1/200) 
for two-three days. All histone H4 antibodies were incubated on the same brain 
sections.  Afterward, fluorescent secondary antibodies (Alexa fluor 546 goat 
anti-mouse and Alexa fluor 647 goat anti-rabbit) were added to sections 
overnight in the dark. Subsequently, sections were incubated with the nuclei 
marker DAPI (20mg/ml stock; 1/1000 working dilution) for 20 minutes then 
mounted onto coverslips. At least two random and non-overlapping image stacks 
of the hippocampal formation in the DG and CA1 region for each section were 
collected on a Leica SP5 Confocal microscope equipped with diode (405nm), 
argon (488nm), diode pumped solid-state (DPSS; 561nm) and red helium-neon 
(633nm) lasers.  
Differences in all histone protein intensities between Mecp2 positive and 
negative nuclei were quantified using a custom written (Dr David Kelly, 
University of Edinburgh) automated script in Image-pro Plus 6.0 described in 
detail in chapter two. The script determined three parameters for every nucleus 
in the image stack: 1. the mean intensity for that particular histone antibody, 2. 
the nuclei volume and 3. whether Mecp2 was present or not. In order to avoid 
the problem of determining which parameter (stack, section or animal) to 
normalise the data to when quantifying intensities, a chi-square test was 
performed. For each histone protein, the chi-square test derived whether there 
was a change in the distribution of Mecp2 positive and negative nuclei above the 
median or in the upper quartile intensity values.  
Firstly the histone protein intensities for each nucleus in the section were 
ranked in order from highest to lowest. The number of Mecp2 positive and 
negative nuclei with histone intensities above the median or in the upper 
quartile was then calculated, these were referred to as the observed values. If 
the histone intensities of both nuclei types are normally distributed then it is 
expected that 50% of each nuclei type would have histone intensities above the 
median and 25% of each nuclei type would have histone intensities in the upper 
quartile. For example if there were 60 nuclei in total and 40 nuclei were 
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negative for Mecp2 and 20 nuclei positive for Mecp2, then you would expect 20 
Mecp2 negative and 10 Mecp2 positive nuclei to be above the median histone 
intensity. Furthermore you would expect 10 Mecp2 positive nuclei and 5 Mecp2 
negative nuclei above the upper quartile histone intensity. Collectively these 
were referred to as the expected values. A chi-square analysis then determined 
if the observed value for each nuclei type significantly differed from the 
expected value. If a difference was present, this could indicate that there was a 
relationship between Mecp2 levels and levels of that specific histone protein. 
The statistics were done on the raw number counts and not percentages of 
Mecp2 positive and negative nuclei to ensure that sections with smaller numbers 
of nuclei do not disproportionately affect the overall chi-squared value. 
Percentages were summarised at the end to obtain the magnitude of any affect 
present. 
5.4 Results 
5.4.1 Nuclei deficient in Mecp2 display a 5% reduction in their 
nuclear volume 
Measurement of nuclear volume is essential for accurately calculating nuclear 
protein abundance. To investigate whether there were any differences in 
architecture of Mecp2 positive and negative nuclei, the volume of each nucleus 
was quantified from 3D images in which DAPI labelling was used to detect the 
nucleus. Analysis was performed from three different mice under saline control 
conditions in the hippocampal formation (DG and CA1). The micrograph in Figure 
5-1A shows a representative image of DAPI immunostained nuclei co-localised 
with Mecp2 positive nuclei.  Three dimensional reconstructions of DG granule 
nuclei revealed the nuclear volume to be smaller in Mecp2-deficient nuclei 
(195.4 ± 1.6µm3) compared to neighbouring Mecp2 containing nuclei (204.5 ± 
2.3µm3). This corresponded to a 5% reduction in nuclear volume (Figure 5-1Bi-ii; 
p<0.001, unpaired t-test, n = 177-243 nuclei from three mice). A similar effect 
was observed in pyramidal nuclei in the CA1 whereby nuclear volume was 
smaller in Mecp2-deficient nuclei (328.4 ± 4.3µm3) compared to Mecp2 positive 
nuclei (344.8 ± 5.4µm3). This also equated to a 5% reduction in nuclear volume in 
this area (Figure 5-1Ci-ii; p<0.05, unpaired t-test, n = 89-179 nuclei from three 
mice).  
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Figure 5-1 5% reduction in nuclear volume in nuclei deficient in Mecp2  
(A) Example micrograph showing DAPI immunostained nuclei (and co-localised Mecp2 positive 
nuclei) in the DG of the hippocampal formation used to create the 3D images for volume 
measurements. The white box shows the location of nuclei in the bottom higher magnification 
image. White arrows highlight nuclei which do not contain Mecp2 and blue arrows indicate those 
that do. (Bi) Bar graph of nuclei volume in the DG showing a 5% decrease in volume in nuclei that 
lack Mecp2 compared to those that do not (p<0.001, unpaired t-test, n = 177-243 nuclei from three 
mice). The spread of this data is shown in the scatter plot (Bii). (Ci) Quantification of nuclei volume 
in the CA1 displaying a 5% reduction in nuclei deficient in Mecp2 (p<0.05, unpaired t-test, n = 89-
179 nuclei from three mice). The spread of this data is expressed in the scatter plot (Cii). Data 
expressed as mean ± SEM in the bar graphs. Scale bar = 25µM; +ve = positive nuclei and –ve = 
negative nuclei. 
 
5.4.2 Levels of histone H3 acetylation was unaltered between 
Mecp2 containing and Mecp2-deficient nuclei in the 
hippocampal formation  
Three dimensional reconstructions of CA1 and DG nuclei in the hippocampal 
formation revealed the nuclear volume to be smaller by 5% in Mecp2-deficient 
nuclei compared to neighbouring Mecp2 containing nuclei. This could affect the 
measures of mean intensity of histone proteins; therefore all mean intensity 
values for each nucleus were multiplied by their volume measurement to 
compensate and obtain an integrated density value. Previously I observed no 
change in histone H3 acetylation (H3Ac) levels between Mecp2-/y male mice and 
their WT littermates in the hippocampus under saline control conditions 
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cell level, I determined whether there was a difference in the distribution of 
H3Ac intensities in nuclei positive and negative for Mecp2 from heterozygous 
female mice. In Figure 5-2, a representative micrograph can be observed of 
nuclei immunostained with H3Ac and Mecp2 status displayed through 
fluorescence of the EGFP fusion protein in the DG of the hippocampal formation 
(Figure 5-2A). There was no difference in the observed and expected number of 
Mecp2 negative nuclei above the median H3Ac intensity value. (Figure 5-2B; 
p=0.905, chi-square test; n = 7 sections from three mice). Therefore the 
percentage of Mecp2 positive (46.5 ± 1.3%) and negative nuclei (53.1 ± 2%) above 
the H3Ac median intensity value (Figure 5-2Di) were not different as the chi-
square value indicated no significance. 
Furthermore, to determine if a subset of the population of nuclei varied in H3Ac 
protein levels, the number of nuclei that were positive or negative for Mecp2 in 
the top 25% (in the upper quartile) of H3Ac intensities was measured. Similarly, 
there was no difference in the observed number of Mecp2 negative nuclei in the 
upper quartile H3Ac intensity values and the expected number of top 25% Mecp2 
negative nuclei (Figure 5-2C; p=0.766, chi-square test). As this chi-square 
statistic was not significant, there was no difference in the percentage of Mecp2 
positive nuclei (22.9 ± 1.1%) in the upper quartile H3Ac intensity values 
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H3Ac Section 1 2 3 4 5 6 7 
# of -ve nuclei above the median 28 25 28 13 31 60 25 
# of +ve nuclei above the median 46 34 22 35 23 41 23 
Expected (E) 24 24 27 14 31 53 22 
(O-E) 4 1 1 -1 0 7 3 
(O-E)
2 16 1 1 1 0 49 9 
(O-E)
2
/E 0.666 0.041 0.037 0.071 0 0.924 0.409 
        Degrees of freedom 6
      Sum chi-squared 2.15
      P-value 0.90 5
      
 
 
Figure 5-2 Unaltered H3AC levels in DG granule cell nuclei of the hippocampal formation 
between Mecp2 nuclei type under saline control conditions 
(A) Representative image of DG granule cell nuclei immunostained for H3Ac and Mecp2 status 
displayed through fluorescence of the EGFP fusion protein. White arrows highlight example nuclei 
which do not contain Mecp2 and blue arrows indicate those that do. (B-C) Tables showing the 
number of Mecp2 positive and negative nuclei above the overall median (B) and upper quartile (C) 
for H3Ac intensity values from sections used for chi-square analysis. Chi-square statistic is derived 
from the expected and observed number of Mecp2 negative nuclei present. The number of 
observed nuclei was not different to the expected number in both cases (p= 0.905 for (B) and 
p=0.766 (C), chi-square test, n = 7 sections from 3 mice). (Di-ii) Summary plots showing the 
percentage of each nuclei type above the median (Di) and in the upper quartile (Dii) H3Ac intensity 
values. Data expressed as mean ± SEM in the bar graphs. Scale bar = 25µM; +ve = positive nuclei 
and –ve = negative nuclei. 
 
H3Ac Section 1 2 3 4 5 6 7 
# of -ve nuclei in the upper quartile  14 15 13 5 16 31 13 
# of +ve nuclei in the upper quartile  23 15 12 19 20 19 11 
Expected (E) 12 12 14 7 14 26 11 
(O-E) 2 3 -1 -2 2 5 2 
(O-E)
2 4 9 1 4 4 25 4 
(O-E)
2
/E 0.333 0.75 0.071 0.571 0.285 0.961 0.363 
        Degrees of freedom 6
      Sum chi-squared 3.33
      P-value 0.766
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To verify the distribution of H3Ac intensities the investigation was extended by 
conducting a similar analysis in hippocampal area CA1. In Figure 5-3, a 
representative micrograph of nuclei immunostained with H3Ac and Mecp2 status 
displayed through fluorescence of the EGFP fusion protein in the CA1 of the 
hippocampal formation is shown (Figure 5-3A). Quantification revealed there 
was no difference in the observed and expected number of Mecp2 negative 
nuclei above the median H3Ac intensity value (Figure 5-3B; p=0.92, chi-square 
test; n = 10 sections from three mice).  As this chi-square statistic was not 
significant, there was no difference in the percentage of Mecp2 positive nuclei 
(43.5 ± 2.5%) above the median H3Ac intensity values compared to Mecp2 
negative nuclei (53.7 ± 1.8%; Figure 5-3Di). Any slight deviations in percentage 
were thus likely due to random chance. 
Additionally there was no difference in the observed and expected number of 
Mecp2 negative nuclei in the upper quartile H3Ac intensity values although a 
small increase in the number of observed Mecp2 negative nuclei was seen in 7 
out of 10 sections (Figure 5-3C; p=0.42, chi-square test). This would account for 
the percentage of nuclei in the upper quartile H3Ac intensity values in Mecp2 
positive nuclei (19.8 ± 2.1%) to be lower than Mecp2 negative nuclei (28.9 ± 
1.7%) however as the chi-square statistic was not significant and the difference 
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Figure 5-3 Unaltered H3AC levels in CA1 pyramidal cell nuclei of the hippocampal formation 
between Mecp2 nuclei type under saline control conditions 
(A) Representative image of CA1 pyramidal cell nuclei immunostained for H3Ac and Mecp2 status 
displayed through fluorescence of the EGFP fusion protein. White arrows highlight example nuclei 
which do not contain Mecp2 and blue arrows indicate those that do. (B-C) Tables showing the 
number of Mecp2 positive and negative nuclei above the overall median (B) and upper quartile (C) 
for H3Ac intensity values from sections used for chi-square analysis. Chi-square statistic is derived 
from the expected and observed number of Mecp2 negative nuclei present. The number of 
observed nuclei was not different to the expected number in both cases (p= 0.92 for (B) and p=0.42 
(C), chi-square test, n = 10 sections from 3 mice). (Di-ii) Summary plots showing the percentage of 
each nuclei type above the median (Di) and in the upper quartile (Dii) H3Ac intensity values. Data 
expressed as mean ± SEM in the bar graphs. Scale bar = 25µM; +ve = positive nuclei and –ve = 
negative nuclei. 
H3Ac Section 1 2 3 4 5 6 7 8 9 10 
# of -ve nuclei above the median 26 27 24 28 11 18 33 30 19 23 
# of +ve nuclei above the median 16 13 25 21 16 9 16 12 17 20 
Expected (E) 24 24 24 27 16 17 33 25 21 20 
(O-E) 2 3 0 1 -5 1 0 5 -2 3 
(O-E)
2 4 9 0 1 25 1 0 25 4 9 
(O-E)
2
/E 0.166 0.375 0 0.037 1.56 0.058 0 1 0.190 0.45 
           Degrees of freedom 9 
         Sum chi-squared 3.8 
         P-value 0.92 
         
H3Ac Section 1 2 3 4 5 6 7 8 9 10 
# of -ve nuclei in the upper quartile  16 16 10 15 3 10 18 14 8 14 
# of +ve nuclei in the upper quartile  5 4 14 9 12 3 6 7 10 8 
Expected (E) 12 12 12 14 8 9 17 12 11 10 
(O-E) 4 4 -2 1 -5 1 1 2 -3 4 
(O-E)
2 16 16 4 1 25 1 1 4 9 16 
(O-E)
2
/E 1.333 1.333 0.333 0.071 3.125 0.111 0.058 0.333 0.818 1.6 
           Degrees of freedom 9
         Sum chi-squared 9.11
         P-value 0.42
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In Chapter 4, I observed a 0.5 fold increase in H3Ac protein levels as revealed by 
western blot in the hippocampus of Mecp2-/y male mice compared to their WT 
littermates following three hours of neuronal activity. To determine the 
regulation of H3Ac under similar conditions using my refined method of 
quantification, I investigated whether there was a difference in the proportion 
of Mecp2 positive and negative nuclei with H3Ac following the induction of 
neuronal activity by application of the convulsant drug kainic acid. A 
representative micrograph of the nuclei immunostained with H3Ac and Mecp2 
status displayed through fluorescence of the EGFP fusion protein in the DG of 
the hippocampal formation following induction of neuronal activity is shown in 
Figure 5-4A. Chi-square analysis revealed that there was no difference in the 
number of observed Mecp2 negative nuclei above 50% (Figure 5-5B; p=0.99, chi-
square test; n= 15 sections from four mice) or 25% (Figure 5-4C; p=0.99, chi-
square test) of the highest H3Ac intensities and expected numbers. Chi square 
tests thus confirmed that there was no significant difference in the percentage 
of Mecp2 positive above the median (47.9 ± 2.1%) and upper quartile (25.8 ± 
1.3%) H3Ac intensity values compared to Mecp2 negative nuclei (51.1 ± 1.3% for 
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H3Ac Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
# of -ve nuclei in the 
upper quartile  7 10 9 7 16 16 11 13 16 8 13 5 7 21 14 
# of +ve nuclei in the 
upper quartile 16 16 16 15 5 11 4 12 16 9 13 9 8 6 10 
Expected (E) 9 8 11 9 14 18 11 11 15 8 12 7 7 19 15 
(O-E) -2 2 -2 -2 2 -2 0 2 1 0 1 -2 0 2 -1 
(O-E)
2 4 4 4 4 4 4 0 4 1 0 1 4 0 4 1 
(O-E)
2
/E 0.444 0.5 0.364 0.444 0.286 0.222 0 0.364 0.067 0 0.083 0.574 0 0.211 0.066 
                Degrees of freedom 14
              Sum chi-squared 3.62
              P-value 0.99
              
 
Figure 5-4 Unaltered H3AC levels in DG granule cell nuclei of the hippocampal formation 
between Mecp2 nuclei type after kainic acid application 
(A) Representative image of DG granule cell nuclei immunostained for H3Ac and Mecp2 status 
displayed through fluorescence of the EGFP fusion protein following neuronal activity. White 
arrows highlight example nuclei which do not contain Mecp2 and blue arrows indicate those that 
do. (B-C) Tables showing the number of Mecp2 positive and negative nuclei above the overall 
median (B) and upper quartile (C) for H3Ac intensity values from sections used for chi-square 
analysis. Chi-squared statistic is derived from the expected and observed number of Mecp2 
negative nuclei present. The number of observed nuclei was not different to the expected number 
in both cases (p= 0.99 for (B) and (C), chi-square test, n = 15 sections from 4 mice). (Di-ii) 
Summary plots showing the percentage of each nuclei type above the median (Di) and in the upper 
quartile (Dii) H3Ac intensity values. Data expressed as mean ± SEM in the bar graphs. Scale bar = 
25µM; +ve = positive nuclei and –ve = negative nuclei. 
H3Ac Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
# of -ve nuclei above the 
median 21 16 24 17 32 36 18 23 31 16 24 12 15 42 30 
# of +ve nuclei above the 
median 26 35 27 26 9 18 12 26 32 18 29 16 15 13 17 
Expected (E) 19 17 22 17 29 36 21 21 31 16 23 15 14 39 30 
(O-E) 2 -1 2 0 3 0 -3 2 0 0 1 -3 1 3 0 
(O-E)
2 4 1 4 0 9 0 9 4 0 0 1 9 1 9 0 
(O-E)
2
/E 0.210 0.059 0.181 0 0.310 0 0.429 0.190 0 0 0.043 0.6 0.071 0.231 0 
                Degrees of freedom 14
              Sum chi-squared 2.32
              P-value 0.99
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Equally, there was no difference in the observed number of Mecp2 negative 
nuclei above the median H3Ac intensity value and expected 50% of the total 
MeCP2 negative nuclei number in the CA1 following neuronal activity induction 
(Figure 5-5B; p=0.98, chi-square test; n = 14 sections from four mice).  As this 
chi-square statistic was not significant there was no difference in the percentage 
of Mecp2 positive nuclei (43 ± 2.2%) above the median H3Ac intensity value 
compared to Mecp2 negative nuclei (54.9 ± 2.1%; Figure 5-5Di). 
Finally, there was no difference in the observed number of Mecp2 negative 
nuclei in the upper quartile H3Ac intensity values and the expected number of 
Mecp2 negative nuclei following induction of neuronal activity (Figure 5-5C; 
p=0.85, chi-square test). Therefore the percentage of Mecp2 positive nuclei 
(20.2 ± 2.5%) compared to Mecp2 negative nuclei (29.4 ± 1.9%) nuclei in the 
upper quartile H3Ac intensity values was also due to random chance as the chi-
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H3Ac Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
# of -ve nuclei above the 
median 18 20 18 13 20 13 7 11 17 16 19 15 20 21 
# of +ve nuclei above the 
median 18 13 11 19 6 3 5 6 7 6 11 10 8 6 
Expected (E) 19 16 20 14 19 12 6 8 13 14 19 14 18 20 
(O-E) -1 4 -2 -1 1 1 1 3 4 2 0 1 2 1 
(O-E)
2 1 16 4 1 1 1 1 9 16 4 0 1 4 1 
(O-E)
2
/E 0.053 1 0.2 0.071 0.053 0.083 0.167 1.125 1.231 0.286 0 0.071 0.222 0.05 
               Degrees of freedom 13
             Sum chi-squared 4.56
             P-value 0.98
              
H3Ac Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
# of -ve nuclei in the 
upper quartile 9 11 10 6 8 6 3 7 8 11 10 9 12 10 
# of +ve nuclei in the 
upper quartile 9 6 5 10 5 2 3 2 4 0 5 3 2 3 
Expected (E) 9 8 10 7 10 6 3 4 7 7 10 7 9 10 
(O-E) 0 3 0 -1 -2 0 0 3 1 4 0 2 3 0 
(O-E)
2 0 9 0 1 4 0 0 9 1 16 0 4 9 0 
(O-E)
2
/E 0 1.125 0 0.143 0.4 0 0 2.25 0.138 2.286 0 0.571 1 0 
               Degrees of freedom 13
             Chi-squared 7.917
             P-value 0.85
             
Figure 5-5 Unaltered H3AC levels in CA1 pyramidal cell nuclei of the hippocampal formation 
between Mecp2 nuclei type after kainic acid application 
(A) Representative image of CA1 pyramidal cell nuclei immunostained for H3Ac and Mecp2 status 
displayed through fluorescence of the EGFP fusion protein following neuronal activity. White 
arrows highlight example nuclei which do not contain Mecp2 and blue arrows indicate those that 
do. (B-C) Tables showing the number of Mecp2 positive and negative nuclei above the overall 
median (B) and upper quartile (C) for H3Ac intensity values from sections used for chi-square 
analysis. Chi-square statistic is derived from the expected and observed number of Mecp2 
negative nuclei present. The number of observed nuclei was not different to the expected number 
in both cases (p= 0.98 for (B) and p= 0.85 for (C), chi-square test, n = 14 sections from 4 mice). 
(Di-ii) Summary plots showing of the percentage of each nuclei type above the median (Di) and in 
the upper quartile (Dii) H3Ac intensity values. Data expressed as mean ± SEM in the bar graphs. 
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5.4.3 Levels of total histone H3 was unaltered between Mecp2 
containing and Mecp2-deficient nuclei in the hippocampal 
formation 
As a set of control experiments, I also examined levels of total Histone H3 
protein to establish whether Mecp2 deficiency affects basal histone levels. I 
investigated the difference in the proportion of Mecp2 positive and negative 
nuclei with total histone H3 in the hippocampus under saline control conditions 
as well as following induction of neuronal activity using kainic acid as described 
previously. An example image of the nuclei immunostained with total histone H3 
and Mecp2 status displayed through fluorescence of the EGFP fusion protein in 
the DG of the hippocampus under saline control conditions is shown in Figure 5-
6A. Chi-square analysis revealed that there was no difference in the number of 
observed Mecp2 negative nuclei above 50% (Figure 5-6B; p=0.55, chi-square test; 
n= 8 sections from 3 mice) or 25% (Figure 5-6C; p=0.64, chi-square test) of the 
highest histone H3 intensities and expected numbers. The lack of significance in 
these tests confirmed that there was no difference in the percentage of Mecp2 
positive above the median (47.6 ± 4.3%) and in the upper quartile (24.3 ± 2.4%) 
H3Ac intensity values compared to Mecp2 negative nuclei (53.6 ± 1.3% for above 
median; 26.8 ± 2.6% for in the upper quartile) as the results were due to random 
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H3 Section 1 2 3 4 5 6 7 8 
# of -ve nuclei above the median 10 18 14 18 16 12 30 17 
# of +ve nuclei above the median 9 19 7 4 15 22 30 16 
Expected % (E) 11 17 15 16 12 16 25 12 
(O-E) -1 1 -1 2 4 -4 5 5 
(O-E)
2 1 1 1 4 16 16 25 25 
(O-E)
2
/E 0.091 0.059 0.066 0.25 1.33 1 1 2.08 
         Degrees of freedom 7
       Sum chi-squared 5.88
       P-value 0.55
       
 
 
H3 Section 1 2 3 4 5 6 7 8 
# of -ve nuclei in the upper quartile  4 11 8 7 8 5 15 8 
# of +ve nuclei in the upper quartile 5 7 2 4 7 12 15 9 
Expected % (E) 6 8 8 8 6 8 12 6 
(O-E) -2 3 0 -1 2 -3 3 2 
(O-E)
2 4 9 0 1 4 9 9 4 
(O-E)
2
/E 0.66666 1.125 0 0.125 0.66666 1.125 0.75 0.66666 
         Degrees of freedom 7
       Sum chi-squared 5.125
       P-value 0.64
       
Figure 5-6 Unaltered total histone H3 levels in DG granule cell nuclei of the hippocampal 
formation between Mecp2 nuclei type under saline control conditions 
(A) Representative image of DG granule cell nuclei immunostained for total histone H3 and Mecp2 
status displayed through fluorescence of the EGFP fusion protein. White arrows highlight example 
nuclei which do not contain Mecp2 and blue arrows indicate those that do. (B-C) Tables showing 
the number of Mecp2 positive and negative nuclei above the overall median (B) and upper quartile 
(C) for total histone H3 intensity values from sections used for chi-square analysis. Chi-square 
statistic is derived from the expected and observed number of Mecp2 negative nuclei present. The 
number of observed nuclei was not different to the expected number in both cases (p= 0.55 for (B) 
and p=0.64 (C), chi-square test, n = 8 sections from 3 mice). (Di-ii) Summary plots showing the 
percentage of each nuclei type above the median (Di) and in the upper quartile (Dii) total histone 
H3 intensity values. Data expressed as mean ± SEM in the bar graphs. Scale bar = 25µM; +ve = 
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To investigate basal levels of total histone H3 intensity further, I extended my 
analysis to hippocampal area CA1. Similarly there was no difference in the 
observed number of Mecp2 negative nuclei above 50% of total histone H3 
intensities and expected numbers in the CA1 under saline control conditions 
(Figure 5-7B; p=0.96, chi-square test; n= 6 sections from 3 mice). Additionally 
there was no variation in the number of observed Mecp2 negative nuclei and 
expected numbers in the upper quartile (Figure 5-7C; p=0.97, chi-square test; n= 
6 sections from 3 mice). Collectively there was no difference in percentage of 
Mecp2 positive nuclei above the median (42.4 ± 4.5%) and in the upper quartile 
(24.7 ± 4.5%) total histone H3 intensity values compared to Mecp2 negative 
nuclei (53.9 ± 2.6% for above the median; 25.3 ± 1.6% for in the upper quartile)  
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H3 Section 1 2 3 4 5 6 
# of -ve nuclei above the median 15 12 11 11 7 12 
# of +ve nuclei above the median 6 2 5 3 5 7 
Expected (E) 13 11 11 10 6 14 
(O-E) 2 1 0 1 1 -2 
(O-E)
2 4 1 0 1 1 4 
(O-E)
2
/E 0.308 0.09 0 0.1 0.167 0.286 
       Degrees of freedom 5
     Chi-squared 0.95
     P-value 0.96
      
H3 Section 1 2 3 4 5 6 
# of -ve nuclei in the upper quartile  6 6 4 6 3 7 
# of +ve nuclei in the upper quartile  4 1 4 1 3 3 
Expected (E) 6 6 6 5 3 7 
(O-E) 0 0 -2 1 0 0 
(O-E)
2 0 0 4 1 0 0 
(O-E)
2
/E 0 0 0.667 0.2 0 0 
       Degrees of freedom 5
     Sum chi-squared 0.87
     P-value 0.97
     
 
Figure 5-7 Unaltered total histone H3 levels in CA1 pyramidal cell nuclei of the hippocampal 
formation between Mecp2 nuclei type under saline control conditions 
(A) Example micrograph of CA1 pyramidal cell nuclei immunostained for total histone H3 and 
Mecp2 status displayed through fluorescence of the EGFP fusion protein following neuronal 
activity. White arrows highlight example nuclei which do not contain Mecp2 and blue arrows 
indicate those that do. (B-C) Tables showing the number of Mecp2 positive and negative nuclei 
above the overall median (B) and upper quartile (C) for total histone H3 intensity values from 
sections used for chi-square analysis. Chi-square statistic is derived from the expected and 
observed number of Mecp2 negative nuclei present. The number of observed nuclei was not 
different to the expected number in both cases (p= 0.96 for (B) and p=0.97 (C), chi-square test, n = 
6 sections from 3 mice). (Di-ii) Summary plots showing the percentage of each nuclei type above 
the median (Di) and in the upper quartile (Dii) total histone H3 intensity values. Data expressed as 
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Following induction of neuronal activity by kainic acid, the immunostaining of 
total histone H3 and Mecp2 status displayed through fluorescence of the EGFP 
fusion protein in the cell body layer of the DG can be observed in Figure 5-8A. As 
before, no difference in the number of observed Mecp2 negative nuclei and 
expected nuclei above the median total histone H3 intensity was seen (Figure 5-
8B; p=0.99, chi-square test; n= 15 sections from 4 mice) after neuronal activity. 
Therefore, there was no difference in percentage of Mecp2 negative nuclei (45.4 
± 1.4%) above the median total histone H3 intensity value compared to Mecp2 
positive nuclei (53.5 ± 2%) and was down to random chance as the chi-square 
value was not significant (Figure 5-8Di). 
Furthermore, there was no difference observed in the number of Mecp2 negative 
nuclei and expected number in the upper quartile even though a few differ in 
their number by 4-5 nuclei (Figure 5-8C; p=0.76, chi-square test). Consequently 
there was no difference in the percentage of Mecp2 negative nuclei (21.4 ± 
2.1%) in the upper quartile compared to the percentage of Mecp2 positive nuclei 











  135 
 
 





H3 Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
# of -ve nuclei 
above the median 8 7 11 6 18 23 17 26 19 20 25 18 11 11 16 
# of +ve nuclei 
above the median 16 16 8 6 10 15 12 10 21 23 15 20 19 17 11 
Expected (E) 10 8 11 6 20 23 18 23 23 23 28 22 15 12 15 
(O-E) -2 -1 0 0 -2 0 -1 3 -4 -3 -3 -4 -4 -1 1 
(O-E)
2 4 1 0 0 4 0 1 9 16 9 9 16 16 1 1 
(O-E)
2
/E 0.4 0.125 0 0 0.2 0 0.056 0.391 0.696 0.391 0.321 0.727 1.067 0.083 0.067 
                Degrees of freedom 14
              Sum chi-squared 4.52
              P-value 0.99
               
H3 Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
# of -ve nuclei in 
the upper quartile  1 2 4 5 8 8 9 12 11 12 9 9 5 6 7 
# of +ve nuclei in 
the upper quartile  11 9 5 1 6 11 5 6 9 11 11 10 10 8 7 
Expected (E) 5 4 5 3 10 11 9 12 12 11 14 11 7 6 8 
(O-E) -4 -2 -1 2 -2 -3 0 0 -1 1 -5 -2 -2 0 -1 
(O-E)
2 16 4 1 4 4 9 0 0 1 1 25 4 4 0 1 
(O-E)
2
/E 3.2 1 0.2 1.333 0.4 0.818 0 0 0.083 0.091 1.786 0.364 0.571 0 0.125 
                Degrees of freedom 14
              Sum chi-squared 9.97
              P-value 0.76
              
Figure 5-8 Unaltered total histone H3 levels in DG granule cell nuclei of the hippocampal 
formation between Mecp2 nuclei type after kainic acid administration  
(A) Example micrograph of DG granule cell nuclei immunostained for total histone H3 and Mecp2 
status displayed through fluorescence of the EGFP fusion protein following neuronal activity. White 
arrows highlight example nuclei which do not contain Mecp2 and blue arrows indicate those that 
do. (B-C) Tables showing the number of Mecp2 positive and negative nuclei above the overall 
median (B) and upper quartile (C) for total histone H3 intensity values from sections used for chi-
square analysis. Chi-square statistic is derived from the expected and observed number of Mecp2 
negative nuclei present. The number of observed nuclei was not different to the expected number 
in both cases (p= 0.99 for (B) and p=0.76 (C), chi-square test, n = 15 sections from 4 mice). (Di-ii) 
Summary plots showing the percentage of each nuclei type above the median (Di) and in the upper 
quartile (Dii) total histone H3 intensity values. Data expressed as mean ± SEM in the bar graphs. 
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Finally, the immunostaining of total histone H3 and Mecp2 status displayed 
through fluorescence of the EGFP fusion protein in the cell body layer of the CA1 
following initiation of neuronal activity can be seen in Figure 5-9A. There was no 
difference detected in the number of observed Mecp2 negative nuclei and 
expected nuclei above the median total histone H3 intensity (Figure 5-9B; 
p=0.99, chi-square test; n= 12 sections from 4 mice) after neuronal activity. As a 
consequence, the percentage of Mecp2 negative nuclei (48.5 ± 1.3%) above the 
median total histone H3 intensity value compared to Mecp2 positive nuclei (50.2 
± 1.9%) was down to random chance as the chi-square value was not significant 
(Figure 5-9Di). Moreover, there was no significant difference observed in Mecp2 
negative nuclei and expected nuclei in the upper quartile (Figure 5-9C; p=0.99, 
chi-square test). This confirmed that the overall percentage difference in Mecp2 
negative nuclei in the upper quartile (24 ± 1.1) compared to Mecp2 positive 
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H3 Section 1 2 3 4 5 6 7 8 9 10 11 12 
# of -ve nuclei above the 
median 9 11 19 18 15 11 18 20 16 11 27 19 
# of +ve nuclei above the 
median 16 10 11 10 5 7 13 19 8 13 8 8 
Expected (E) 11 12 21 19 15 12 18 19 15 11 24 18 
(O-E) -2 -1 -2 -1 0 -1 0 1 1 0 3 1 
(O-E)
2 4 1 4 1 0 1 0 1 1 0 9 1 
(O-E)
2
/E 0.364 0.083 0.190 0.053 0 0.083 
 
0.053 0.067 0 0.375 0.056 
             Degrees of freedom 11
           Sum chi-squared 1.32
           P-value 0.99
            
H3 Section 1 2 3 4 5 6 7 8 9 10 11 12 
# of -ve nuclei in upper 
quartile  6 5 9 8 8 7 8 10 6 4 14 8 
# of +ve nuclei in the 
upper quartile  6 5 6 6 2 2 7 9 6 8 4 5 
Expected (E) 6 6 10 10 8 6 9 9 8 6 12 9 
(O-E) 0 -1 -1 -2 0 1 -1 1 -2 -2 2 -1 
(O-E)
2 0 1 1 4 0 1 1 1 4 4 4 1 
(O-E)
2
/E 0 0.167 0.1 0.4 0 0.167 0.111 0.111 0.5 0.667 0.333 0.111 
             Degrees of freedom 11
           Sum chi-squared 2.7
           P-value 0.99
           
Figure 5-9 Unaltered total histone H3 levels in CA1 pyramidal cell nuclei of the hippocampal 
formation between Mecp2 nuclei type after kainic acid application 
(A) Example micrograph of CA1 pyramidal cell nuclei immunostained for total histone H3 and 
Mecp2 status displayed through fluorescence of the EGFP fusion protein following neuronal 
activity. White arrows highlight example nuclei which do not contain Mecp2 and blue arrows 
indicate those that do. (B-C) Tables showing the number of Mecp2 positive and negative nuclei 
above the overall median (B) and upper quartile (C) for total histone H3 intensity values from 
sections used for chi-square analysis. Chi-square statistic is derived from the expected and 
observed number of Mecp2 negative nuclei present. The number of observed nuclei was not 
different to the expected number in both cases (p= 0.99 for (B) and (C), chi-square test, n = 12 
sections from 4 mice). (Di-ii) Summary plots showing the percentage of each nuclei type above the 
median (Di) and in the upper quartile (Dii) total histone H3 intensity values. Data expressed as 
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5.4.4 Levels of histone H4 acetylation was unaltered between 
Mecp2 containing and Mecp2-deficient nuclei in the 
hippocampal formation 
In Chapter 4, I found the levels of histone H4 acetylation (H4Ac) to be unaltered 
between Mecp2-deficient mice and their wild-type littermates in the 
hippocampus under control conditions. To study potential modifications in H4Ac 
occurring at the single cell level, my quantitative immunofluorescence approach 
was again used to determine if there were differences in the proportion of H4Ac 
in Mecp2 positive and negative nuclei after saline (control). An example 
micrograph showing immunostained H4Ac and Mecp2 status displayed through 
fluorescence of the EGFP fusion protein in DG granule nuclei of the hippocampal 
formation under saline control conditions is shown in Figure 5-10A. Although 
there was no significant change in the observed and expected number of Mecp2 
negative nuclei above the median H4Ac intensity, (Figure 5-10B; p=0.21, chi-
square test, n= 9 sections from three mice) there appeared to be a trend 
towards less observed Mecp2 negative nuclei as some sections had up to10 fewer 
nuclei. This lower chi-square statistic gave more confidence in the trend that 
there was a decrease in the percentage of Mecp2 negative nuclei (41.8 ± 3.1%) 
compared to Mecp2 positive nuclei (55 ± 2.5%) however the effect could still be 
due to random chance as significance was not achieved (Figure 5-10Di). 
Correspondingly, there was no significant difference in the number of observed 
and expected negative Mecp2 nuclei in the upper quartile (Figure 5-10C, p=0.32, 
chi-square test) although a trend was present towards a decrease in observed 
nuclei. This gave a margin of confidence in the trend towards a decline in the 
percentage of Mecp2 negative nuclei (21.4 ± 2.5%) in the upper quartile H4Ac 
intensity compared to Mecp2 positive nuclei (26.9 ±2.1%) but the effect could 
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H4Ac Section 1 2 3 4 5 6 7 8 9 
# of -ve nuclei above the median 8 38 21 38 51 10 17 11 11 
# of +ve nuclei above the median 28 29 43 25 13 45 24 18 12 
Expected (E) 14 37 31.5 40 48 18 20 13 11 
(O-E) -6 1 -10.5 -2 3 -8 -3 -2 0 
(O-E)
2 36 1 110.25 4 9 64 9 4 0 
(O-E)
2
/E 2.571 0.027 3.5 0.1 0.1875 3.556 0.45 0.308 0 
          
          Degrees of freedom 8
        Sum chi-squared 10.69
        P-value 0.21
         
H4Ac Section 1 2 3 4 5 6 7 8 9 
# of -ve nuclei in the upper quartile  3 21 9 21 26 4 8 8 5 
# of +ve nuclei in the upper quartile  15 13 23 10 6 24 13 6 7 
Expected (E) 7 19 16 20 24 9 10 7 6 
(O-E) -4 2 -7 1 2 -5 -2 1 -1 
(O-E)
2 16 4 49 1 4 25 4 1 1 
(O-E)
2
/E 2.286 0.211 3.063 0.05 0.167 2.778 0.4 0.143 0.167 
          
          Degrees of freedom 8
        Sum chi-squared 9.26
        P-value 0.32
        
 
Figure 5-10  Unaltered H4AC levels in DG granule cell nuclei of the hippocampal formation 
between Mecp2 nuclei type under saline control conditions 
(A) Example micrograph of DG granule cell immunostained for H4Ac and Mecp2 status displayed 
through fluorescence of the EGFP fusion protein. White arrows highlight example nuclei which do 
not contain Mecp2 and blue arrows indicate those that do. (B-C) Tables showing the number of 
Mecp2 positive and negative nuclei above the overall median (B) and upper quartile (C) for H4Ac 
intensity values from sections used for chi-square analysis. Chi-square statistic is derived from the 
expected and observed number of Mecp2 negative nuclei present. The number of observed nuclei 
was not different to the expected number in both cases (p=0.21 for (B) and p=0.32 for (C), chi-
square test, n = 9 sections from 3 mice). (Di-ii) Summary plots showing the percentage of each 
nuclei type above the median (Di) and in the upper quartile (Dii) H4Ac intensity values. Data 
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To verify the distribution of H4Ac intensities, analysis of the CA1 in the 
hippocampal formation was also investigated. In contrast to the above results, 
no trend was present in Mecp2 positive nuclei immunostained with H4Ac in the 
CA1 of the hippocampus (Figure 5-11A) as there was no significant change and 
values were similar in the observed and expected Mecp2 negative nuclei above 
the median (Figure 5-11B; p=0.99, chi-square test, n=10 sections from three 
mice) and in the upper quartile (Figure 5-11C; p=0.93, chi-square test) H4Ac 
intensities. The percentage of positive nuclei above the median (45.4 ± 1.8%) 
and in the upper quartile (22.7 ± 1.8%) H3Ac intensity values compared to the 
percentage of Mecp2 negative nuclei (53.1 ± 1.2% above the median; 27.3 ± 1.2% 
in the upper quartile) was not different as no significance was achieved in the 
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H4Ac Section 1 2 3 4 5 6 7 8 9 10 
# of -ve nuclei above the median 33 20 22 35 29 18 22 20 22 23 
# of +ve nuclei above the median 16 9 8 10 18 17 16 16 14 13 
Expected (E) 32 19 23 32 26 18 19 19 23 20 
(O-E) 1 1 -1 3 3 0 3 1 -1 3 
(O-E)
2 1 1 1 9 9 0 9 1 1 9 
(O-E)
2
/E 0.031 0.0526 0.043 0.281 0.346 0 0.47 0.053 0.043 0.45 
           Degrees of freedom 9
         Sum chi-squared 1.77
         P-value 0.99
          
H4Ac Section 1 2 3 4 5 6 7 8 9 10 
# of -ve nuclei in the upper quartile  16 10 11 20 13 12 12 9 10 11 
# of +ve nuclei in the upper quartile  8 5 4 3 11 6 7 9 8 7 
Expected (E) 16 9 11 16 13 9 9 9 12 10 
(O-E) 0 1 0 4 0 3 3 0 -2 1 
(O-E)
2 0 1 0 16 0 9 9 0 4 1 
(O-E)
2
/E 0 0.111 0 1 0 1 1 0 0.333 0.1 
           Degrees of freedom 9
         Sum chi-squared 3.54
         P-value 0.93
         
 
Figure 5-11 Unaltered H4AC levels in CA1 pyramidal cell nuclei of the hippocampal 
formation between Mecp2 nuclei type under saline control conditions 
(A) Example micrograph of CA1 pyramidal cell nuclei immunostained for H4Ac and Mecp2 status 
displayed through fluorescence of the EGFP fusion protein. White arrows highlight example nuclei 
which do not contain Mecp2 and blue arrows indicate those that do. (B-C) Tables showing the 
number of Mecp2 positive and negative nuclei above the overall median (B) and upper quartile (C) 
for H4Ac intensity values from sections used for chi-square analysis. Chi-square statistic is derived 
from the expected and observed number of Mecp2 negative nuclei present. The number of 
observed nuclei was not different to the expected number in both cases (p=0.99 for (B) and p=0.99 
for (C), chi-square test, n = 10 sections from 3 mice). (Di-ii) Summary plots showing the percentage 
of each nuclei type above the median (Di) and in the upper quartile (Dii) H4Ac intensity values. 
Data expressed as mean ± SEM in the bar graphs. Scale bar = 25µM; +ve = positive nuclei and –
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Previously, no difference was observed in H4Ac protein levels between Mecp2-
deficient mice and their WT littermates following induction of neuronal activity 
through kainic acid application (Chapter 4). Quantification using my 
immunostaining approach was thus used to study the level of H4Ac 
immunoreactivity in the Mecp2 mosaic brain. A representative micrograph of the 
immunostaining in the DG following neuronal activity induction can be observed 
in Figure 5-12A. No difference is evident in the number of observed and 
expected nuclei above the median H3Ac intensity (Figure 5-12B; p=0.99, chi-
square test; n=15 sections from four mice). As this statistic was not significant, 
there was no difference in the percentage of Mecp2 positive and negative (49.1 
± 0.9%) nuclei above the median (Figure 5-12Di).  
Similarly, no significant alterations were shown in the observed and expected 
number of Mecp2 negative nuclei in the upper quartile for H4Ac intensities 
(Figure 5-12C; p=0.98, chi-square test) thus the percentage difference in Mecp2 
positive nuclei (26.1 ± 1.2%) compared to the Mecp2 negative nuclei (23.7 ± 
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H4Ac Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
# of -ve nuclei above 
the median 27 27 36 23 52 62 44 27 36 33 39 31 20 32 12 
# of +ve nuclei 
above the median 19 24 22 23 11 32 26 38 44 26 38 23 22 16 16 
Expected (E) 24 28 34 24 47 62 45 30 39 31 40 33 22 34 13 
(O-E) 3 -1 2 -1 5 0 -1 -3 -3 2 -1 -2 -2 -2 -1 
(O-E)
2 9 1 4 1 25 0 1 9 9 4 1 4 4 4 1 
(O-E)
2
/E 0.375 0.036 0.118 0.042 0.532 0 0.022 0.3 0.231 0.129 0.025 0.121 0.182 0.118 0.077 
                Degrees of freedom 15 
              Sum chi-squared 2.31 
              P-value 0.99 
               
H4Ac Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
# of -ve nuclei in the 
upper quartile  12 11 18 13 23 31 22 11 18 20 19 20 8 18 4 
# of +ve nuclei in 
the upper quartile  11 14 11 10 8 16 13 21 22 9 20 7 13 6 10 
Expected (E) 12 14 17 12 24 31 22 15 20 16 20 16 11 17 6 
(O-E) 0 -3 1 1 -1 0 0 -4 -2 4 -1 4 -3 1 -2 
(O-E)
2 0 9 1 1 1 0 0 16 4 16 1 16 9 1 4 
(O-E)
2
/E 0 0.643 0.059 0.083 0.042 0 0 1.067 0.2 1 0.05 1 0.818 0.059 0.667 
                Degrees of freedom 15 
              Sum chi-squared 5.8 
              P-value 0.98 
              
Figure 5-12 Unaltered H4AC levels in DG granule cell nuclei of the hippocampal formation 
between Mecp2 nuclei type after kainic acid application 
(A) Representative micrograph of DG granule cell nuclei immunostained for H4Ac and Mecp2 
status displayed through fluorescence of the EGFP fusion protein following neuronal activity. White 
arrows highlight example nuclei which do not contain Mecp2 and blue arrows indicate those that 
do. (B-C) Tables showing the number of Mecp2 positive and negative nuclei above the overall 
median (B) and upper quartile (C) for H4Ac intensity values from sections used for chi-square 
analysis. Chi-square statistic is derived from the expected and observed number of Mecp2 
negative nuclei present. The number of observed nuclei was not different to the expected number 
in both cases (p=0.99 for (B) and p=0.98 for (C), chi-square test, n = 15 sections from 4 mice). (Di-
ii) Summary plots showing the percentage of each nuclei type above the median (Di) and in the 
upper quartile (Dii) H4Ac intensity values. Data expressed as mean ± SEM in the bar graphs. Scale 














































































Finally an immunostained micrograph of H4Ac in the CA1 of the hippocampus can 
be seen in Figure 5-13A. As above no difference is evident in the expected and 
observed Mecp2 negative nuclei number above the median (Figure 5-13B; 
p=0.99, chi-square test; n=15 sections from four mice) and upper quartile 
(Figure 5-13C, p=0.97, chi-square test) H4Ac intensity values. Considering no 
significance is achieved in either chi-square test, the was no difference between 
Mecp2 positive nuclei above the median (47.5 ± 1.9%) and in the upper quartile 
(21.8 ± 1.6%) H3Ac intensity values compared to Mecp2 negative nuclei (51.8 ± 
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H4Ac Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
# of -ve nuclei 
above the median 14 17 15 16 17 15 13 16 18 20 28 18 17 15 25 
# of +ve nuclei 
above the median 15 19 13 11 10 16 12 23 17 12 12 7 10 11 11 
Expected (E) 13 18 12 17 19 17 12 16 16 19 27 15 17 14 25 
(O-E) 1 -1 3 -1 -2 -2 1 0 2 1 1 3 0 1 0 
(O-E)
2 1 1 9 1 4 4 1 0 4 1 1 9 0 1 0 
(O-E)
2
/E 0.077 0.056 0.75 0.059 0.211 0.235 0.083 0 0.25 0.053 0.037 0.6 0 0.071 0 
                Degrees of 
freedom 14 
              Sum chi-squared 2.5
              P-value 0.99 
               
H4Ac Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
# of -ve nuclei in the 
upper quartile  9 8 9 9 9 7 5 11 10 10 16 10 9 8 13 
# of +ve nuclei in 
the upper quartile  6 10 5 5 5 8 7 9 7 6 4 2 5 5 5 
Expected (E) 7 9 6 8 10 8 6 8 8 9 13 8 9 7 13 
(O-E) 2 -1 3 1 -1 -1 -1 3 2 1 3 2 0 1 0 
(O-E)
2 4 1 9 1 1 1 1 9 4 1 9 4 0 1 0 
(O-E)
2
/E 0.571 0.111 1.5 0.125 0.1 0.125 0.167 1.125 0.5 0.111 0.692 0.5 0 0.143 0 
                Degrees of freedom 14
              Sum chi-squared 5.8
              P-value 0.97 
              
Figure 5-13 Unaltered H4AC levels in CA1 pyramidal cell nuclei of the hippocampal 
formation between Mecp2 nuclei type after kainic acid application 
(A) Representative micrograph of CA1 pyramidal cell nuclei immunostained for H4Ac and Mecp2 
status displayed through fluorescence of the EGFP fusion protein following neuronal activity. White 
arrows highlight example nuclei which do not contain Mecp2 and blue arrows indicate those that 
do. (B-C) Tables showing the number of Mecp2 positive and negative nuclei above the overall 
median (B) and upper quartile (C) for H4Ac intensity values from sections used for chi-square 
analysis. Chi-square statistic is derived from the expected and observed number of Mecp2 
negative nuclei present. The number of observed nuclei was not different to the expected number 
in both cases (p=0.99 for (B) and p=0.97 for (C), chi-square test, n = 15 sections from 4 mice). (Di-
ii) Summary plots showing the percentage of each nuclei type above the median (Di) and in the 
upper quartile (Dii) H4Ac intensity values. Data expressed as mean ± SEM in the bar graphs. Scale 










































































  146 
 
 
5.4.5 Levels of total histone H4 was unaltered between Mecp2 
containing and Mecp2-deficient nuclei in the hippocampal 
formation 
I also included control experiments to rule out potential changes as a 
consequence of cellular Mecp2 deficiency. The differences in the proportion of 
total histone H4 between Mecp2 positive and negative nuclei in the hippocampus 
were investigated under saline control conditions and after the induction of 
neuronal activity by kainic acid. Figure 5-14A shows the staining of total histone 
H4 and Mecp2 status displayed through fluorescence of the EGFP fusion protein 
in the DG of saline control mice. No difference in the number of observed and 
expected Mecp2 negative nuclei above the median total histone H4 intensity 
value was seen (Figure 5-14B; p=0.56, chi-square test; n=9 sections from 3 
mice). As a result there was no difference in the percentage of Mecp2 positive 
nuclei (54 ± 1.9%) above the median total histone H4 intensity value compared 
to Mecp2 negative nuclei (42.9 ± 2.5%) and was due to random chance (Figure 5-
14Di). 
Conversely, there was a trend towards a decrease in the number of observed 
Mecp2 negative nuclei in the DG in the upper quartile intensity values for total 
histone H4 as shown in nearly half of sections and the chi-squared being close to 
significance (Figure 5-14C; p=0.18, chi-square test). Therefore more confidence 
can be given in the decrease in the percentage of Mecp2 negative nuclei (19.6 ± 
2.5%) in the top 25% of total histone H4 intensity values compared to the 
percentage of Mecp2 positive nuclei (29.1 ±1.9%). Nonetheless as the overall chi-
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H4 Section 1 2 3 4 5 6 7 8 9 
# of -ve nuclei above the median 9 37 26 39 51 11 17 11 10 
# of +ve nuclei above the median 27 30 38 24 13 44 24 18 12 
Expected (E) 14 37 21 40 48 18 20 13 11 
(O-E) -5 0 5 -1 3 -7 -3 -2 -1 
(O-E)
2 25 0 25 1 9 49 9 4 1 
(O-E)
2
/E 1.788 0 1.190 0.025 0.188 2.722 0.45 0.308 0.091 
          Degrees of freedom 8
        Sum chi-squared 6.76
        P-value 0.56
         
H4 Section 1 2 3 4 5 6 7 8 9 
# of -ve nuclei in the upper quartile  2 21 8 19 24 4 9 7 4 
# of +ve nuclei in the upper quartile  16 13 24 12 8 24 13 7 8 
Expected (E) 7 19 16 20 24 9 10 7 6 
(O-E) -5 2 -8 -1 0 -5 -1 0 -2 
(O-E)
2 25 4 64 1 0 25 1 0 4 
(O-E)
2
/E 3.571 0.211 4 0.05 0 2.778 0.1 0 0.667 
          Degrees of freedom 8
        Sum chi-squared 11.37
        P-value 0.18
        
 
Figure 5-14 Unaltered total histone H4 levels in DG granule cell nuclei of the hippocampal 
formation between Mecp2 nuclei type under saline control conditions 
(A) Example micrograph of DG granule cell nuclei immunostained for total histone H4 and Mecp2 
status displayed through fluorescence of the EGFP fusion protein. White arrows highlight example 
nuclei which do not contain Mecp2 and blue arrows indicate those that do. (B-C) Tables showing 
the number of Mecp2 positive and negative nuclei above the overall median (B) and upper quartile 
(C) for total histone H4 intensity values from sections used for chi-square analysis. Chi-square 
statistic is derived from the expected and observed number of Mecp2 negative nuclei present. The 
number of observed nuclei was not different to the expected number in both cases (p=0.56 for (B) 
and p=0.18 for (C), chi-square test, n = 9 sections from 3 mice). (Di-ii) Summary plots showing the 
percentage of each nuclei type above the median (Di) and in the upper quartile (Dii) total histone 
H4 intensity values. Data expressed as mean ± SEM in the bar graphs. Scale bar = 25µM; +ve = 
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The micrograph showing total histone H4 and Mecp2 status displayed through 
fluorescence of the EGFP fusion protein in the CA1 region of the hippocampus is 
shown in Figure 5-15A. No difference was determined in observed and expected 
Mecp2 negative nuclei either above the median (Figure 5-15B; p=0.99, chi-
square test, n=10 sections from three mice) or upper quartile (Figure 5-15C, 
p=0.98, chi-square test) total histone H4 intensity values.  As no significance was 
observed in these chi-square values, the percentage change in Mecp2 positive 
nuclei above the median (46.9 ± 1.6%) and in the upper quartile (27.6 ± 2.6%) 
total histone H4 intensity values compared to Mecp2 negative nuclei (52.1 ± 1.2% 
for above the median; 24.2 ± 1.2% in the upper quartile) was due to random 
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H4 Section 1 2 3 4 5 6 7 8 9 10 
# of -ve nuclei above the median 32 19 22 33 27 17 21 20 23 24 
# of +ve nuclei above the median 17 10 8 12 20 18 17 16 13 12 
Expected (E) 32 19 23 32 26 18 19 19 23 20 
(O-E) 0 0 -1 1 1 -1 2 1 0 4 
(O-E)
2 0 0 1 1 1 1 4 1 0 16 
(O-E)
2
/E 0 0 0.043 0.031 0.038 0.056 0.211 0.053 0 0.8 
           Degrees of freedom 9
         Sum chi-squared 1.23
         P-value 0.99
          
H4 Section 1 2 3 4 5 6 7 8 9 10 
# of -ve nuclei in the upper quartile  15 10 8 19 12 7 10 9 10 11 
# of +ve nuclei in the upper quartile  9 5 7 4 12 11 9 9 8 7 
Expected (E) 16 9 11 16 13 9 9 9 12 10 
(O-E) -1 1 -3 3 -1 -2 1 0 -2 1 
(O-E)
2 1 1 9 9 1 4 1 0 4 1 
(O-E)
2
/E 0.063 0.111 0.818 0.5625 0.077 0.444 0.111 0 0.333 0.1 
           Degrees of freedom 9
         Sum chi-squared 2.6
         P-value 0.98
         
 
Figure 5-15 Unaltered total histone H4 levels in CA1 pyramidal cell nuclei of the 
hippocampal formation between Mecp2 nuclei type under saline control conditions 
(A) Example micrograph of CA1 pyramidal cell nuclei immunostained for total histone H4 and 
Mecp2 status displayed through fluorescence of the EGFP fusion protein. White arrows highlight 
example nuclei which do not contain Mecp2 and blue arrows indicate those that do. (B-C) Tables 
showing the number of Mecp2 positive and negative nuclei above the overall median (B) and upper 
quartile (C) for total histone H4 intensity values from sections used for chi-square analysis. Chi-
square statistic is derived from the expected and observed number of Mecp2 negative nuclei 
present. The number of observed nuclei was not different to the expected number in both cases 
(p=0.99 for (B) and p=0.98 for (C), chi-square test, n = 10 sections from 3 mice). (Di-ii) Summary 
plots showing the percentage of each nuclei type above the median (Di) and in the upper quartile 
(Dii) total histone H4 intensity values. Data expressed as mean ± SEM in the bar graphs. Scale bar 
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To investigate the effect neuronal activity has on total histone H4, kainic acid 
was applied as detailed before and tissues assessed at three hours post seizure 
induction. The immunostaining of this histone and Mecp2 status displayed 
through fluorescence of the EGFP fusion protein in the DG following this 
treatment is shown in Figure 5-16A. The was no overall difference between 
observed and expected Mecp2 negative nuclei above the median total histone H4 
intensity value with variable increases and decreases in sections (Figure 5-16B; 
p=0.93, chi-square test, n= 15 sections from four mice). As a result, there was 
no difference in the percentage of Mecp2 negative cells (45.4 ± 1.3%) and Mecp2 
positive cells (54.2 ± 1.9%) above the median total histone H4 intensity value 
(Figure 5-16Di). Similarly there was no difference in the observed and expected 
nuclei in the upper quartile of total histone H4 intensity value (Figure 5-16C; 
p=0.92, chi-square test). Therefore there was no difference detected between 
the percentage of Mecp2 positive (29.2 ± 0.9%) and negative (22 ± 0.8%) nuclei in 
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H4 Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
# of -ve nuclei 
above the median 29 25 34 24 51 61 43 14 25 33 36 28 19 29 9 
# of +ve nuclei 
above the median 17 26 24 22 12 33 27 8 40 47 41 26 23 19 19 
Expected (E) 24 28 34 24 47 62 45 13 30 39 40 33 22 34 13 
(O-E) 5 -3 0 0 4 -1 -2 1 -5 -6 -4 -5 -3 -5 -4 
(O-E)
2 25 9 0 0 16 1 4 1 25 36 16 25 9 25 16 
(O-E)
2
/E 1.042 0.321 0 0 0.34 0.016 0.089 0.077 0.833 0.923 0.4 0.758 0.409 0.735 1.231 
                Degrees of freedom 14 
              Sum chi-squared 7.17 
              P-value 0.93 
               
H4 Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
# of -ve nuclei in 
the upper quartile  13 15 17 11 21 30 19 6 9 15 15 13 9 15 5 
# of +ve nuclei in 
the upper quartile  10 10 12 12 10 17 16 5 23 25 24 14 12 9 9 
Expected (E) 12 14 17 12 24 31 22 7 15 20 20 16 11 17 6 
(O-E) 1 1 0 -1 -3 -1 -3 -1 -6 -5 -5 -3 -2 -2 -1 
(O-E)
2 1 1 0 1 9 1 9 1 36 25 25 9 4 4 1 
(O-E)
2
/E 0.083 0.071 0 0.083 0.38 0.032 0.409 0.143 2.4 1.25 1.25 0.563 0.364 0.236 0.167 
                Degrees of freedom 14 
              Sum chi-squared 7.4 
              P-value 0.92 
              
Figure 5-16 Unaltered total histone H4 levels in DG granule cell nuclei of the hippocampal 
formation between Mecp2 nuclei type after kainic acid application 
(A) Representative micrograph of DG granule cell nuclei immunostained for total histone H4 and 
Mecp2 status displayed through fluorescence of the EGFP fusion protein following neuronal 
activity. White arrows highlight example nuclei which do not contain Mecp2 and blue arrows 
indicate those that do.  (B-C) Tables showing the number of Mecp2 positive and negative nuclei 
above the overall median (B) and upper quartile (C) for total histone H4 intensity values from 
sections used for chi-square analysis. Chi-square statistic is derived from the expected and 
observed number of Mecp2 negative nuclei present. The number of observed nuclei was not 
different to the expected number in both cases (p=0.93 for (B) and p=0.92 for (C), chi-square test, 
n = 15 sections from 4 mice). (Di-ii) Summary plots showing the percentage of each nuclei type 
above the median (Di) and in the upper quartile (Dii) total histone H4 intensity values. Data 
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Finally, the immunostaining of total histone H4 and Mecp2 status displayed 
through fluorescence of the EGFP fusion protein in the CA1 of the hippocampus 
is shown in Figure 5-17A. As in the DG no difference was noted in the observed 
and expected number of Mecp2 negative nuclei above the median total histone 
H4 intensity value in the CA1 (Figure 5-17B; p=0.99, chi-square test; n= 15 
sections from four mice). Consequently, there was no difference in the 
percentage of Mecp2 negative (45.2 ± 1.4%) and positive (54.7 ± 1.6%) Mecp2 
nuclei above the median intensity value (Figure 5-17Di). Equally there was no 
difference in observed and expected number of Mecp2 negative nuclei in the 
upper quartile total histone H4 intensity values (Figure 5-17C; p=0.96, chi-square 
test). As a result, there was no difference in percentage of Mecp2 negative (21.4 
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H4 Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
# of -ve nuclei 
above the median 10 16 13 16 17 13 10 12 16 16 26 14 19 13 23 
# of +ve nuclei 
above the median 19 20 15 11 10 18 15 27 19 16 14 11 8 13 13 
Expected (E) 13 18 12 17 19 17 12 16 16 19 27 15 17 14 25 
(O-E) -3 -2 1 -1 -2 -4 -2 -4 0 -3 -1 -1 2 -1 -2 
(O-E)
2 9 4 1 1 4 16 4 16 0 9 1 1 4 1 4 
(O-E)
2
/E 0.692 0.222 0.083 0.059 0.211 0.941 0.333 1 0 0.474 0.037 0.067 0.235 0.071 0.16 
                
Degrees of freedom 14 
              Sum chi-squared 4.58
              P-value 0.99
               
 
H4 Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
# of -ve nuclei in 
the upper quartile  5 9 6 7 9 6 5 9 5 5 12 5 9 6 11 
# of +ve nuclei in 
the upper quartile  10 9 8 7 5 9 7 11 12 11 8 7 5 7 7 
Expected (E) 7 9 6 8 10 8 6 8 8 9 13 8 9 7 13 
(O-E) -2 0 0 -1 -1 -2 -1 1 -3 -4 -1 -3 0 -1 -2 
(O-E)
2 4 0 0 1 1 4 1 1 9 16 1 9 0 1 4 
(O-E)
2
/E 0.571 0 0 0.125 0.1 0.5 0.167 0.125 1.125 1.778 0.077 1.125 0 0.143 0.308 
                
Degrees of freedom 14 
              Sum chi-squared 6.14
              P-value 0.96
               
Figure 5-17 Unaltered total histone H4 levels in CA1 pyramidal cell nuclei of the 
hippocampal formation between Mecp2 nuclei type after kainic acid administration 
(A) Representative micrograph of CA1 pyramidal cell nuclei immunostained for total histone H4 and 
Mecp2 status displayed through fluorescence of the EGFP fusion protein following neuronal 
activity. White arrows highlight example nuclei which do not contain Mecp2 and blue arrows 
indicate those that do. (B-C) Tables showing the number of Mecp2 positive and negative nuclei 
above the overall median (B) and upper quartile (C) for total histone H4 intensity values from 
sections used for chi-square analysis.. Chi-square statistic is derived from the expected and 
observed number of Mecp2 negative nuclei present. The number of observed nuclei was not 
different to the expected number in both cases (p=0.99 for (B) and p=0.96 for (C), chi-square test, 
n = 15 sections from 4 mice). (Di-ii) Summary plots showing the percentage of each nuclei type 
above the median (Di) and in the upper quartile (Dii) total histone H4 intensity values. Data 















































































A large number of studies suggest Mecp2 acts in part through recruitment of 
histone deacetylase enzymes (Adachi et al. 2009; Bird and Wolffe 1999; 
Nan et al. 1998; Jones et al., 1998; Nelson, Kavalali, and Monteggia 2006). In 
order to accurately investigate the role MeCP2 has in controlling levels of 
histone protein acetylation, and thus gene expression, with a high degree of 
specificity and resolution, I developed a quantitative immunohistochemistry 
method to compare levels of histone acetylation at a single nuclei resolution. I 
utilised mice which were heterozygous for the Mecp2 knockout mutation to 
compare the possible differential effects on various histone proteins in cells 
which were either positive or negative for Mecp2 expression. This method 
enabled me to sample many neurons and use the cells positive for Mecp2 as an 
internal control to minimise technical variables that can be present with 
quantitative immunofluorescence imaging. The major finding from this chapter 
was that there was a modest but significant (5%; p<0.001) reduction in the 
nuclear volume in Mecp2-deficient cells compared to cells expressing a 
functional Mecp2. However there was no significant difference in total histone 
H3, total histone H4, H3Ac and H4Ac between Mecp2 positive and negative cells 
within the hippocampal formation. Whilst there was a trend towards a reduction 
in the percentage of Mecp2-deficient nuclei in the CA1 of the hippocampus to be 
in the top 25% of H4Ac and total histone H4 intensities within each brain section, 
this never achieved statistical significance. 
The decrease in nuclear volume reported in this chapter (Figure 5-1) agrees with 
other studies which also report a reduction in nuclear volume in the 
hippocampus of Mecp2-deficient mice compared to WT mice 
(Giacometti et al. 2007; Johnson et al. 2011; Yazdani et al. 2012). Since Mecp2 
is a highly abundant nuclear protein (Skene et al., 2010) it is perhaps not 
surprising that’s its absence causes a reduction in the volume of the nucleus. 
Correspondingly,  work performed on the Embryonic Stem (ES) cell-derived 
neurons derived from WT mice correlate the size of neuronal nuclei during 
maturation with the levels of Mecp2 and that lack of Mecp2 disrupts this process 
(Yazdani et al., 2012).  
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A decrease in the soma size has also been documented in neurons in Mecp2-
deficient male and heterozygous female mice 
(Fukuda et al. 2005; Robinson et al. 2012; Taneja et al. 2009). As the size of the 
nucleus is directly proportional to the size of the cytoplasm, a decrease in the 
nucleus and cytoplasm volume with age was attributed to potential loss of DNA 
or a cytoplasmic influence on nuclear size (Ledda et al., 2000).  Similarly Mecp2-
deficient cells could have a reduced nuclear volume because there is a loss of 
DNA or cytoplasm volume is reduced. Interestingly, transcriptional rates are 
reduced in nuclei isolated from ES cell driven neurons from Mecp2-deficient 
mice (Yazdani et al., 2012). Furthermore nucleoli have been shown to be smaller 
in Mecp2-deficient neuronal cells and as these structures are formed by 
transcriptionally active ribosomal DNA in the nucleus, measurements of their 
size give an approximation of active ribosomal DNA transcription (Singleton et 
al., 2011). A decrease in their size could be attributed to a decrease in 
ribosomal DNA transcription in Mecp2-deficient cells. This group also 
documented a decrease in the size of chromocenters, transcriptionally silent 
DNA positioned around nucleoli (Singleton et al., 2011). Collectively, the 
functional consequences of these differences observed in neuronal nuclei and 
cell volume are still unknown but it could relate to the size of the area of the 
brain composed of that specific neuron type. For example the adrenal medulla 
of Mecp2-deficient mice have been shown to be reduced compared to WT mice 
(Ladas et al., 2009) thus potentially contributing to the abnormal catecholamine 
function in this brain region observed in RTT. It could even relate to the 
microcephaly phenotype associated with RTT patients (Schultz et al., 1993). 
Some of the main structures in the nucleus such as heterochromatin and 
euchromatin (compact and non-tightly packed DNA respectively) undergo 
dynamic changes throughout maturation (Martou and De Boni 2000). Histone 
proteins are the main components of chromatin around which DNA is wrapped 
and are amenable to a variety of modifications (as detailed in chapter one and 
four) which will contribute to these alterations during maturation (reviewed by 
MacDonald and Roskams, 2009). One such modification involves histone 
deacetylase proteins which Mecp2 has been shown to recruit (Jones et al., 1998; 
(Nan et al., 1998) to repress gene transcription. As activity–dependent regulation 
of gene expression plays an important role in postnatal neuronal maturation 
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(reviewed by West and Greenberg, 2011), the interaction Mecp2 has with histone 
proteins to control gene expression may also be influenced by activity (Guy et 
al., 2011). I initially investigated this theory in chapter four by quantifying the 
differences in H3Ac and H4Ac under basal conditions and following induction of 
neuronal activity (kainic acid treatment) in WT and Mecp2-deficient mice by 
western blot.  However the results obtained were variable and subtle therefore 
the quantitative immunostaining method used in this chapter was devised and 
the differences in histone proteins measured in nuclei from mice heterozygous 
for Mecp2. This enabled the quantification of large number of cells and also had 
the advantage of providing an internal standard (Mecp2 positive and negative 
cells in the same brain). 
The effects of H3Ac under basal conditions and following induction of neuronal 
activity were observed first. If Mecp2 recruited histone deacetylase proteins 
under normal conditions (Jones et al., 1998; Nan et al., 1998), lack of Mecp2 
could disrupt this interaction leading to an increase in acetylated histones. 
Furthermore the levels of total histone H3 were quantified to determine if there 
were any differences as this would have a direct effect on alterations in 
acetylation. No difference in the proportion of Mecp2 positive and negative 
nuclei above the median or in the upper quartile H3Ac (lysine 9 and 14; key 
regulatory sites as documented by Roh et al., 2005) and total histone H3 
intensity levels under any experimental conditions was detected in the 
hippocampus. Therefore, no overall difference in the levels of these histone 
proteins was evident between nuclei types (Figure 5-2-Figure 5-9). These results 
in H3Ac under basal conditions agree with my results in chapter 4 but are 
contradictory to other published data in which a 2.6 fold increase in H3Ac (lysine 
9 and 14) from FACS sorted neuronal nuclei in Mecp2-deficient mice whole brain 
(Skene et al., 2010). One explanation for this might be that the effects on 
acetylation are restricted to specific brain regions or to discrete/ other 
acetylated lysine residues. For example there was an increase in acetylation 
specifically at histone H3 lysine 9 from nuclei in the cerebral cortex of Mecp2-/y 
mice (Thatcher and LaSalle, 2006). Skene et al studied the effects in whole brain 
but there could be specific cells types which have large acetylation changes thus 
accounting for the differences observed in the entire brain. My result showing no 
difference in H3Ac in the hippocampus may be specific to this brain region. 
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Furthermore, levels of H3Ac have also been shown to differ depending on the 
mutation type in mouse models and human tissue samples specific for a certain 
mutation. For example, an increase in the H3Ac (lysine 9 and 14) protein was 
observed in Mecp2308/y mice in the cerebellum and cortex compared to WT 
littermates (Shahbazian et al., 2002). An increase in H3Ac (lysine 9 and 14) 
protein was also detected at specific promoters, namely Arc and Tubb5 in the 
striatum of Mecp2308/y mice compared to WT littermates (Su et al., 2012). 
Additionally, human cerebral cortex tissue samples from females (Mecp2-
deficient cells) with a R138X mutation exhibit an increase in acetylation 
specifically at histone H3 lysine 9 (Thatcher and LaSalle, 2006). Conversely, no 
difference in H3Ac (lysine 9 and 14) were seen in cell cultures from RTT patients 
with truncated mutations R168X and 803delG (Wan et al., 2001) and a decrease 
in H3Ac (lysine 9 and 14; although driven by a decrease in histone H3 lysine 14) 
was observed from RTT patients lymphocyte lysates with nonsense mutations 
(Kaufmann et al., 2005). Collectively the above studies from Mecp2-/y and 
Mecp2308/y mice and RTT with specific mutations focus on alterations in histone 
acetylation under basal conditions. Uniquely in this study, I investigated the 
effects of H3Ac following induction of neuronal activity. However the lack of 
alteration in H3Ac observed between Mecp2 positive and negative nuclei 
suggests that neuronal activity has no effect on the interaction Mecp2 has with 
H3Ac and control of gene expression in the hippocampus.  An increase (0.5 fold) 
in H3Ac was observed in Mecp2stop/y mice compared to WT littermates from my 
results in chapter four but these effects were subtle. Moreover the difference in 
total histone H3 between WT and mutant cells under basal or following neuronal 
activity has not been observed before and only used as a loading control for 
western blot experiments in one study mentioned above 
(Shahbazian et al. 2002). They were used in this context as it is assumed the 
levels of total histone H3 are not affected by lack of Mecp2 and my results do 
not contradict this theory. 
Similarly to the effects of H3Ac under basal conditions and following induction of 
neuronal activity, no significant difference in the proportion of Mecp2 positive 
and negative nuclei above the median or in the upper quartile H4Ac (lysines 5, 8, 
12 and 16 key regulatory sites as documented by Clarke et al., 1993) and total 
histone H4 intensity levels under any experimental conditions was detected in 
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the hippocampus. Therefore, no overall difference in these histone proteins was 
evident between nuclei types (Figure 5-10-Figure 5-17). These results, under 
basal conditions, agree with my results from chapter four and also with studies 
performed in other regions of the brain; no difference was detected in H4Ac 
(lysine 5, 8, 12 and 16) in protein extracts from the whole cortex, midbrain and 
cerebellum in WT and Mecp2-/y mice (Urdinguio et al., 2007). These results 
suggest the absence of Mecp2 has no effect on H4Ac. However mice with specific 
mutations in Mecp2 in mouse models and human tissue samples show varied 
results. For example no difference was detected in  H4Ac (lysines 5, 8, 12 and 
16) protein in Mecp2308/y mice in the cerebellum and cortex compared to WT 
littermates (Shahbazian et al., 2002) or in H4Ac (lysines 5, 8, 12 and 16; 
although driven by histone H4 lysine 16) from RTT patients lymphocyte lysates 
with nonsense mutations (Kaufmann et al., 2005). Conversely an increase in 
H4Ac (lysines 5, 8, 12 and 16) was seen in cell cultures from RTT patients with 
truncated mutations R168X and 803delG (Wan et al., 2001). These studies 
suggest specific mutation types in Mecp2 could be affecting the levels of H4Ac.  
Although no significant difference was observed in H4Ac under basal conditions, 
there was a trend towards a reduction in the percentage of Mecp2-deficient 
nuclei in the CA1 of the hippocampus to be in the top 25% of H4Ac and total 
histone H4 intensities within each section. This would imply that the decrease in 
histone acetylation was attributed to the reduction in total histone H4 and that 
cell types can be differentially regulated by Mecp2 even in the same region of 
the brain. Additionally, as with H3Ac, investigating the effects of H4Ac following 
induction of neuronal activity in my model was unique. Nonetheless the lack of 
alteration in H4Ac observed between Mecp2 positive and negative nuclei 
suggests that neuronal activity has no effect on the interaction of Mecp2 with 
H4Ac and control of gene expression in the hippocampus.  This agrees with 
results obtained from chapter four. Moreover, the difference in total histone H4 
between WT and mutant cells under basal or following neuronal activity has not 
been observed before. It is assumed that the levels of total histone H4 are not 
affected by lack of Mecp2 and overall my data does not contradict this. 
Another phenomenon that needs to be taken into consideration and could 
explain why no difference was observed in all the histone proteins from my 
results is non-cell autonomous effects. In multicellular organisms, if only cells 
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with a specific mutation exhibit the mutant phenotype then the effects are 
referred to as cell autonomous. However if the mutant cells also have a direct 
influence on adjacent cells with a normal genotype, they are referred to as non-
cell autonomous. In the case of mice and patients with RTT that are 
heterozygous for Mecp2, this would mean negative Mecp2 cells inflicting their 
mutant trait onto Mecp2 positive cells.  
Studies have previously described non-cell autonomous effects. For instance one 
group has shown non-cell autonomous effects in dendritic arborization from 
cortical pyramidal neurons in WT mice transfected with Mecp2-/y cortical 
neuroblasts (Kishi and Macklis, 2010). Furthermore another study has shown 
dendritic abnormalities in Mecp2 positive cells in the cerebral cortex of 
heterozygous female mice (Belichenko et al., 2009a). Interestingly, glial cells 
deficient in MeCP2 have also been shown to display a non-cell autonomous trait. 
For example having co-cultured WT and Mecp2 mutated hippocampal neurons in 
astrocyte conditioned media (ACM) from WT or Mecp2 mutated astrocytes, one 
group discovered that the ACM from mutant neurons was unable to support the 
growth of WT or mutant hippocampal neurons but WT ACM could (Ballas et al., 
2009). Moreover, another group have shown a similar finding but with the 
conditioned media from microglia (Maezawa and Jin, 2010).  With regards to my 
data non-cell autonomous effects on Mecp2 negative cells could lead to deficits 
in histone protein levels in Mecp2 positive cells thus preventing accurate 
assessment of the direct effect of Mecp2 on histone proteins. In future studies 
comparisons could be made between WT cells and Mecp2 positive cells from 
heterozygous females to investigate this phenomenon further.  
In conclusion, my quantitative immunostaining method enabled me to 
investigate in what I consider a robust manner, the influence of the presence or 
absence of cellular Mecp2 in determining levels of acetylated histone H3 and H4 
protein levels in the hippocampus and dentate gyrus principal cells. This method 
enabled a higher degree of specificity and resolution than in Chapter four. 
However my results show that whilst there is a 5% reduction in the nuclear 
volume of Mecp2-deficient cells, there is no difference in H3Ac, H4Ac, total 
histone H3 and total histone H4 between Mecp2 positive and negative nuclei in 
the hippocampus under control and also following the induction of neuronal 
activity which is largely in agreement with my previous results in chapter four. 
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This result for histone proteins might be dependent on the brain region, specific 
acetylated histones or mutation type investigated and even influenced by non-
cell autonomous effects. There could also be possible adaptive mechanisms 
occurring that are regulating the effects of histone acetylation as seen in 
adaptive physiological mechanisms in response to stress (reviewed by McEwen, 
2000). Therefore further experiments using models in which Mecp2 is knocked 
down genetically (Cheval et al., 2012) or through RNA interference in cultured 
systems at specific time points in development instead of from birth might 
reveal different results. 
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Chapter 6 
Altered regulation of immediate early genes levels 






Activity-dependent transcription in the brain is important because it is 
correlated with and directly required for experience-dependent synaptic 
changes which underlie maturation of neural networks (Dragunow et al. 2000; 
Marek, Kurtz, and Spitzer 2010; West and Greenberg, 2011). For example, visual 
input shapes synaptic organisation of the visual cortex during a critical period of 
development in postnatal life (Hubel, 1982). Nuclear proteins, such as 
immediate early genes (IEGs) are important regulators in coupling extracellular 
stimuli with intracellular adaptations in neurons. The principal action of these 
genes first became clear in experiments conducted in fibroblasts, in which the 
IEG Fos became rapidly upregulated in response to growth factors (Greenberg 
and Ziff, 1984). Since these key experiments, many IEG families have been 
identified comprising members of the Fos, Jun, early growth response (Egr) and 
nuclear receptor families of transcription factors (Herdegen and Leah, 1998) 
which are rapidly and transiently induced in response to a variety of 
environmental stimuli. Additionally, cell type and stimulus specificity have been 
shown to govern the functional consequences of IEG induction (Hill and 
Treisman, 1999). 
The proto-oncogene c-Fos, from the Fos IEG family, can be rapidly induced by 
neurotransmitters (Greenberg et al., 1986), nerve growth factor (Curran and 
Morgan, 1985) and high concentrations of potassium (Morgan and Curran, 1986) 
in neuronal cultures. Kainic acid-induced seizures have also been shown to 
induce c-Fos in the hippocampus (Ben-Ari 1985; Popovici et al. 1990). Mice in 
which c-Fos was knocked out in the hippocampus (Tsien et al., 1996) displayed 
more severe seizures in response to kainic acid application (Zhang et al., 2002) 
suggesting that c-Fos can regulate cellular mechanisms mediating neuronal 
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excitability. Interestingly I have shown that Mecp2-deficient mice and 
heterozygous female mice display a hyperexcitability phenotype following 
induction of neuronal activity using the convulsant drug kainic acid (chapter 
three). Additionally, as Mecp2 can be dynamically regulated through 
phosphorylation at specific residues (Chen et al., 2003;  Tao et al., 2009; 
(Zhou et al. 2006; chapter four) in response to neuronal activity, there could be 
a role for phosphorylated MeCP2 protein to regulate IEGs levels such as c-Fos in 
an activity dependent manner. This interaction might be dysfunctional in Mecp2-
deficient mice thus contributing to the hyperexcitability phenotype observed in 
my mice. To investigate this phenomenon further I utilised the quantitative 
immunohistochemistry method previously used to analyse histone proteins 
(chapter five) to investigate whether Mecp2 positive and negative nuclei in 
heterozygous female mice differ in their expression of IEGs following induction 
of neuronal activity. 
6.2 Study aims 
The overall objective of this chapter was to establish whether IEGs are altered 
depending on the presence or absence of functional Mecp2 in the nucleus. The 
specific aims were to: 
i. Determine whether the expression of two different IEGs, c-Fos and Egr-1 
vary in their intensity levels in nuclei positive and negative for Mecp2 
under saline control (quiescent) conditions and following induction of 
neuronal activity (kainic acid). 
ii. Conduct further analysis to ask the related question whether Mecp2 
positive and negative nuclei differ in the number of nuclei that express 
detectable c-Fos or Egr1 in a quiescent and activity induced environment. 
6.3 Methods 
Pre-symptomatic Mecp2+/- and Mecp2GFP/- female mice aged 10-13 weeks were 
administered kainic acid (25mg/kg) or saline (controls) intraperitoneally in the 
absence of anaesthesia (Chapter 2). Mice were monitored for a 0-3 hour 
observation period after which they were given an overdose of sodium 
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pentobarbital (Euthatal) and fixed by intracardiac perfusion (4% PFA) with the 
brain subsequently removed and processed for immunohistochemistry as 
described in Chapter two. Alternatively, a subset of mice was culled by cervical 
dislocation and the hippocampi removed and processed for western blot as 
described in Chapter two. 
Hippocampal proteins were probed over night with the following primary 
antibodies:  rabbit anti-c-Fos (1/1000), rabbit anti-Egr-1 (1/1000) or rabbit anti-
histone H3 (1/20,000) as a loading control. Subsequently anti-rabbit HRP-
conjugated secondary antibodies were applied to membranes and results 
visualized using ECL. Additionally immunohistochemistry was completed as 
described in chapter two whereby brain sections were incubated with primary 
antibody rabbit anti-c-Fos (1/4500), rabbit anti-Egr-1 (1/100) or mouse anti-
MeCP2 (1/500).  Afterward, fluorescent secondary antibodies (Alexa fluor 488 
goat anti-mouse and Alexa fluor 647 goat anti-rabbit) were added to sections in 
the dark, prior to incubation with the nuclei marker DAPI (1/1000) and mounted 
onto coverslips. 
Following immunohistochemistry, at least two randomly selected and non-
overlapping image stacks of the hippocampal formation in the DG and CA1 region 
for each section were captured using a Leica SP5 Confocal microscope (Dr David 
Kelly, University of Edinburgh).  Nuclei intensity differences in IEGs between 
Mecp2 positive and negative nuclei were quantified using an automated script in 
Image-pro Plus 6.0 described in detail in Chapters two and Chapter five. Only a 
few nuclei were clearly immunostained for c-Fos under saline control conditions 
(Figure 6-1) and following 0.5 hour of kainic acid treatment therefore the 
majority of nuclei selected from the automated script are background signal 
(identifies nuclei based on the DAPI staining). Consequently, a frequency 
distribution of all raw c-Fos intensities for each section was performed (Figure 6-
1) before any analysis was carried out to distinguish nuclei genuinely expressing 
c-Fos from background fluorescence signal. A larger peak with low intensity 
values would form which represents nuclei containing background signal. There 
would be fewer genuinely c-Fos expressing nuclei which represent smaller peaks 
in the distribution with higher intensities. Typically there is a clear separation 
between these two intensity types (as shown in Figure 6-1 by the dotted line) 
thus the background signalling can be identified and excluded from the analysis. 
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The accuracy of this method for determining genuinely expressing nuclei were 
confirmed by manually counting the c-Fos expression in several sections. 





Figure 6-1 Example distribution of c-Fos fluorescent intensities and identification of 
background signal. 
An example of the frequency fluorescent intensity distribution from nuclei in a saline control section 
immunostained for c-Fos. Examples of genuinely expressing c-Fos nuclei are indicated in the 
micrograph by white arrows. There are fewer nuclei immunostained with c-Fos, represented by the 
small higher intensity peaks. The background signal will be all the remaining nuclei with no c-Fos 
expression thus forming a larger lower intensity peak. The dotted line in the distribution graph 
indicates the clear division between the two. 
Subsequently, a chi-square analysis was performed for each immediate early 
gene as described in Chapter five to determine whether there was a change in 
the distribution of positive and negative nuclei above the median or upper 
quartile immediate early gene intensity values. As done previously, the statistics 
were done on the raw number counts and not percentages to ensure that 
sections with smaller numbers of nuclei do not disproportionately affect the 
overall chi-squared value. Furthermore the difference between the total 
numbers of nuclei immunostained for c-Fos in Mecp2 positive and negative nuclei 
were quantified manually using Image J software as described in chapter two. A 
2x2 contingency table chi-square test was carried out for each animal comparing 
the total number of Mecp2 positive and negative nuclei immunostained against 
























6.4.1 Mecp2+/- mice display an increase in c-Fos expression 
following induction of neuronal activity compared to saline 
controls 
The induction of c-Fos expression has been shown to occur in the DG of the 
hippocampus within 90 minutes of intraperitoneal injection of the convulsant 
drug kainic acid in rats (Popovici et al., 1990). The authors showed that c-Fos 
staining was maximal at three hours post kainic acid with labelling in other 
regions of the hippocampus (CA1 and CA3) only occurring after three hours. 
Furthermore, the authors reported that elevated c-Fos was still detectable 12 
hours after kainic acid treatment. As the expression of c-Fos in the hippocampus 
of Mecp2+/- heterozygous female mice has not been documented before, I 
studied the expression of c-Fos in the hippocampal formation during saline 
control conditions and at 0.5, 1.5 and 3 hours following application of the 
convulsant drug kainic acid. Within minutes after kainic acid treatment, mice 
develop seizures similar to Mecp2stop/y male mice (Chapter 3). No detectable c-
Fos signal was observed by western blot under saline control conditions but a 
strong band of c-Fos was detected after 1.5 and 3 hours following induction of 
kainic acid treatment (Figure 6-2A). However the micrographs in Figure 6-2B 
showed a small selection of nuclei were immunostained for c-Fos in the DG 
under saline control conditions (Figure 6-2Bi) and after 0.5 hours of kainic acid 
(Figure 6-2Bii). A few nuclei in the CA1 were also immunostained for c-Fos after 
0.5 hours but every nucleus in the cell body layer of the hippocampus became 
brightly immunostained with c-Fos following 3 hours of kainic acid administration 
(Figure 6-2Biii). 
 














Figure 6-2 Time course of c-Fos protein expression in the hippocampal formation of 
Mecp2
+/-
 female mice after application of kainic acid. 
(A) Representative western blot showing a graded increase in c-Fos expression over time following 
kainic acid (KA) application. Blot reveals the absence of detectable c-Fos is detected in saline 
controls and at 0.5 hours of kainic acid. In contrast, brains samples at 1.5 hours and 3 hours post 
kainic acid show strong c-Fos expression. Samples are taken from hippocampal extracts and total 
histone H3 (H3) used as a loading control. (B) Representative micrographs showing c-Fos 
immunoreactivity in the hippocampal formation following administration of saline (i), 0.5 hours 
kainic acid (ii) or  three hours kainic acid (iii). Note the comparable immunostaining (subtle) of 
saline and 0.5 hour after kainic acid in contrast to the clear increase in c-Fos staining 3 hours after 
kainic acid. Scale bar = 100µm 
6.4.2 Levels of c-Fos was unaltered between Mecp2 positive and 
negative nuclei in the hippocampal formation 
Having established that the neurons in the hippocampus of Mecp2+/- female mice 
display increased levels of c-Fos upon induction of neuronal activity, I then went 
on to determine whether there were any differences in the intensity of c-Fos 
expression between nuclei positive and negative for Mecp2 in the DG and CA1 of 
the hippocampal formation.  Firstly, I determined whether there was any 
difference in basal expression levels under saline control conditions. In Figure 6-
3A, a representative micrograph of nuclei immunostained with c-Fos and Mecp2 
status displayed through fluorescence of the EGFP fusion protein in the DG of a 
mouse treated with saline can be observed (Figure 6-3A). There was no 
difference in the observed number of Mecp2 negative nuclei and expected 
number of Mecp2 negative nuclei above the median c-Fos intensity (Figure 6-3B; 
p=0.73, chi-square test; n = 6 sections from three mice). As the chi-squared was 
not significantly different, there was no difference in the percentage of Mecp2 
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positive (56.5 ± 2.4%) and negative nuclei (40.5 ± 3.3%) above the c-Fos median 
intensity value (Figure 6-3Di). 
Similarly, there was no difference in the observed and expected number of 
Mecp2 negative nuclei in the top quartile of c-Fos intensities (Figure 6-3C; 
p=0.75, chi-square test). Although there appears to be a decrease in the 
percentage of Mecp2 negative nuclei (18.8 ± 1.7%) in the upper quartile c-Fos 
intensities compared to Mecp2 positive nuclei (30 ± 1%), this was not significant 
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c-Fos Section 1 2 3 4 5 6 
# of -ve nuclei above the median 9 5 26 8 4 8 
# of +ve nuclei above the median 9 24 10 8 20 11 
Expected (E) 10 8 28 8 7 9 
(O-E) -1 -3 -2 0 -3 -1 
(O-E)
2 1 9 4 0 9 1 
(O-E)
2
/E 0.1 1.125 0.143 0 1.286 0.111 
       Degrees of freedom 5
     Sum chi-square 2.8
     P-value 0.73
      
c-Fos Section 1 2 3 4 5 6 
# of -ve nuclei in the upper quartile 4 2 13 3 2 4 
# of +ve nuclei in the upper quartile 5 12 5 5 10 5 
Expected (E) 5 4 14 4 4 5 
(O-E) -1 -2 -1 -1 -2 -1 
(O-E)
2 1 4 1 1 4 1 
(O-E)
2
/E 0.2 1 0.071 0.25 1 0.2 
       Degrees of freedom 5
     Sum chi-square 2.7
     P-value 0.75
     
 
Figure 6-3 Unaltered c-Fos levels in DG granule cell nuclei of the hippocampal formation 
between Mecp2 nuclei type under saline control conditions 
(A) Representative image of DG granule cell nuclei immunostained for c-Fos and Mecp2 status 
displayed through fluorescence of the EGFP fusion protein. White arrows highlight example nuclei 
which do not contain Mecp2 and blue arrows indicate those that do. (B-C) Tables showing the 
number of Mecp2 positive and negative nuclei above the overall median (B) and upper quartile (C) 
for c-Fos intensity values from sections used for chi-square analysis. Chi-square statistic is derived 
from the expected and observed number of Mecp2 negative nuclei present. The number of 
observed nuclei was not different to the expected number in both cases (p= 0.73 for (B) and p=0.75 
(C), chi-square test, n =6 sections from 3 mice). (Di-ii) Summary plots showing the percentage of 
each nuclei type above the median (Di) and in the upper quartile (Dii) c-Fos intensity values. Data 
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As initially observed in the lower power image (20x objective) in Figure 6-2B, 
there was no detectable c-Fos immunostaining in the CA1 region of the 
hippocampus under control conditions therefore the distribution of c-Fos 
intensities in Mecp2 positive and negative nuclei could not be analysed. A higher 
power image (63x objective) showing a lack of detectable c-Fos expression in 






Figure 6-4 Lack of c-Fos expression in Mecp2 positive and negative nuclei in the CA1 region 
of the hippocampus under saline control conditions. 
High (20x objective; left) and low (63x objective; right) micrograph images displaying the lack of c-
Fos expression in Mecp2 positive and negative nuclei in the CA1 region of the hippocampus under 
control conditions. Scale bar = 100µm for 20x objective image and 25µm for 63x objective image. 
Subsequently, I also determined whether there was a difference in the 
distribution of c-Fos intensities in nuclei positive and negative for Mecp2 at 0.5 
and 3 hours following application of kainic acid treatment. An example 
micrograph of the nuclei immunostained with c-Fos and Mecp2 in the DG of the 
hippocampal formation after 0.5 hour of kainic acid administration is shown in 
Figure 6-5A. Chi-square analysis revealed that there was no difference in the 
number of observed and expected Mecp2 negative nuclei within the top 50% 
(Figure 6-5B; p=0.97, chi-square test; n= 8 sections from 3 mice) or 25% (Figure 
6-5C; p=0.55, chi-square test) of the highest c-Fos intensities. The percentage of 
Mecp2 positive nuclei above the median (50.1 ± 2.4%) and in the upper quartile 
(23.5 ± 1.9%) c-Fos intensity values compared to Mecp2 negative nuclei (49.4 ± 
2.8% for above the median; 23.6 ± 2.2% for above in the upper quartile) was 
likely due to random chance as no significance was observed in either chi-square 
(Figure 6-5Di-Dii).    
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c-Fos Section 1 2 3 4 5 6 7 8 
# of -ve nuclei above the median 9 6 7 7 11 11 10 13 
# of +ve nuclei above the median 3 9 13 28 11 12 9 8 
Expected (E) 9 7 5 7 12 12 8 13 
(O-E) 0 -1 2 0 -1 -1 2 0 
(O-E)
2 0 1 4 0 1 1 4 0 
(O-E)
2
/E 0 0.143 0.8 0 0.083 0.083 0.5 0 
         Degrees of freedom 7
       Sum chi-square 1.6
       P-value 0.97
        
c-Fos Section 1 2 3 4 5 6 7 8 
# of -ve nuclei in the upper quartile  5 4 5 2 7 5 4 6 
# of +ve nuclei in the upper quartile  1 3 5 16 4 6 5 4 
Expected (E) 4 3 2 3 6 6 4 7 
(O-E) 1 1 3 -1 1 -1 0 -1 
(O-E)
2 1 1 9 1 1 1 0 1 
(O-E)
2
/E 0.25 0.333 4.5 0.333 0.167 0.167 0 0.143 
         Degrees of freedom 7
       Sum chi-square 5.9
       P-value 0.55
       
 
Figure 6-5 Unaltered c-Fos levels in DG granule cell nuclei of the hippocampal formation 
between Mecp2 nuclei type following 0.5 hour of kainic acid application. 
(A) Representative image of DG granule cell nuclei immunostained for c-Fos and Mecp2 following 
0.5 hours of neuronal activity. White arrows highlight example nuclei which do not contain Mecp2 
and blue arrows indicate those that do. (B-C) Tables showing the number of Mecp2 positive and 
negative nuclei above the overall median (B) and upper quartile (C) for c-Fos intensity values from 
sections used for chi-square analysis. Chi-square statistic is derived from the expected and 
observed number of Mecp2 negative nuclei present. The number of observed nuclei was not 
different to the expected number in both cases (p= 0.97 for (B) and p=0.55 (C), chi-square test, 
n=8 sections from 3 mice). (Di-ii) Summary plots showing the percentage of each nuclei type above 
the median (Di) and in the upper quartile (Dii) c-Fos intensity values. Data expressed as mean ± 
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Analysis of immunostaining in the putative pyramidal cells of area CA1 after 0.5 
hour of kainic acid treatment (Figure 6-6A), showed that there was no difference 
in the number of observed and expected Mecp2 negative nuclei above the 
median c-Fos intensity (Figure 6-6B; p=0.95, chi-square test; n= 7 sections from 
3 mice). As a result there was no significant difference in the percentage of 
Mecp2 positive (48 ± 3.2%) and Mecp2 negative nuclei (51 ± 2.4%) above the 
median (Figure 6-6Di).  Similarly, there was no difference in the number of 
expected and observed Mecp2 negative nuclei in the upper quartile c-Fos 
intensities (Figure 6-6C; p=0.58, chi-square test). Therefore there was no 
difference in the percentage of Mecp2 negative nuclei (22.9 ± 0.6%) and Mecp2 
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c-Fos Section 1 2 3 4 5 6 7 
# of -ve nuclei above the median 8 4 6 9 13 3 14 
# of +ve nuclei above the median 8 15 10 7 3 10 13 
Expected (E) 10 5 6 7 11 3 13 
(O-E) -2 -1 0 2 2 0 1 
(O-E)
2 4 1 0 4 4 0 1 
(O-E)
2
/E 0.4 0.2 0 0.571 0.364 0 0.077 
        Degrees of freedom 6
      Sum chi-square 1.6
      P-value 0.95
       
c-Fos Section 1 2 3 4 5 6 7 
# of -ve nuclei in the upper quartile  4 2 3 4 5 3 6 
# of +ve nuclei in the upper quartile  4 8 5 4 3 3 8 
Expected (E) 5 2 3 3 6 1 6 
(O-E) -1 0 0 1 -1 2 0 
(O-E)
2 1 0 0 1 1 4 0 
(O-E)
2
/E 0.2 0 0 0.333 0.167 4 0 
        Degrees of freedom 6
      Sum chi-square 4.7
      P-value 0.58
      
 
Figure 6-6 Unaltered c-Fos levels in CA1 pyramidal cell nuclei of the hippocampal formation 
between Mecp2 nuclei type following 0.5 hour of kainic acid application 
(A) Representative image of CA1 pyramidal cell nuclei immunostained for c-Fos and Mecp2 
following 0.5 hours of neuronal activity. White arrows highlight example nuclei which do not contain 
Mecp2 and blue arrows indicate those that do. (B-C) Tables showing the number of Mecp2 positive 
and negative nuclei above the overall median (B) and upper quartile (C) for c-Fos intensity values 
from sections used for chi-square analysis. Chi-square statistic is derived from the expected and 
observed number of Mecp2 negative nuclei present. The number of observed nuclei was not 
different to the expected number in both cases (p= 0.95 for (B) and p=0.58 (C), chi-square test, 
n=7 sections from 3 mice). (Di-ii) Summary plots showing the percentage of each nuclei type above 
the median (Di) and in the upper quartile (Dii) c-Fos intensity values. Data expressed as mean ± 
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Finally, an example micrograph of the nuclei immunostained with c-Fos and 
Mecp2 status displayed through fluorescence of the EGFP fusion protein in the 
DG of the hippocampal formation after three hours of kainic acid administration 
is shown in Figure 6-7A. Similar to the effects after 0.5 hours, there was no 
difference in the observed and expected numbers of Mecp2 negative nuclei 
above the median c-Fos intensity (Figure 6-7B; p=0.77, chi-square test; n= 15 
sections from four animals). Subsequently, as the chi-square value was not 
significant, there was no difference in the percentage of Mecp2 positive (51.3 ± 
0.9%) and negative (48.1 ± 1.3%) nuclei observed above the median c-Fos 
intensity value (Figure 6-7Di). Furthermore, there was no difference in the 
number of expected and observed Mecp2 negative nuclei in the upper quartile c-
Fos intensities (Figure 6-7B; p=0.92, chi-square test). Thus overall, there was no 
significant difference in the percentage of Mecp2 positive (25.9 ± 0.5%) and 
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c-Fos Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
# of -ve nuclei 
above the median 43 41 58 90 268 80 92 141 77 44 60 141 108 126 141 
# of +ve nuclei 
above the median 113 78 118 80 94 30 53 119 63 77 75 92 84 78 68 
Expected (E) 52 52 78 91 268 81 95 137 76 46 61 143 115 128 139 
(O-E) -9 -11 -20 -1 0 -1 -3 4 1 -2 -1 -2 -7 -2 2 
(O-E)
2 81 121 400 1 0 1 9 16 1 4 1 4 49 4 4 
(O-E)
2
/E 1.558 2.327 5.128 0.011 0 0.012 0.095 0.117 0.013 0.087 0.016 0.028 0.426 0.031 0.029 
                Degrees of freedom 14
              Sum chi-square 9.9
              P-value 0.77
               
c-Fos Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
# of -ve nuclei in 
the upper quartile  20 23 27 46 129 42 52 71 41 24 31 69 55 58 68 
# of +ve nuclei in 
the upper quartile  58 37 61 40 52 13 20 59 29 37 36 48 41 44 37 
Expected (E) 26 26 39 45 134 41 48 68 38 23 30 72 58 64 69 
(O-E) -6 -3 -12 1 -5 1 4 3 3 1 1 -3 -3 -6 -1 
(O-E)
2 36 9 144 1 25 1 16 9 9 1 1 9 9 36 1 
(O-E)
2
/E 1.385 0.346 3.692 0.022 0.187 0.024 0.333 0.132 0.237 0.043 0.033 0.125 0.155 0.563 0.014 
                Degrees of 
freedom 14 
              Sum chi-square 7.3
              P-value 0.92
              
Figure 6-7 c-Fos expression is elevated following 3 hours of kainic acid induced seizures 
but is not different between Mecp2 nuclei type in DG granule cell nuclei 
(A) Representative image of nuclei in DG granule cell nuclei immunostained for c-Fos and Mecp2 
status displayed through fluorescence of the EGFP fusion protein following 3 hours of neuronal 
activity. White arrows highlight example nuclei which do not contain Mecp2 and blue arrows 
indicate those that do. (B-C) Tables showing the number of Mecp2 positive and negative nuclei 
above the overall median (B) and upper quartile (C) for c-Fos intensity values from sections used 
for chi-square analysis. Chi-square statistic is derived from the expected and observed number of 
Mecp2 negative nuclei present. The number of observed nuclei was not different to the expected 
number in both cases (p= 0.77 for (B) and p=0.92 (C), chi-square test, n=15 sections from 4 mice). 
(Di-ii) Summary plots showing the percentage of each nuclei type above the median (Di) and in the 
upper quartile (Dii) c-Fos intensity values. Data expressed as mean ± SEM in the bar graphs. Scale 










































































  175 
 
 
Analysis of immunostaining in the CA1 after three hours of kainic acid treatment 
(Figure 6-8A), showed there was no difference in the number of observed and 
expected Mecp2 negative nuclei above the median (Figure 6-8B; p=0.95, chi-
square test; n= 14 sections from 4 mice) or upper quartile (Figure 6-8C; p=0.89, 
chi-square test) c-Fos intensity values. Therefore, there was no significant 
difference in the percentage of Mecp2 positive nuclei above the median (53.4 ± 
1.5%) and upper quartile (26.9 ± 1.3%) c-Fos intensity values compared to Mecp2 
negative nuclei (46.3 ± 1.4% for above the median; 22.7 ± 1.4% in the upper 
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c-Fos Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
# of -ve nuclei 
above the median 25 28 42 27 29 34 40 42 65 57 33 36 25 36 
# of +ve nuclei 
above the median 38 39 14 24 18 19 12 13 15 25 23 21 18 21 
Expected (E) 34 37 41 28 29 33 41 44 59 54 33 39 26 36 
(O-E) -9 -9 1 -1 0 1 -1 -2 6 3 0 -3 -1 0 
(O-E)
2 81 81 1 1 0 1 1 4 36 9 0 9 1 0 
(O-E)
2
/E 2.382 2.189 0.024 0.036 0 0.030 0.024 0.091 0.610 0.167 0 0.231 0.038 0 
               Degrees of freedom 13
             Sum chi-square 5.8
             P-value 0.95
              
c-Fos Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
# of -ve nuclei in the 
upper quartile 12 10 20 13 16 18 20 21 36 28 17 20 15 19 
# of +ve nuclei in the 
upper quartile  20 24 8 13 7 9 6 6 4 13 11 9 7 10 
Expected (E) 17 18 20 14 15 16 20 22 30 27 16 20 13 18 
(O-E) -5 -8 0 -1 1 2 0 -1 6 1 1 0 2 1 
(O-E)
2 25 64 0 1 1 4 0 1 36 1 1 0 4 1 
(O-E)
2
/E 1.471 3.556 0 0.071 0.067 0.25 0 0.045 1.2 0.037 0.063 0 0.308 0.056 
               Degrees of freedom 14
             Sum chi-square 7.12
             P-value 0.89
             
Figure 6-8 c-Fos expression is elevated following 3 hours of kainic acid induced seizures 
but is not different between Mecp2 nuclei type in CA1 pyramidal cell nuclei 
(A) Representative image of CA1 pyramidal cell nuclei immunostained for c-Fos and Mecp2 status 
displayed through fluorescence of the EGFP fusion protein following 3 hours of neuronal activity. 
White arrows highlight example nuclei which do not contain Mecp2 and blue arrows indicate those 
that do. (B-C) Tables showing the number of Mecp2 positive and negative nuclei above the overall 
median (B) and upper quartile (C) for c-Fos intensity values from sections used for chi-square 
analysis. Chi-square statistic is derived from the expected and observed number of Mecp2 
negative nuclei present. The number of observed nuclei was not different to the expected number 
in both cases (p= 0.95 for (B) and p=0.89 (C), chi-square test, n=14 sections from 4 mice). (Di-ii) 
Summary plots showing the percentage of each nuclei type above the median (Di) and in the upper 
quartile (Dii) c-Fos intensity values. Data expressed as mean ± SEM in the bar graphs. Scale bar = 
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6.4.3 Greater proportion of Mecp2-deficient nuclei express c-Fos 
in the hippocampal formation 
An alternative theory to variations in c-Fos intensity between nuclei types is the 
presence of a disproportionate number of Mecp2 negative nuclei expressing c-
Fos regardless of intensity. At three hours, following the induction of kainic acid 
treatment, every nucleus in the cell body layer of the DG and CA1 of the 
hippocampal formation shows detectable c-Fos expression. However, under 
control conditions in the DG and following 0.5 hour of kainic acid application 
(CA1 and DG), there are only a subpopulation of nuclei labelled. As a result, it is 
possible there could be variations in the number of nuclei that have c-Fos 
depending on nuclei type Mecp2-status. A chi-square test was used to determine 
whether there was a significant difference in the proportion of Mecp2 positive 
and Mecp2 negative nuclei immunostaining positively for c-Fos in the DG under 
saline control. This difference was found to be significant (Figure 6-9Aiv; 
p<0.0001, chi-square test, n= 9 sections from three mice) and this pattern was 
observed in the majority of mice analysed (Figure6-9Ai-iii). Overall, 61% of 
Mecp2 negative nuclei contained c-Fos compared to 39% of Mecp2 positive nuclei 
(Figure 6-9B). This result was not influenced by the total number of each nuclei 
type present in each section as the total number of Mecp2 positive and negative 
nuclei immunostained were significantly different from the total number of each 
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Ai        ii          B 
 
iii        iv 
 
 
Figure 6-9 Increased percentage of Mecp2 negative nuclei expressing c-Fos in the DG of the 
hippocampal formation under saline control conditions. 
 (Ai-iv) Chi-square analysis of the total number (labelled total in table) of Mecp2 positive and Mecp2 
negative nuclei immunostained in the DG under saline control conditions compared to the number 
of each nuclei type immunostained for c-Fos (labelled c-Fos in the table). The first three tables 
represent the data from a different animal whereby a significant difference was observed in two (Ai-
ii) out of three (Aiii) mice (p<0.05, chi-square test, n = three sections per animal). The fourth table 
represents the pooled data for all three mice (p<0.0001, chi-square test). (B) Summary plot from 
the pooled data showing an increase in the percentage of Mecp2 negative nuclei (61%) expressing 
c-Fos compared to Mecp2 positive nuclei (39%). 
A similar analysis was conducted for the effects observed in the DG and CA1 of 
the hippocampal formation following 0.5 hour of kainic acid treatment. Once 
again there was a significant difference in the proportion of Mecp2 positive and 
Mecp2 negative nuclei staining positively for c-Fos (Figure 6-10Bi; p<0.0001, chi-
square test, n= 12 sections from four mice). This difference was seen in all four 
mice analysed (Figure 6-10Ai-iv). Overall, 62% of Mecp2 positive nuclei contain c-
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Figure 6-10 Increased percentage of MeCP2 negative nuclei expressing c-Fos in the DG of 
the hippocampal formation after 0.5 hour of kainic acid application. 
(Ai-iv) Chi-square analysis of the total number (labelled total in table) of MeCP2 positive and 
Mecp2 negative nuclei immunostained in the DG after 0.5 hour of kainic acid treatment compared 
to the number of each nuclei type immunostained for c-Fos (labelled c-Fos in the table). Each table 
represents a different animal whereby a significant difference was observed in all mice (p<0.05, 
chi-square test, n = three sections per animal). (Bi) Pooled data for all four mice (p<0.0001, chi-
square test). (Bii) Summary plot from the pooled data showing an increase in the percentage of 
Mecp2 negative nuclei (62%) expressing c-Fos compared to Mecp2 positive nuclei (38%). 
Pooled data mouse data from the CA1 showed a significant difference in the 
proportion ofMecp2 positive and MeCP2 negative nuclei staining positively for c-
Fos(Figure 6-11Bi; p<0.0001, chi-square test, n= 12 sections from four mice). 
This difference was observed in three (Figure 6-11Ai, iii and iv) out of four 
(Figure 6-11Aii) mice analysed. Overall, 59% of Mecp2 negative nuclei contain c-
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Figure 6-11 Increased percentage of Mecp2 negative nuclei expressing c-Fos in the CA1 of 
the hippocampal formation after 0.5 hour of kainic acid application. 
(Ai-iv) Chi-square analysis of the total number (labelled total in table) of Mecp2 positive and Mecp2 
negative nuclei immunostained in the CA1 after 0.5 hour of kainic acid treatment compared to the 
number of each nuclei type immunostained for c-Fos (labelled c-Fos in the table). Each table 
represents a different animal whereby a significant difference was observed three (Ai, iii and iv) out 
of four (Aii) mice (p<0.05, chi-square test, n = three sections per animal). (Bi) Pooled data for all 
four mice (p<0.0001, chi-square test). (Bii) Summary plot from the pooled data showing an 
increase in the percentage of Mecp2 negative nuclei (59%) expressing c-Fos compared to Mecp2 
positive nuclei (41%). 
6.4.4 Mecp2+/- mice display an increase in Egr-1 expression 
following induction of neuronal activity compared to saline 
controls 
In order to investigate whether other IEG families have altered expression in the 
hippocampal formation of Mecp2-deficient nuclei, the early growth response 
(Egr) family of transcription factors, specifically Egr1, was also studied. In 
comparison to c-Fos, Egr-1 has been shown to have a high basal expression in the 
hippocampus (Waters et al., 1990). However the expression of Egr-1 in the 
hippocampal formation of Mecp2+/- heterozygous female mice has not been 
documented before. Therefore, I investigated the expression of Egr-1 in the 
hippocampal formation during saline control conditions and after 0.5, 1.5 and 3 
hours of the convulsant drug kainic acid. Low levels of Egr-1 expression were 
detected by western blot under saline control conditions and following 0.5 hour 
of kainic acid treatment but a clear increase was observed after 1.5 hour and 
three hours of kainic acid administration (Figure 6-12A). The micrographs in 
Figure 6-12B showed that nuclei in the CA1 express Egr-1 under saline control 
conditions (Figure 6-12Bi) and following 0.5 hour of kainic acid treatment (Figure 
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nuclei in the cell body layer of the hippocampus became brightly immunostained 








Figure 6-12 Time course of Egr-1 protein expression in the hippocampal formation of 
Mecp2
+/- 
female mice after application of kainic acid 
(A) Representative western blot showing marked increase in Egr-1 expression at 0.5hr and 3hrs 
after kainic acid (KA) administration. Subtle levels of Egr-1 are detected in saline controls and after 
0.5 hour of kainic acid. Samples are taken from hippocampal extracts and total histone H3 (H3) 
used as a loading control. (B) Representative immunostaining of Egr-1 expression in the entire 
hippocampal formation following administration of saline (i), 0.5 hour kainic acid (ii) and  3 hours 
kainic acid (iii). Note the staining in the CA1 of the saline sample which has spread further in the 
CA1 after 0.5 hour before the entire hippocampus is strongly immunostained at 3 hours. Scale bar 
= 100µm 
6.4.5 Decreased levels of Egr-1 in Mecp2-deficient nuclei after 
kainic acid treatment in the hippocampal formation 
Having established that neurons in the hippocampal formation of Mecp2+/- 
heterozygous female mice display increased levels of Egr-1 upon induction of 
neuronal activity, I then went on to determine whether there was any 
differences in the intensity of Egr-1 expression between nuclei positive and 
negative for Mecp2 in the DG and CA1 of the hippocampal formation. As 
originally observed in the lower power image (20x objective) in Figure 6-12B, 
there was no Egr-1 immunostaining in the DG under saline control conditions. A 
higher power image (63x objective) showing an absence of Egr-1 expression in 
the DG of the hippocampus can be seen in Figure 6-13. 
 








Figure 6-13 Lack of Egr-1 expression in Mecp2 positive and negative nuclei in the DG region 
of the hippocampal formation under saline control conditions. 
High (20x objective; left) and low (63x objective; right) micrograph images displaying the lack of 
Egr-1 expression in Mecp2 positive and negative nuclei in the DG region of the hippocampal 
formation under control conditions. Scale bar = 100µm for 20x objective image and 25µm for 63x 
objective image. 
Conversely, all nuclei within the CA1 of the hippocampus under saline control 
conditions are immunostained with Egr-1 as shown in Figure 6-14A. However, 
there was no difference in the number of observed and expected Mecp2 negative 
nuclei above the median Egr-1 intensity value (Figure 6-14B; p=0.97, chi-square 
test; n= 9 sections from 3 mice). As a result there was no significant difference 
in the percentage of Mecp2 positive (50 ± 2.6%) and negative nuclei (49.1 ± 1.8%)  
with Egr-1 intensity values above the median (Figure 6-14Di). Additionally, there 
was no difference in the number of expected and observed Mecp2 negative 
nuclei in the upper quartile Egr-1 intensities (Figure 6-14C; p=0.99, chi-square 
test). Therefore there was no significant difference in the percentage of Mecp2 
negative nuclei (25 ± 0.6%) and positive nuclei (25.3 ± 1.3%) in the upper quartile 
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Egr-1 Section 1 2 3 4 5 6 7 8 9 
# of -ve nuclei above the median 42 79 62 18 43 42 47 40 47 
# of +ve nuclei above the median 20 36 34 24 15 24 25 29 23 
Expected (E) 40 80 66 23 38 44 47 39 47 
(O-E) 2 -1 -4 -5 5 -2 0 1 0 
(O-E)
2 4 1 16 25 25 4 0 1 0 
(O-E)
2
/E 0.1 0.013 0.242 1.087 0.658 0.091 0 0.026 0 
          Degrees of freedom 8
        Sum chi-square 2.2
        P-value 0.97
         
Egr-1 Section 1 2 3 4 5 6 7 8 9 
# of -ve nuclei in the upper quartile  23 39 29 11 20 23 23 18 24 
# of +ve nuclei in the upper quartile 8 18 19 10 9 10 13 17 11 
Expected (E) 20 40 33 12 19 22 23 20 23 
(O-E) 3 -1 -4 -1 1 1 0 -2 1 
(O-E)
2 9 1 16 1 1 1 0 4 1 
(O-E)
2
/E 0.45 0.025 0.485 0.083 0.053 0.045 0 0.2 0.043 
          Degrees of freedom 8
        Sum chi-square 1.4
        P-value 0.99
        
 
Figure 6-14 Unaltered Egr-1 levels in CA1 pyramidal cell nuclei of the hippocampal 
formation between Mecp2 nuclei type under saline control conditions 
(A) Representative image of CA1 pyramidal cell nuclei immunostained for Egr-1 and Mecp2 status 
displayed through fluorescence of the EGFP fusion protein. White arrows highlight example nuclei 
which do not contain Mecp2 and blue arrows indicate those that do. (B-C) Tables showing the 
number of Mecp2 positive and negative nuclei above the overall median (B) and upper quartile (C) 
for Egr-1 intensity values from sections used for chi-square analysis. Chi-square statistic is derived 
from the expected and observed number of Mecp2 negative nuclei present. The number of 
observed nuclei was not different to the expected number in both cases (p= 0.97 for (B) and p=0.99 
(C), chi-square test, n =9 sections from 3 mice). (Di-ii) Summary plots showing the percentage of 
each nuclei type above the median (Di) and in the upper quartile (Dii) Egr-1 intensity values. Data 
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Subsequently, I also determined whether there was a difference in the 
distribution of Egr-1 intensities in nuclei positive and negative for Mecp2 
following 0.5 and 3 hours of treatment with the convulsant drug kainic acid. 
Similarly to saline control conditions in the DG at 0.5 hour following kainic acid 
application, no detectable Egr-1 expression was evident and therefore 
distribution analysis was not performed in this area. This is demonstrated in the 






Figure 6-15 Lack of Egr-1 expression in Mecp2 positive and negative nuclei in the DG region 
of the hippocampal formation following 0.5 hour of kainic acid treatment 
High (20x objective; left) and low (63x objective; right) micrograph images displaying the lack of 
Egr-1 expression in Mecp2 positive and negative nuclei in the DG region of the hippocampal 
formation after 30 minutes of kainic acid (KA) treatment. Scale bar = 100µm for 20x objective 
image and 25µm for 63x objective image. 
 
Immunostaining of nuclei in CA1 of the hippocampus following 0.5 hour kainic 
acid treatment can be observed in Figure 6-16A. Similarly to saline control 
conditions, no difference was evident in the number of observed and expected 
Mecp2 negative nuclei above the median Egr-1 intensity value (Figure 6-15B; 
p=0.73, chi-square test; n= 12 sections from 3 mice). There was no significant 
difference in the percentage of positive nuclei (48.7 ±1.5%) compared to 
negative nuclei (51 ± 2.1%) above the median Egr-1 intensity (Figure 6-169Di). 
Furthermore, although there were a  few sections with less than expected 
negative nuclei above the 3rd quartile Egr-1 intensity, the overall chi-square 
value was not significant (Figure 6-16C; p=0.32, chi-square test). Therefore, 
there was no significant difference in the percentage of Mecp2 negative nuclei 
(23.3 ± 1.6%) positive nuclei (26.1 ± 1.1%) with intensities in the upper quartile 
(Figure 6-16Dii). 
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Egr-1 Section 1 2 3 4 5 6 7 8 9 10 11 12 
# of -ve nuclei above the median 36 51 38 43 26 24 76 63 31 35 78 72 
# of +ve nuclei above the median 46 27 35 25 26 33 26 56 112 127 60 63 
Expected (E) 38 53 32 35 25 25 74 65 35 47 76 65 
(O-E) -2 -2 6 8 1 -1 2 -2 -4 -12 2 7 
(O-E)
2 4 4 36 64 1 1 4 4 16 144 4 49 
(O-E)
2
/E 0.105 0.075 1.125 1.83 0.04 0.04 0.054 0.062 0.457 3.064 0.053 0.754 
             Degrees of freedom 11
           Sum chi-square 7.7
           P-value 0.73
            
Egr-1 Section 1 2 3 4 5 6 7 8 9 10 11 12 
# of -ve nuclei in the upper quartile  22 26 18 23 13 12 37 27 13 11 44 39 
# of +ve nuclei in the upper quartile  19 13 18 11 13 16 14 33 58 70 25 28 
Expected (E) 19 27 16 18 13 12 37 32 18 23 38 33 
(O-E) 3 -1 2 5 0 0 0 -5 -5 -12 6 6 
(O-E)
2 9 1 4 25 0 0 0 25 25 144 36 36 
(O-E)
2
/E 0.474 0.038 0.25 1.389 0 0 0 0.781 1.389 6.261 0.948 1.091 
             Degrees of freedom 11
           Sum chi-square 12.6
           P-value 0.32
           
 
Figure 6-16 Unaltered Egr-1 levels in CA1 pyramidal cell nuclei of the hippocampal 
formation between Mecp2 nuclei type following 0.5 hour of kainic acid administration 
(A) Representative image of CA1 pyramidal cell nuclei immunostained for Egr-1 and Mecp2 
following 0.5 hour of neuronal activity. White arrows highlight example nuclei which do not contain 
Mecp2 and blue arrows indicate those that do. (B-C) Tables showing the number of Mecp2 positive 
and negative nuclei above the overall median (B) and upper quartile (C) for Egr-1 intensity values 
from sections used for chi-square analysis. Chi-square statistic is derived from the expected and 
observed number of Mecp2 negative nuclei present. The number of observed nuclei was not 
different to the expected number in both cases (p= 0.73 for (B) and p=0.32 (C), chi-square test, 
n=12 sections from 3 mice). (Di-ii) Summary plots showing the percentage of each nuclei type 
above the median (Di) and in the upper quartile (Dii) Egr-1 intensity values. Data expressed as 
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Following three hours of kainic acid application, 100% of nuclei express Egr-1 in 
the DG of the hippocampal formation.  A high power (63x objective) image of 
this can be observed in Figure 6-17A. However analysis of the number of 
observed and expected Mecp2 negative nuclei above the median (Figure 6-17B; 
p=0.96, chi-square test; n= 12 sections from 4 mice) or in the upper quartile 
(Figure 6-17C; p=0.84, chi-square test) Egr-1 intensity values showed no 
difference between the two. Therefore there was no significant difference in 
the percentage of Mecp2 positive nuclei above the median (47.3 ± 1.5%) and 
upper quartile (23.7 ± 0.8%) Egr-1 intensity values compared to Mecp2 negative 
nuclei (52.2 ± 1.4% for above the median; 25.8 ± 1.1% in the upper quartile) 
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Egr-1 Section 1 2 3 4 5 6 7 8 9 10 11 12 
# of -ve nuclei above the median 37 38 20 14 189 108 97 67 23 49 31 57 
# of +ve nuclei above the median 68 95 65 103 126 51 50 46 61 85 44 74 
Expected (E) 40 40 18 13 182 107 86 66 21 41 29 55 
(O-E) -3 -2 2 1 7 1 11 1 2 8 2 2 
(O-E)
2 9 4 4 1 49 1 121 1 4 64 4 4 
(O-E)
2
/E 0.225 0.1 0.222 0.077 0.269 0.009 1.407 0.015 0.190 1.561 0.138 0.073 
             Degrees of freedom 11
           Sum chi-square 4.3
           P-value 0.96
            
Egr-1 Section 1 2 3 4 5 6 7 8 9 10 11 12 
# of -ve nuclei in the upper quartile  18 22 11 8 99 62 51 36 12 25 13 29 
# of +ve nuclei in the upper quartile 34 45 32 50 59 18 23 20 30 42 25 37 
Expected (E) 20 20 9 7 91 53 43 33 10 21 15 28 
(O-E) -2 2 2 1 8 9 8 3 2 4 -2 1 
(O-E)
2 4 4 4 1 64 81 64 9 4 16 4 1 
(O-E)
2
/E 0.2 0.2 0.444 0.143 0.703 1.528 1.488 0.273 0.4 0.762 0.267 0.036 
             Degrees of freedom 11
           Sum chi-square 6.4
           P-value 0.84
           
 
Figure 6-17 Egr-1 expression is elevated following 3 hours of kainic acid induced seizures 
but is not different between Mecp2 nuclei type in DG granule cell nuclei 
(A) Representative image of DG granule cell nuclei immunostained for Egr-1 and Mecp2 status 
displayed through fluorescence of the EGFP fusion protein following 3 hours of neuronal activity. 
White arrows highlight example nuclei which do not contain Mecp2 and blue arrows indicate those 
that do. (B-C) Tables showing the number of Mecp2 positive and negative nuclei above the overall 
median (B) and upper quartile (C) for Egr-1 intensity values from sections used for chi-square 
analysis. Chi-square statistic is derived from the expected and observed number of Mecp2 
negative nuclei present. The number of observed nuclei was not different to the expected number 
in both cases (p= 0.96 for (B) and p=0.84 (C), chi-square test, n=12 sections from 4 mice). (Di-ii) 
Summary plots showing the percentage of each nuclei type above the median (Di) and in the upper 
quartile (Dii) Egr-1 intensity values. Data expressed as mean ± SEM in the bar graphs. Scale bar = 
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Finally, the expression of Egr1 between Mecp2 positive and negative nuclei in 
the CA1 following three hours of kainic acid treatment can be observed in the 
micrograph in Figure 6-18A. Although there was no significant difference in the 
observed and expected number of Mecp2 negative nuclei above the median Egr-1 
intensity, (Figure 6-18B; p=0.17, chi-square test, n= 16 sections from four mice) 
there appeared to be a trend towards less than expected nuclei as a number of 
sections had up to half the amount of nuclei as expected. This lower chi-square 
p-value gave more confidence in the trend that there was a decrease in the 
percentage of Mecp2 negative nuclei (40.8. ± 2%) compared to Mecp2 positive 
nuclei (61.8 ± 1.9%) however the effect could still be due to random chance as 
significance was not achieved (Figure 6-18Di). 
Interestingly, there was a significant difference in the number of observed and 
expected Mecp2 negative nuclei in the upper quartile Egr-1 intensity values 
(Figure 6-18C; p=0.03, chi-square test). This suggest that there is a significant 
difference the percentage of Mecp2 negative nuclei (19.1 ± 1.7%) in the upper 
quartile Egr1 intensity values compared to the percentage of Mecp2 positive 
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Egr-1 Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
# of -ve nuclei above 
the median 23 77 55 24 44 35 37 35 6 5 36 46 19 32 18 14 
# of +ve nuclei above 
the median 38 22 42 32 30 38 31 36 20 5 19 17 25 15 30 21 
Expected (E) 29 78 60 28 53 44 44 42 12 11 39 48 27 33 27 15 
(O-E) -6 -1 -5 -4 -9 -9 -7 -7 -6 -6 -3 -2 -8 -1 -9 -1 
(O-E)
2 36 1 25 16 81 81 49 49 36 36 9 4 64 1 81 1 
(O-E)
2
/E 1.241 0.013 0.417 0.571 1.528 1.841 1.114 1.167 3 3.273 0.231 0.083 2.370 0.03 3 0.067 
                 Degrees of freedom 15
               Sum chi-square 19.9
               P-value 0.17
                
Egr-1 Section 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
# of -ve nuclei above 
3
rd
 quartile  10 43 28 14 22 12 19 11 3 2 17 22 4 15 7 9 
# of +ve nuclei above 
3
rd
 quartile  16 7 21 15 15 25 15 25 10 10 11 9 18 8 17 10 
Expected (E) 14 39 30 14 26 22 22 21 6 5 19 24 14 16 14 7 
(O-E) -4 4 -2 0 -4 -10 -3 -10 -3 -3 -2 -2 -10 -1 -7 2 
(O-E)
2 16 16 4 0 16 100 9 100 9 9 4 4 100 1 49 4 
(O-E)
2
/E 1.143 0.41 0.133 0 0.615 4.545 0.409 4.762 1.5 1.8 0.211 0.167 7.143 0.063 3.5 0.571 
                 Degrees of freedom 15
               Sum chi-square 26.9
               P-value 0.03
               
Figure 6-18 Decreased Egr-1 levels in CA1 pyramidal cell nuclei deficient in Mecp2 following 
3 hours of kainic acid administration 
(A) Representative image of CA1 pyramidal cell nuclei immunostained for Egr-1 and Mecp2 status 
displayed through fluorescence of the EGFP fusion protein following 3 hours of neuronal activity. 
White arrows highlight example nuclei which do not contain Mecp2 and blue arrows indicate those 
that do. (B-C) Tables showing the number of Mecp2 positive and negative nuclei above the overall 
median (B) and upper quartile (C) for Egr-1 intensity values from sections used for chi-square 
analysis. Chi-square statistic is derived from the expected and observed number of Mecp2 
negative nuclei present. The number of observed nuclei was not different to the expected number 
above the median intensity (p= 0.17 chi-square test, n=16 sections from 4 mice). However there 
was a significant difference in the number of observed and expected nuclei in the upper quartile. 
(Di-ii) Summary plots showing the percentage of each nuclei type above the median (Di) and in the 
upper quartile (Dii) Egr-1 intensity values. Data expressed as mean ± SEM in the bar graphs. Scale 























































































Activity-dependent regulation of genes is important for the precise maturation 
and maintenance of neuronal networks in the brain during development and 
adulthood (reviewed by West and Greenberg, 2011). As the onset of neurological 
symptoms occur early (4-6 weeks) in the development of the Mecp2 mutant male 
mice (Chen et al. 2001; Guy et al. 2001) and the levels of Mecp2 increase greatly 
in postnatal life (Kishi and Macklis 2004; Skene et al. 2010) this would suggest an 
important role for MeCP2 during neuronal maturation too. Indeed recent studies 
show that MeCP2 may be more important in the mature nervous system rather 
than during neurodevelopment per se (McGraw et al., 2011; Cheval et al., 2012).  
Mecp2 has been shown to be dynamically regulated by neuronal activity 
(Chen et al., 2003;  Tao et al., 2009; Zhou et al. 2006; Chapter four) however 
the downstream effects of this event on gene regulation is still debatable.  
Considering IEGs are induced rapidly in response to neuronal activity and 
regulate the transcription of genes (Herdegen and Leah, 1998), there could be 
an association between the activity dependent regulation of MeCP2 and IEGs in 
the control of gene expression during maturation. To investigate this in greater 
detail, I used the quantitative immunofluorescence method (explained in 
chapter two and five) to determine whether there were any alterations in the 
expression of two IEGs, c-Fos and Egr-1, between Mecp2 positive and negative 
nuclei under saline control conditions and in response to neuronal activity. The 
results from this chapter showed there was an elevation of c-Fos levels in the 
entire hippocampal formation of Mecp2+/- heterozygous female mice following 
induction of neuronal activity, but no difference in the distribution of c-Fos 
intensities between Mecp2 positive and negative nuclei. However there was a 
greater proportion of Mecp2-deficient nuclei expressing c-Fos under saline 
control conditions and following neuronal activity. This might suggest that c-Fos 
has a lower threshold for induction in Mecp2-deficient cells. In addition to c-Fos, 
there was also an activity-dependent increase in Egr-1 levels in the whole 
hippocampal formation of Mecp2+/- heterozygous female mice following kainic 
acid. However, this was accompanied by a reduction in the percentage of Mecp2 
negative nuclei in the top 25% of Egr-1 intensities in the CA1 following three 
hours of neuronal activity. This result suggests that Egr-1 may have a higher 
threshold for induction in Mecp2-deficient cells. 
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There are at least 30-40 neuronal IEG (Lanahan and Worley, 1998) which can be 
referred to as biomarkers of activity as they are the first response elements 
following neuronal activity induction into a cell with Egr-1 and c-Fos amongst 
the best characterised. Upon activity-dependent stimulation, c-Fos proteins 
dimerize with c-Jun, from Jun IEG family, and form a complex with activator 
protein (AP-1) transcription factor to regulate gene expression through binding 
promoters containing AP-1 activation elements (Halazonetis et al., 1988). In 
contrast, Egr-1 proteins (also known as NGFI-A, krox-24, zif268 and TIS8) are a 
subclass of zinc finger motif-containing proteins which act as interaction 
modules that bind DNA, RNA and proteins (Lemaire et al., 1988).  As these two 
IEGs have different structural properties and DNA binding motifs it is anticipated 
that they will differentially regulate gene expression and potentially interact 
with Mecp2. 
From my results I have shown that although there was no difference in the 
distribution of intensities of c-Fos between nuclei types (Figure 6-2 to 6-7) in the 
hippocampal formation, there was an increased percentage (~20%) of Mecp2 
negative nuclei expressing c-Fos in the CA1 and DG under saline control 
conditions and following 0.5 hour of the convulsant drug kainic acid (Figure 6-8 
to 6-10). These results suggest that there is an overall upregulation of c-Fos 
expression but no difference in c-Fos intensity between Mecp2 containing and 
Mecp2-deficient nuclei. Interestingly, as Mecp2 can be phosphorylated upon 
induction of neuronal activity and at low levels in basal conditions 
(Chen et al., 2003; Tao et al., 2009; Zhou et al., 2006; chapter four) there could 
be a link between the two whereby MeCP2 regulates the expression of c-Fos 
upon phosphorylation of its protein. Other studies have shown that Mecp2308 
mutant mice have normal intensity levels of c-Fos mRNA expression in the 
striatum following cocaine induction (Su et al., 2012). This agrees with my 
studies in terms of c-Fos intensity differences. Furthermore hippocampal 
cultures with mutations in phosphorylated S421 on Mecp2 had comparable c-Fos 
mRNA expression levels to WT controls in response to 55mM KCl (Zhou et al., 
2006). However my study was unique in determining the differences in the 
number of cells expressing c-Fos suggesting that c-Fos has a lower threshold for 
induction in Mecp2-deficient cells. 
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Stimulation with kainic acid in vivo generates a range of epileptic seizures 
(Chapter three). Application of this convulsant drug to mutant mice in which c-
Fos knocked out in the hippocampus (Tsien et al., 1996) resulted in mice 
displaying more severe seizures (Zhang et al., 2002). Interestingly I have shown 
that Mecp2-deficient mice also display increased severity of kainic-induced 
seizures (chapter three). These combined results suggest that c-Fos can regulate 
neuronal excitability and that a reduction in c-Fos in Mecp2 mutant mice could 
contribute to the hyperexcitability phenotype observed. However, I detected 
the opposite in this chapter in which a greater proportion of Mecp2-deficient 
nuclei expressed c-Fos in the hippocampus. One explanation for this could be  
expression of c-Fos needs to be tightly regulated for the appropriate control of 
cellular mechanisms involved in neuronal excitability, with too much just as 
detrimental as too little. This could be similar to the requirement for tightly 
regulated MeCP2 expression with overexpression of Mecp2 being shown to be 
just as detrimental as its absence (Collins et al. 2004;  Na et al. 2012). 
Alternatively, instead of c-Fos contributing to the hyperexcitable phenotype, it 
could be the opposite in Mecp2-deficient mice. As the neurons are already 
hyperexcitable, they are more likely to respond to environmental influences. I 
have shown that Mecp2-deficient nuclei are 20% more likely to express c-Fos 
under control conditions and that this percentage difference is the same after 
induction of neuronal activity. Therefore there is a possibility that this increase 
in c-Fos expression is due to Mecp2-deficient nuclei being highly excitable and 
more likely to respond to subtle changes in the environment, even background 
activity under basal conditions.  
In contrast to c-Fos, there was a reduction in the percentage of Mecp2 negative 
nuclei in the top 25% of Egr-1 intensities in the CA1 following three hours of 
neuronal activity (Figure 6-17) but not at any other time point (Figure 6-12 to 6-
16). This suggests that following neuronal activity, Egr-1 expression in Mecp2-
deficient nuclei becomes desensitized. As with c-Fos, there could be a link 
between phosphorylation of MeCP2 and regulation of Egr-1 levels, except instead 
of increasing levels under WT conditions, there is a decrease in Egr-1 protein in 
nuclei deficient in MeCP2. Interestingly a recent study has highlighted the type 
of phosphorylation of Mecp2 and exact gene being studied are important for 
determining whether Mecp2 acts as a repressor or activator of gene transcription 
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(Gonzales et al., 2012). This could be the case here whereby MeCP2 
phosphorylation could activate Egr-1 expression but repress c-Fos in response to 
neuronal activity. A study has shown that another member of the IEG Egr family, 
Egr-2, displays reduced protein expression levels in the cortex of Mecp2-
deficient mice, cultured human neuroblastoma cells in which MeCP2 is knocked 
down by RNA interference and in RTT post-mortem cortex samples (Swanberg et 
al., 2009). This suggests a dysregulation in the expression of Egr-1 and Egr-2 may 
be a common feature in MeCP2-deficient cells. 
Egr-1 also has high basal expression in the hippocampus (Waters et al., 1990) 
especially in the CA1 region of Mecp2+/- heterozygous female mice (Figure 6-10 
and Figure 6-13) which is likely due to on-going synaptic input in the brain 
(Worley et al., 1991). This expression can be abolished by NMDA receptor 
antagonists (Worley et al., 1991) and L-type voltage-gated calcium channel 
antagonists (Murphy et al., 1991). These studies suggest that basal levels of Egr-
1 expression could be maintained by synaptic plasticity as the above receptors 
are key components in this physiological event.  Furthermore there is an 
increase in Egr-1 expression following induction of LTP in the hippocampus 
(Cole et al. 1989;  Wisden et al. 1990). As Mecp2-deficient mice have been 
shown to have an impairment in LTP in the hippocampus (Moretti et al. 2006; 
Weng et al. 2011), the decrease I observed in Egr-1 expression in the CA1 
following induction of neuronal activity would be consistent with this model. 
In conclusion I have shown that there is a dysregulation in the expression of two 
IEGs, c-Fos and Egr-1, in the hippocampal formation within Mecp2-deficient 
nuclei. These effects could be correlated to alterations in activity-dependent 
phosphorylation of Mecp2. Further experiments immunostaining for the effects 
of phosphorylated Mecp2 in the hippocampus of Mecp2+/- heterozygous female 
mice would enable a more direct association to be made between IEGs. However 
my results could also be secondary to the hyperexcitability or LTP defects seen 
in Mecp2-deficient neurons. Either way, my results show that there are 
alterations in neuronal activity and IEG protein expression in Mecp2-deficient 
neurons. Importantly, the strength, stimulus type 
(Hardingham, Fukunaga, and Bading 2002; Traverse et al. 1994), structural DNA 
binding properties of each IEG and cell type will all contribute to the cellular 
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7.1 Major and novel findings 
The general theme of this project was to examine how the presence or absence 
of MeCP2 affects neuronal activity and how in turn neuronal activity affects 
MeCP2 actions. For this I chose to focus my attention on aspects of 
hyperexcitability (epileptiform activity) and how neuronal activity can influence 
post translational modifications of MeCP2 and histone acetylation. Whilst many 
of my results were negative, this thesis nevertheless gives important novel 
insights into a number of areas. 
7.1.1 Reduced seizure threshold and altered oscillatory 
properties in Mecp2 knockout mice 
In Chapter three the major and novel findings I report are a reduction in seizure 
threshold and an increase in the power of gamma oscillations in Mecp2-deficient 
mice.  Seizures are a major RTT phenotype (Glaze et al., 2010), and are a  
feature of mice models overexpressing Mecp2 (Collins et al., 2004) and those 
with a truncated Mecp2 mutation (Shahbazian et al., 2002). Constitutive 
knockout mice models of Mecp2 do not express an overt epileptic phenotype, 
displaying only a slight tremor that increases in severity with age 
(Chen et al. 2001; Guy et al. 2001). This is also true of the functional knockout 
model I used in my epileptic studies (Guy et al., 2007). Few other studies have 
investigated, in a systematic way, the changes behind generation of seizures in 
vivo using mouse models of RTT. Therefore, my experiments in which I applied 
the convulsant drug kainic acid to mice deficient in Mecp2 and their WT 
littermates to investigate, in quantitative terms, their epileptic phenotype was 
unique. I discovered that Mecp2stop/y mice display a more severe seizure score 
and have a quicker onset of seizures compared to their WT littermates. This is 
consistent with a lack of functional Mecp2 resulting in a compromised nervous 
system that is predisposed to seizure generation. Furthermore, this phenotype 




field events and longer duration of evoked field potentials in Mecp2stop/y mice 
following application of bicuculline in vitro to hippocampal slices. Collectively, 
these results imply that Mecp2 mutant mice have an inherent reduced 
epileptiform threshold which contributes to an increased susceptibility to seizure 
generation. 
Application of kainic acid in vivo is commonly considered a model for temporal 
lobe epilepsy (Nadler, 1981). In contrast, application of kainic acid to 
hippocampal slices in vitro produces rhythmic gamma frequency oscillations 
consistent with normal physiological hippocampal rhythms (Fisahn, 2005). 
Gamma rhythms are present during waking and sleeping states and are 
important for timing of action potential firing in the brain. In my studies, I found 
that mice deficient in Mecp2 display a more powerful (high power) gamma 
oscillation in the presence of kainic acid compared to WT controls. Normal 
generation and maintenance of physiological gamma rhythm is highly dependent 
on inhibitory neurotransmission (GABA mediated) in the brain, namely fast 
spiking interneurons (Hasenstaub et al., 2005; Whittington et al., 1995). 
Furthermore, a recent study has shown that axo-axonic cells are important in 
generating tonic levels of inhibition during gamma activity (Dugladze et al., 
2012). Most intrinsic properties of principal cells in the hippocampus/cortex of 
Mecp2-deficient mice are reported to be normal (Dani et al., 2005; 
Wood et al., 2009; Zhang et al., 2008). This is consistent with the fact that I 
observed no difference in the frequency of gamma oscillations in my studies. 
However, other studies have shown alterations in GABAergic release and kinetics 
(Chao et al., 2010; Medrihan et al., 2008). Whatever the case, the heightened 
gamma power may be indicative of a hippocampal network brought closer to a 
pathological network hyperexcitability/hypersynchrony threshold by MeCP2 
deficiency.  
7.1.2 No alteration in histone protein levels in Mecp2 positive and 
negative neurons in the Mecp2+/- mosaic brain. 
In Chapters four and five, I demonstrated that phosphorylation of Mecp2 is not 
associated with alterations in histone acetylation levels following induction of 
neuronal activity. To understand the alterations in network excitability I 




pathways associated with MeCP2 function that could contribute to this 
dysfunction. Acetylation sites on histone proteins have been shown to be 
amenable to alterations in neuronal activity (reviewed by Riccio, 2010). 
Furthermore, an increase in H3Ac was detected in whole brains from Mecp2-
deficient mice compared to WT controls under basal conditions suggesting that 
the effects of Mecp2 are more global (Skene et al., 2010). However I was never 
able to replicate this finding using either a western blot approach or a 
quantitative immunostaining method. By using whole brains to do their analysis, 
Skene et al could have been picking up a variety of cell types in which some 
possibly non-neuronal populations had big changes in histone acetylation. My 
results showed no difference in histone acetylation between Mecp2 containing 
and Mecp2-deficient neurons in saline control conditions and following induction 
of activity. This could reflect alterations in histone acetylation that are specific 
to regions of the brain or MeCP2 mutation type. For example an increase in 
acetylation at specifically histone H3 lysine 9 from nuclei in the cerebral cortex 
of Mecp2-/y mice has been reported (Thatcher and LaSalle, 2006) but no 
difference in H3Ac (lysine 9 and 14) were seen in cell cultures from RTT patients 
with truncated mutations (Wan et al., 2001). Furthermore there could possibly 
be adaptive mechanisms compensating for deficiencies in MeCP2. 
The effect of MeCP2 deficieny on histone acetylation could also influenced by 
non-cell autonomous effects, in which cells negative for MeCP2 can have 
deleterious effects on neighbouring MeCP2 positive cells. This has been shown to 
occur in cortical pyramidal neurons in WT mice transfected with Mecp2-/y 
cortical neuroblasts (Kishi and Macklis, 2010), with these cells displaying deficits 
in dendritic arborization . Glial cells deficient in MeCP2 have also been shown to 
display a non-cell autonomous trait in which Mecp2-deficient glial cells were 
unable to support the growth of WT neurons (Ballas et al., 2009; Maezawa and 
Jin, 2010). However, in this study I observed cell-autonomous effects in the 
hippocampus of Mecp2+/- heterozygous mice in which I document a robust and 
reliable reduction in nuclear volume in cells that lack Mecp2. Although this has 
been documented in the hippocampus of Mecp2-deficient mice 
(Giacometti et al. 2007; Johnson et al. 2011; Yazdani et al. 2012) and in neurons 
of the locus ceruleus of  Mecp2+/- heterozygous mice (Taneja et al., 2009), this 




argue against a role for non-cell autonomous effects of MeCP2. Overall, the 
quantitative immunofluorescence approach I used to study the effect of MeCP2 
on histone acetylation levels was unique and sensitive enough to determine 
subtle changes in histone levels. My results are predominantly negative findings 
but are nevertheless important as they help to rule out particular mechanisms 
and models of MeCP2 function. Furthermore no other study has attempted to see 
whether neuronal activity affects the levels of histone acetylation in Mecp2-
deficient mice.  
7.1.3 Altered regulation of immediate early gene levels in neurons 
deficient in Mecp2 in the Mecp2+/- mosaic brain 
In Chapter six I demonstrated that at the cellular level, neurons deficient in 
Mecp2 in the Mecp2+/- mosaic brain have a greater proportion of nuclei 
containing the immediate early gene (IEG) c-Fos under basal conditions. 
Furthermore Mecp2 negative nuclei display a reduction in the levels of another 
IEG, Egr-1, in the CA1 of the hippocampal formation following kainic acid 
administration.  These results suggest c-Fos and Egr-1 have differential threshold 
levels for induction in Mecp2-defcient cells. Activity-dependent changes in gene 
expression in response to external stimuli are important for normal development 
and function of the maturing nervous system (Dragunow et al. 2000; 
(Marek et al., 2010;  West and Greenberg, 2011). Therefore, as I observed an 
increase in the excitability of hippocampal neurons deficient in Mecp2 in my 
physiology studies, this could result in or be the result of a dysfunction in the 
regulation of gene expression. IEGs are nuclear transcription factors which are 
usually the first response elements induced following neuronal activity and are 
thus useful targets to test this hypothesis. Additionally, few studies have defined 
the behaviour of these genes in RTT or Mecp2 knockout mice. 
My results are the first to document alterations in c-Fos and Egr-1 in the 
hippocampal formation of Mecp2+/- heterozygous mice. C-Fos and Egr-1 have 
differential structural properties and binding motifs (Halazonetis et al., 1988; 
(Lemaire et al., 1988) which could explain why there is an increase in c-Fos but 
a decrease in Egr-1. Furthermore, I have shown in Chapter four, Mecp2 can 
become phosphorylated in response to the convulsant drug kainic acid. This is in 




Zhou et al., 2006) and may represent a link between phosphorylation of MeCP2 
and regulation of IEGs, in a similar manner to the transcription of c-Fos in 
response to activity induced CREB phosphorylation (Greenberg et al., 1986). 
Potentially, phosphorylation of MeCP2 interacts with various transcription 
factors and result in the regulated expression of genes in in a manner dependent 
on the specific gene and the region of the brain/cell involved.   
7.2 Significance of this study 
My physiology experiments are significant because the in vivo kainic acid seizure 
model could be beneficial in future studies to test novel pharmacological and 
genetic approach therapies in RTT. Reversal of the symptoms of RTT was first 
established in 2007 (Guy et al., 2007) and other groups since then have tried to 
improve the phenotypes of RTT by numerous means 
(Derecki et al., 2012; Gadalla et al., 2011; Lioy et al., 2011; Tropea et al., 2009; 
Weng et al., 2011). A common requirement of these phenotype reversal studies 
is the need to validate successful symptom reversal, including in the epilepsy 
domain. My in vivo kainic acid seizure model is a quantitative behavioural assay 
of hypersensitivity to drug-induced epilepsy which produces a distinctive 
phenotype and could be used to establish the extent of symptom rescue.  
The reduction in seizure threshold and increased oscillatory activity observed in 
Mecp2 mutant mice in my study are important because they help to clarify the 
underlying features leading to a disruption in network excitability in this disease 
model.  A particularly surprising finding is that intrinsic excitability of pyramidal 
neurons is relatively unaltered (Dani et al., 2005; Wood et al., 2009; 
Zhang et al., 2008) whereas at the network level aberrant excitability is very 
clear. It is possible that this results from altered synaptic balance or structural 
changes at the level of the network. The dysfunction in IEG regulation and lack 
of histone acetylation following neuronal activity provides greater detail as to 
the effects of MeCP2 deficiency at the cellular level. My histone acetylation 
results, whilst predominantly negative, are nevertheless important as they help 
to rule out particular mechanisms and models of MeCP2 function. The 
differential alterations in IEGs in Mecp2-deficient mice I report could also 




Additionally, the effects I observed using a mouse model of RTT could 
potentially transfer to other neurodevelopmental disorders. External stimuli in 
the brain following birth is important for neurite outgrowth, synapse formation 
and elimination to create an accurate balance of inhibitory and excitatory 
synapses in the adult brain (reviewed by West and Greenberg, 2011). 
Interestingly, a vast number of other neurodevelopmental disorders have deficits 
during neuronal maturation including disorders such as Fragile-X syndrome 
(FRAX; 300624) and Angelman syndrome (AS; OMIM 105830). Furthermore these 
two disorders are the result of mutations in genes involved in epigenetic 
mechanisms. FRAX results from DNA methylation of an expanded CGC sequence 
within the FMR1 gene. This gene encodes for the fragile-X mental retardation 
protein, FMRP on the X chromosome (Sutcliffe et al., 1992). Most cases of AS are 
caused by deletions in an imprinted gene, Ube3A on the maternal allele 
(Matsuura et al., 1997). Normally genomic imprinting requires DNA methylation 
and histone modifications to silence the expression of a gene on one paternal or 
maternal allele. FRAX, AS and RTT also exhibit similar phenotypes such as a 
dendritic spine loss and abnormalities (reviewed by Fiala et al., 2002). The 
commonalities between these disorders suggest a link between the pathology of 
these disorders whereby information gained on one could translocate to another. 
7.3 Technical considerations and future studies 
There are some technical considerations that need to be addressed from the 
experiments conducted in this thesis which would be incorporated into future 
studies. Firstly, a negative effect of using the convulsant drug kainic acid to 
induce epilepsy is cell death in the hippocampal formation (Sperk et al., 1983b) 
which could potentially complicate the analysis of my physiology and 
immunohistochemistry work. To minimise this occurrence, the strain of mice 
used in all experiments were on a C57BL/6 background strain which display a 
higher resistance to neuronal death (Schauwecker and Steward, 1997). Secondly, 
the ages of male mice used in all physiology experiments in chapter three were 
symptomatic for RTT phenotypes making it more complex to decipher whether 
the deficits I observe are the cause directly by Mecp2 deficiency or are 
secondary pathological changes. Future experiments that could aid clarification 
of this would be to repeat the experiments in pre-symptomatic mice Mecp2 




increase in seizure severity to kainic acid induced seizures in pre-symptomatic 
Mecp2+/- heterozygous mice giving an indication that the effects would also be 
present earlier in development.  
Thirdly, an issue with the automated script developed to determine differences 
in IEG and acetylated histone proteins levels between Mecp2 positive and 
negative nuclei in Mecp2+/- heterozygous mice was that it did not automatically 
count the total number of nuclei that were in an optical image stack therefore 
some analysis had to be quantified manually. To minimise human error, in future 
it would be better to redesign the script to include this function allowing the 
process to be fully automated. Fourthly, a variety of studies investigating the 
role of histone acetylation administer histone deacetylase inhibitors in the first 
instance. I added the histone deacetylase inhibitor sodium butyrate to my 
nuclear preparation; however this might not have been the most optimal 
method. Studies have shown that intraperitoneal injection of the histone 
deacetylase inhibitor trichostatin A (TSA) prior to kainic acid, can lead to an 
increase in acetylated histone levels (Sng et al., 2005). In future experiments, 
incorporating this into the protocol could make it easier to decipher differences 
in histone acetylation between Mecp2 positive and negative nuclei if there was a 
more pronounced increase present from the start. 
Other studies that could also be conducted to build upon the findings of this 
thesis include the specification of which neuronal types in the hippocampal 
formation contribute to the deficits I observe. For example in chapter three, 
altering the input of inhibitory neurotransmission when conducting kainic acid 
experiments in vitro will help clarify the mechanisms involved in the enhanced 
gamma oscillations in Mecp2-deficient mice. Furthermore, in my quantification 
of IEG and histone acetylation levels in nuclei in chapter five and six, it would be 
interesting to determine whether the effects observed are specific to neuronal 
subtypes or if glia cells are involved. Immunostaining for these cell types in the 
hippocampus and in other brain regions could answer this question. 
Immunostaining for phosphorylated Mecp2 proteins in Mecp2+/- heterozygous 
female mice would also enable a better association between IEG regulation and 




Finally conducting experiments using an animal model in which Mecp2 is 
conditionally knocked down (Cheval et al., 2012) will enable the role of Mecp2 in 
the regulation of activity-dependent gene expression to be assessed at different 
developmental stages. A related question is whether the germline knockout 
mouse models of Mecp2 are masking possible effects in histone acetylation due 
to possible adaptive mechanism present. Rapid inactivation or knockdown of 
Mecp2 might reveal undiscovered associations between presence/absence of 
Mecp2 and histone acetylation. 
7.4 Summary 
Focussing on the hippocampus, the aim of this thesis was to investigate the role 
of MeCP2 in activity-dependent brain processes. At the network level I have 
shown that lack of Mecp2 leads to a reduction in seizure threshold and 
enhancement in the power of gamma frequency network oscillations thus 
altering network level excitability in the brain to promote epileptogenesis. At 
the molecular level, I demonstrate that Mecp2 can become phosphorylated 
following the induction of neuronal activity using the convulsant drug kainic acid 
and that this is not associated with global alterations in histone acetylation. 
However, I do report a reduction in nuclear volume and alterations in the levels 
of two IEGs, c-Fos and Egr-1, in Mecp2-deficient nuclei from Mecp2+/- 
heterozygous mice. These results propose a cell-autonomous role for Mecp2 and 
the activity-dependent control Mecp2 exerts on gene transcription. Overall, I 
believe my work contributes to the understanding of how neuronal activity 
affects the function of MeCP2 in neurons at the network and cellular levels thus 







Cell lysate preparation optimisation 
Three cell lysate techniques were optimised to decipher which method gave a 
clear nuclear protein expression for western blot experiments. The decision to 
proceed with homogenising hippocampal tissue in a cell lysate buffer (CL1) in 
which none of the tissue was discarded from the final product was taken as the 
other two methods (CL1 supernatant and RIPA) resulted in an absence of nuclear 






Supplementary Figure 1-1 Comparison of three cell lysate methods for western blot analysis 
Representative western blots comparing three nuclear extract techniques 1. Hippocampal tissue is 
homogenised in a cell lysate buffer (CL1) in which none of the tissue is discarded from the final 
product. 2. Hippocampal tissue is homogenised in the same CL1 buffer but the samples are spun 
down (13000rpm for 5 minutes at 4°C) and the supernatant tissue used for western blot analysis 
(CL1 supernatant). 3. Hippocampal tissue is homogenised in a different nuclear extract buffer 
(50mM TRIS, 150mM NaCl, 1% IGEPAL, 0.5% Triton-X-100 and 0.1% SDS) with the samples then 
spun down and the protein supernatant tissue used for western blot analysis (RIPA). The loading 
control GAPDH is present in all three methods but Mecp2 and total histone H3 (H3) are only 










An annotated automated script developed by Dr David Kelly at the University of 
Edinburgh for quantifying cell intensity differences between Mecp2 positive and 
negative nuclei in Chapters four and five can be observed below. 
Option Explicit 
 
Public RedId As Integer, GreenId As Integer, DAPIId As Integer, DAPIBinary As Integer 
 
Public DAPIMaskId(200) As Integer 
 
Public TotalCount As Integer, RowCount As Integer, pos As Integer 
 
Public seqinfo As Long 
 
Public GetTheVal As String 
 








'**  Macro Written For Use In Image Pro Plus 7.0.1.658 with 3D Constructor     
       
'** Author David Kelly          
             
'**  Final Version 8-11-2011         
            
  
'**            
             
'**  DESCRIPTION          
            
  
'**  Takes 3 colour Z stack Leica .lif images. Turns Dapi image into a 3D thresholded binary mask, the mask is applied  
 
'**  to the green (GFP) image to check for the presence/absence of GFP labelling. The masks are used because its far  
 
'**  easier to threshold a 2D image.         
            
  
'**  The DAPI mask is then applied to the red image to measure total intensity of red within single cells.    
 
'**  All results are then passed to Excel for later analysis.       




















 MakeDAPIMask    'Subroutine to make 3D Dapi mask count number of nuclei 
 
    
 



















 '* Instructs user to open and image and then to manually click on each image in turn to   
 







 ret = MsgBox("Open Image") 
 
 ret = MsgBox("Select Red Image") 
 
 ret = IpDocGet(GETACTDOC, 0, RedId)  'Assigns red image id to variable for later use 
 
 ret = MsgBox("Select Green Image")  
 
 ret = IpDocGet(GETACTDOC, 0, GreenId)  'Assigns green image id to variable for later use 
 
 ret = MsgBox("Select DAPI Image") 
 
 ret = IpDocGet(GETACTDOC, 0, DAPIId)  'Assigns blue image id to variable for later use 
 








 Dim FromVal As Single, ToVal As Single, MaxIntensity(10) As Single 
 






 '* User thresholds the blue (DAPI) intensity image to highlight the whole cell nucleus, cells/objects   
 
 '* which fall below the size threshold are excluded from any measurements. Objects are split using the  
 
 '* watershed split function and any undersize objects ignored. A binary mask is then created for each  
 







 ret = IpAppSelectDoc(DAPIId) 
 
 ret = IpSeqGet(SEQ_NUMFRAMES, seqinfo) 
 
 ret = IpSMPlay(0) 
 
 ret = IpSeqPlay(0) 
 




 '** Section to subtract Background from blue intensity image using an area       
 





 ret = IpBlbEnableMeas(BLBM_DENSITY, 1)   'Enable mean intensity 
 
 ret = IpBlbEnableMeas(BLBM_DENSMAX, 1)   'Enable max intensity 
 
 ret = IpAoiShow(FRAME_RECTANGLE)   'Show rectangle AOI 
 
 ret = MsgBox("Draw AOI to area not containing a DAPI nucleus") 'Prompt for user to draw region on area of background 
 
 ret = IpSegSetRange(0, 0, 4095)    'Set threshold to entire range 
 
 ret = IpSegPreview(CURRENT_C_T) 
 
 ipICal(0) = 0 
 
 ipICal(1) = 4095 
 
 ret = IpBlbMultiRanges(ipICal(0), 1) 
 
 ret = IpBlbCount()     'Measure intensity 
 
 ret = IpBlbUpdate(0) 
 
 ret = IpBlbData(BLBM_DENSMAX, 0, 0, MaxIntensity(0))   'Retrieve Max intensity value 
 
 ret = IpAoiShow(FRAME_NONE)    'Remove AOI 
 





 ret = IpOpNumberArithmetics(MaxIntensity(0), OPA_SUB, 1) 'Subtract Max BkGrd intensity from Dapi image 
 
 ret = IpDocGet(GETACTDOC, 0, TempNum) 
 
 ret = IpAppSelectDoc(DAPIId) 
 
 ret = IpDocClose()     'Close original DAPI image as its now useless. 
 




 '** Section to make binary image from BkGrd   
 




 ret = IpAppSelectDoc(DAPIId)   'Application selects Dapi Image 
 
 ret = MsgBox("Draw region around cells of interest") 'Draw a region around a subset of cells as image too big to  
       process as a whole 
 
 ret = IpSegShow(1)  
 
 ret = MsgBox("Threshold the DAPI Image")  'User prompt to threshold the image 
 
 ret = IpSegGetRange(0, FromVal, ToVal)  'Gets the threshold values to apply to each plane in image 
 
 ipICal(0) = FromVal 
 
 ipICal(1) = ToVal 
 
 ret = IpBlbMultiRanges(ipICal(0), 1) 
 




 '* Loop 1 to identify cells based on intensity in each layer  
 
 '* and then produce a binary from each layer        
 
 For x = 0 To seqinfo -1 
 
  ret = IpAppSelectDoc(DAPIId) 
 
  ret = IpSMPlay(x) 
 
  ret = IpSeqPlay(x) 
 
  ret = IpBlbCount() 
 
  ret = IpBlbUpdate(0) 
 
  ret = IpBlbSplitObjects(1) 
 
  ret = IpBlbSetFilterRange(BLBM_AREA, 55.43291855, 10000000.0)  'Sets filter range to stop too small objects from 
         being counted. 
 
  ret = IpBlbCreateMask() 
 
  ret = IpDocGet(GETACTDOC, 0, DAPIMaskId(x)) 
 




 '* Loop 2 Takes all the binaries created in loop 1 and  
 
 '* re-assembles the z stack made of binaries    
 
 For x = 1 To seqinfo -1 
 
  ret = IpAppSelectDoc(DAPIMaskId(0)) 
 
  ret = IpSeqMergeDoc(DAPIMaskId(x), 0, -1) 
 




 ret = IpSCalSetLong(0, SCAL_UNIT_CONVERT, 1) 
 
 ret = IpSCalSetUnitName("um")    'Sets the units to microns instead of the default nm 
 
 ret = IpSCalSetLong(SCAL_CURRENT_CAL, SCAL_APPLY, 0) 
 
 ret = IpPcTint(TINT_BLUE)    'Applies blue tint to binary 
 




 '* Loop 3 closes all the single binaries made by loop 1 * 
 
 '* which are no longer need to free up system memory * 
 





  ret = IpAppSelectDoc(DAPIMaskId(x)) 
 
  ret = IpDocClose() 
 








 Dim x As Integer, y As Integer, SingleDAPIBinary As Integer 
 
 Dim Filesave As String, Answer As String 
 
 Dim MeanIntensity(10) As Single, TotalMean As Single 
 






 '** Sub-routine makes a 3D image using the dapi binary created in MakeDapiMask. The 3D image  ** 
 
 '** is watershed split to seperate any touching objects, objects which are too firmly joined  ** 
 
 '** and can't be separated have to be ignored using the object size filters. A single cell ** 
 
 '** is extracted from the 3D image and compared slice by slice with the exact same position ** 
 
 '** in the green image to see if any GFP was present in the cell. 3 consecutive GFP positive ** 
 
 '** slices counts as colocalised. The individual cells are then labelled as colocalised (GFP ** 
 
 '** positive) or non-colocalised (GFP negative). The extracted single dapi nucleus is then ** 
 






 '** Load DAPI binary stack into 3d Constructor ** 
 
 ret = IpRendShow(REND_OPTIONS,REND_HIDE) 
 
 ret = IpRendSet(REND_VOXELSIZE, 0.480000, 0.480000, 0.250000)  'Set voxel size 
 
 ret = IpRendSet(REND_SUBSAMPLING, 1, 1, 1) 
 
 ret = IpRendSet(REND_ACTIVE_PORTION, 1, 0, 0) 
 
 ret = IpRendSet(REND_HI_COLOR, 0, 0, 0) 
 
 ret = IpRendSet(REND_RESET_OPTIONS, 0, 0, 0) 
 






 '*** Make 3D volume image of DAPI Binary Stack Image  ***** 
 
 ret = IpAppSelectDoc(DAPIBinary)     'Select Dapi Binary Stack 
 
 ret = IpRendSet(REND_ISO_SUBSAMPLING, 1, 1, 1)   'Turn off subsampling to increase accuracy 
 
 ret = IpRendSet(REND_ISO_FILTER, FLT_3D_None, 0, 0)   'Set No Filtering 
 
 ret = IpRendSet(REND_ISO_CLOSE_EDGES, 0, 0, 0) 
 
 ret = IpRendSet(REND_ISO_COUNT, 1, 0, 0) 
 
 ret = IpRendSet(REND_ISO_SIMPL, ISO_SIMPL_NONE, 0, 0)  'No Simplification 
 
 ret = IpRendElem(ELEM_ADD,IP_REND_ISO_SURF,0,IPNULL) 
 
 ret = IpRendElemSet(ELEM_ISO_LEVEL,IP_REND_ISO_SURF,0,250.000000)  'Set Iso-Surface 
 
 ipDArray(0)=150.000000     'Lower Volume Limit 
 
 ipDArray(1)=500.000000     'Upper Volume Limit 
 
 ret = IpRendVMeas(M_FILTER_RANGES_SET,IVM_SurfVolume,ipDArray(0)) 
 
 ret = IpRendVMeasSet(M_UPDATE,0,0) 
 




 ret = IpFlt3DWatershed(127.500000,-1,0)   'Watershed split joined objects 
 
 ret = IpRendSet(REND_VOXELSIZE, 0.480000, 0.480000, 0.250000) 'Set voxel size 
 





 ret = IpRendSet(REND_ACTIVE_PORTION, 1, 0, 0) 
 
 ret = IpRendSet(REND_HI_COLOR, 0, 0, 0) 
 
 ret = IpRendSet(REND_RESET_OPTIONS, 0, 0, 0) 
 










 ReDim TheVol(NObjects) As Double 
 
 ReDim ReportVol(NObjects) As Double 
 
 ReDim CellType(NObjects) As String 
 




 '** For Loop Iterates through every identified Dapi nucleus and extracts it to a single 1 cell image 
 
 '** Each Nuclear outline applied to green to check if colocalised (ie GFP positive)    
   
 '** Each Nuclear Outline used to measure intensity in Red image     




 ret = IpBlbSetAttr(BLOB_AUTORANGE, 1)   'Set measurements to Bright Objects 
 
 ret = IpBlbSetAttr(BLOB_BRIGHTOBJ, 1) 
 
 ret = IpBlbEnableMeas(BLBM_DENSITY, 1)   'Enable intensity measurements 
 
 For x = 0 To NObjects -1 
 
  ret = IpRendVMeasSet(M_SEL_SET,x,1)  'Selects the next measurement in the 3D data table list 
 
  ret = IpRendVMeasSet(M_SHOW_SELECTED,0,1) 'Show only selected volume measurements 
 
  Answer = InputBox("Is Cell OK y/n","Cell Check","y") 
 
  If Answer = "y" Then 
 
   ret = IpRendVMeasSet(M_CREATE_MASK_IMAGE,0,0) 'Create a binary mask of that selected volume 
 
   ret = IpDocGet(GETACTDOC, 0, SingleDAPIBinary) 'Get ID of the cells mask image so that it can be 
         applied to others 
 
   ret = IpSMPlay(0)    'Select First position in stack 
 
   ret = IpSeqPlay(0) 
 
   'Loop to produce outlines from cell selected from 3D volume 
 
   For y = 0 To seqinfo -1 
 
    ret = IpBlbCount() 
 
    ret = IpBlbUpdate(0) 
 
    ret = IpSeqPlay(SEQ_NEXT) 
 
    ret = IpBlbCount() 
 
    ret = IpBlbUpdate(0) 
 
    Filesave = "C:\Temp\Data_" + CStr(y) + ".scl" 
 
    ret = IpBlbSaveOutline(Filesave) 
 
   Next y 
 
   'Loop applies the outline from the dapi to the green image to check for co-localisation 
 
   ret = IpAppSelectDoc(GreenId)   'Select Green Image Stack 
 
   Count = 0 
 
   For y = 0 To seqinfo -1 
 
    ret = IpSMPlay(y)   'Select First position in stack 
 
    ret = IpSeqPlay(y) 
 
    Filesave = "C:\Temp\Data_" + CStr(y) + ".scl" 
 
    ret = IpBlbLoadOutline(Filesave) 
 







    If MeanIntensity(0) > 750 Then 'Sets mean intensity for cell to be considered colocalised 
 
     Count = Count + 1 
 
     If Count = 3 Then 
 
      CellType(x) = "Colocalised" 
 
     End If 
 
    End If 
 
    If y = seqinfo -2 And Count < 3 Then 
 
     CellType(x) = "Non-Colocalised" 
 
    End If 
 
    ret = IpBlbDelete 
 
    MeanIntensity(0) = 0 
 




   ret = IpAppSelectDoc(RedId)    'Select Red Image Stack 
 
   MeanCount = 0 
 
   For y = 0 To seqinfo -1 
 
    ret = IpSMPlay(y)    'Select First position in stack 
 
    ret = IpSeqPlay(y) 
 
    Filesave = "C:\Temp\Data_" + CStr(y) + ".scl" 
 
    ret = IpBlbLoadOutline(Filesave) 
 
    ret = IpBlbData(BLBM_DENSITY, 0, 0, MeanIntensity(0))  'Retrieve Mean intensity value 
 
    If  MeanIntensity(0) > 0 Then 
 
     MeanCount = MeanCount + 1 
 
     TotalMean = TotalMean + MeanIntensity(0) 
 
    End If 
 
    ret = IpBlbDelete 
 
    MeanIntensity(0) = 0 
 
   Next y 
 
   If TotalMean > 0 Then 
 
    TheMean(x) = TotalMean/MeanCount 
 
   End If 
 
   TotalMean = 0 
 
   ret = IpRendVMeas(M_MEAS_GET, IVM_SurfVolume, TheVol(0)) 
 
   ReportVol(x) = TheVol(x)   'Gets cell volume for measured cell 
 
   ret = IpAppSelectDoc(SingleDAPIBinary) 
 
   ret = IpDocClose()    'Closes the image of the single dapi labelled cell 
 
  End If 
 
   ret = IpRendVMeasSet(M_SHOW_ALL,0,0 
 




 Next x 
 
 ret = IpRendElem(ELEM_DELETE,IP_REND_ISO_SURF,0,IPNULL) 'Delete volume measurement 1 at end of macro run 
 
 ret = IpRendElem(ELEM_DELETE,IP_REND_ISO_SURF,1,IPNULL) 'Delete volume measurement 2 at end of macro run 
 

















 '** or not its GFP positive and the cells red intensity measurement and sends it to Excel 
 






 ret = IpDde(DDE_OPEN, "excel", "sheet1")    'Opens Sheet1 within excel 
 




 'Loop iterates through the array variables passed from MakeMeasurements 
 
 'so that each extracted cell measurements are applied to the correct cell 
 
 For x = 0 To NObjects - 1 
 
  GetTheVal = "R" + CStr(RowCount) + "C1" 
 
  ret = IpDde(DDE_PUT, GetTheVal, CStr(x))   'Cell Number 
 
  GetTheVal = "R" + CStr(RowCount) + "C2" 
 
  ret = IpDde(DDE_PUT, GetTheVal, CStr(TheMean(x)))  'Mean Red intensity 
 
  GetTheVal = "R" + CStr(RowCount) + "C3"     
 
  ret = IpDde(DDE_PUT, GetTheVal, CStr(ReportVol(x)))  'Cell Volume 
 
  GetTheVal = "R" + CStr(RowCount) + "C4" 
 
  ret = IpDde(DDE_PUT, GetTheVal, CStr(CellType(x)))  'GFP positive/Negative 
 
  RowCount = RowCount + 1 
 






 'Section sets the column labels so user can identify measurements 
 
 ret = IpDde(DDE_PUT, "R1C1", "Measurement Number") 
 
 ret = IpDde(DDE_PUT, "R1C2", "Mean Intensity") 
 
 ret = IpDde(DDE_PUT, "R1C3", "Cell Volume") 
 
 ret = IpDde(DDE_PUT, "R1C4", "Status") 
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